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ABSTRACT 
 
Bird flu or Avian flu is an infectious disease caused by an influenza A virus of the 
Orthomyxoviridae family. Avian influenza virus (AIV) causes significant economic losses to the 
poultry industry worldwide and threatens human life with a pandemic. Pandemic of AIV is the 
human infection caused by the appearance of a “new” influenza virus as a result of antigenic 
shift or antigenic drift. Several outbreaks of AIV caused by the rapid spread of infection have 
been identified. Therefore, there is an urgent need for rapid diagnostic methods that would 
enable early detection and improved measurements to control the AIV outbreak. Classical 
method for detection and identification of AIV is time consuming (3-10 days), laborious, 
requires high amount of virus for detection and also special laboratory facilities and trained staff. 
Molecular diagnostic systems using RT-PCR amplification have significantly improved the 
speed, sensitivity and specificity of detecting AIV but are still cumbersome, expensive and time-
consuming (1-2 days). In both classical and molecular diagnosis, the transportation of sample to 
the near-by reference or diagnostic laboratory is needed, and this will increases the time for 
diagnostic result. A simple approach would be to have a point-of-care (POC) diagnostic test at or 
near the site of sample collection to provide results in very short time and that can improve 
medical decision-making. The available commercial POC tests that are used for screening of 
influenza A virus are rapid (5-30 minutes), but have low sensitivity and false negative results are 
of major concern. Ultimately, the miniaturization of molecular diagnostics using Lab-on-a-chip 
(LOC) systems could provide the next-generation rapid POC diagnostics. 
 
This study has been focused on developing rapid diagnostic methods for the identification and 
subtyping of the AIV towards POC diagnosis. The first step in molecular diagnostic is sample 
preparation which is the key to the success of diagnosis. To address this, a novel method was 
developed for selective separation and purification of AIV from chicken faecal sample using 
monoclonal antibody (mAb) conjugated magnetic beads where RNA extraction step is not 
required. The developed bead-based system was able to capture, concentrate and purify all of the 
16 H subtypes of AIV from the AIV spiked faecal samples, demonstrating the efficiency of the 
mAb conjugated beads and the developed method. Subsequently, the newly developed bead-
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based method was used in a microfluidic magnetic microsystem for the automation of sample 
preparation. Using LOC system with a Cyclic-Olefin-Copolymer (COC) polymer chip, the RT-
PCR was miniaturized and the entire process was detected in less than 2 h. This integrated LOC 
system has a great potential for POC clinical diagnostics. 
 
Subtyping of AIV is important in the diagnosis to identify the pathogenic virus. A DNA 
microarray-based solid-phase PCR approach has been developed for rapid detection of influenza 
virus types A and simultaneous identification of pathogenic virus subtypes of H5 and H7. This 
solid-phase RT-PCR method combines a reverse-transcription amplification of RNA extract in 
the liquid-phase with sequence-specific nested PCR on the solid phase. The examination of 33 
avian faecal and tracheal swab specimens was completed in less than 2 h with 94% accuracy. 
Subsequently, the approach of solid-phase-PCR was extended to a microfluidic chip to reduce 
sample and reagent consumption. The whole processing time for identifying and simultaneously 
subtyping AIV was further reduced to 1h. 
 
Apart from the RT-PCR method, two immunological methods based on; fluorescent DNA 
barcode and fluorescent beads were also developed for rapid detection and identification of the 
AIV. In both methods, the detection involved sandwiching of the target AIV between 
monoclonal antibodies for nucleoproteins and for matrix proteins. In the fluorescent DNA 
barcode-based immunoassay, fluorophore-tagged oligonucleotides were used as surrogates for 
signal detection with sensitivity comparable to conventional RT-PCR for allantoic fluid 
containing H16N3 AIV. While in the fluorescent bead-based immunoassay, the fluorescent 
beads were used as the direct detection signal from AIV. In both methods the entire detection 
time was less than 2 h. 
 
 
Keywords: Avian Influenza Virus - Diagnostics – Faecal sample - Sample Preparation - 
Magnetic Beads – RT-PCR – Microfluidics – Magnetic microsystem – Lab-on-a-chip – 
Solidphase PCR – Microarray – Biobarcode immunoassay – Fluorescent beads.  
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SAMMENDRAG (Danish) 
 
Fugle influenza eller Aviær influenza er en infektiøs lidelse, der skyldes smitte med et influenza 
A virus af Orthomyxoviridae familien. Verden over har sygdoms udbrud i fjerkræ forsaget af 
Aviær influenza virus (AIV) givet store tab fjerkræindustrien, og der hersker stor frygt for at 
smitten kan overføres til mennesker og udvikle sig til en verdensomspændende pandemi. En 
pandemi kan opstå når mennesker bliver følsomme for AIV virus, som følge af ændringer i det 
oprindelige virus. Dette kan ske ved mutation eller små ændringer i virus genomet, hvorved der 
opstår nye ukendte typer. Som følge af en meget hurtig spredning af virus er der indtil nu påvist 
en del mindre udbrud med AIV. For at kunne kontrollere disse udbrud er det meget nødvendigt 
at have hurtige og sikre metoder til at påvise infektionen så tidligt i forløbet så muligt. Påvisning 
af AIV med de klassiske metoder med dyrkning af virus er meget langsommelig og 
arbejdskrævende og langsommelig (3-10 dage); ydermere er metoderne ikke særlig følsomme og 
kræver sikrede laboratorie faciliteter samt trænet personale. Indførelsen af molekylære 
påvisningsmetoder som reverse transcription polymerase chain reaction (RT-PCR), har øget 
følsomhed og specificiteten i analysen væsentligt, og man kan nu få svar indenfor 1-2 dage, men 
metoden er stadigvæk arbejdskrævende og bekostelig.  
 
Uafhængigt af påvisningsmetoden, tager det tid at transportere prøver til det nærmeste 
kvalificerede laboratorium, hvilket det øger tiden inden en diagnose kan stilles. En simpel måde 
at løse dette problem på er at anvende point-of-care (POC) diagnostiske tests, hvor påvisningen 
foretage ude ved den smittede patient.  Der findes allerede i dag kommercielle hurtigtest kits som 
kan give svar indenfor 5-30 minutter, men de har oftest for lav følsomhed til at kunne stille en 
sikker diagnose. Til næste generations POC diagnostiske test vil det derfor være interessant at 
nedskalere de hidtidige molekylære påvisnings metoder, således at de kan anvendes i et mikro 
laboratorium som feks i ”Lab-on-a-chip” (LOC) systemer.   
 
Dette studie har fokuseret på at udvikle hurtig-diagnostiske metoder til at identificere og 
typebestemme AIV. Det første vigtige trin i diagnosticering med molekylære metoder er en god 
prøveforberedelse. For at optimere denne, er der blevet udviklet en ny metode baseret på 
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monoklonale antistoffer (mAb) bundet til magnetiske kugler, til selektivt at binde og oprense 
viruspartikler fra kyllingegødning, hvilket overflødiggør oprensning af RNA.   
 
Med det udviklede kuglebaserede oprensningssystem var det muligt at binde og oprense alle 16 
H AIV subtyper fra gødningsprøver tilsat virus eksperimentelt. Efterfølgende blev dette system 
overført til et mikrofluidisk magnetisk mikrosystem, hvori prøveforberedelsen kunne 
automatiseres. RT-PCR blev nedskaleret således at det kunne foregå i et LOC system baseret på 
en Cyclic-Olefin-Copolymer (COC) polymer chip. Hele forløbet fra oprensning til påvisning 
kunne ske på mindre end to timer, så dette integrerede LOC system har derfor et stort potientale 
som fremtidigt POC testkit.   
 
Typning af AIV er vigtig for at kunne adskille de sygdomsfremkaldende virus fra de ufarlige. Et 
DNA microarray-baseret solid-phase PCR, er blevet udviklet til både at kunne påvise Influenza 
A samt vise de H5 og H7 undertyper som er sygdomsfremkaldende. Denne solid-phase RT-PCR 
metode kombinerer RT amplifikationen af oprenset RNA i væskefasen, med en sekvensspecifik 
nested PCR i Solid phasen. Undersøgelsen af 33 svabere fra kloak eller svælg fra fugle kunne 
foretages på mindre end 2 timer og med en nøjagtighed på 94 %. Dette system blev også overført 
til et microfluidic chip system for at reducere prøve og reagens mængden. Proces tiden for denne 
detektions og typnings metode kunne herefter nedsættes med 1 time.   
 
Udover RT-PCR detektions metoden blev der også udviklet en immunologisk metode baseret 
dels på fluorescerende DNA stregkoder samt på fluorescerende kugler. Med begge metoder 
påvistes AIV som en sandwich med monoklonale antistoffer rettet imod nucleoproteiner og 
matrix proteiner. I det fluorescerende DNA stregkode baserede immunoassay brugtes korte 
fluorescensmærkede nukleotider som erstatning for traditionel signal forstærkning, og metoden 
kunne påvise virus med en følsomhed tilsvarende konventionel RT-PCR i allantois væske 
indeholdende AIV H16N3. Med det immunoassay baseret på fluorescerende kugler foretages 
direkte detektion af signal fra AIV. Med begge metoder var detektionstiden mindre end 2 timer.  
 
 
  
 
 
vii 
 
PREFACE AND ACKNOWLEDGEMENT 
 
This thesis is submitted in partial fulfilment of the requirements for the Ph.D degree at Technical 
University of Denmark (DTU). This work was carried out at the Laboratory of Applied Micro-
Nanotechnology (LAMINATE), National Veterinary Institute, Technical University of Denmark. 
The project was funded by DTU Globalization-food pathogen project no. 8 and grant no. 
150627. 
 
First, I would like to express my thanks and sincere gratitude to my advisor, senior scientist Dr. 
Dang Doung Bang for giving me an opportunity to pursue my doctoral studies. Also for his 
extended support during the entire tenure of my Ph.D was memorable. I express my deep sense 
of gratitude to my co-supervisor, Associate Prof. Dr. Anders Wolff for his fruitful discussions. 
Likewise, I would like to thank my head of the department Dr. Flemming Bager for his support. 
 
My thesis would not have been complete without collaboration with the Avian virology group. I 
was very fortunate to associate with Dr. Kurt Handberg and Dr. Poul Henrik Jørgensen for their 
helps and thoughtful advices. I enjoyed the most working with Hanne, Lisbeth, Tanja, Susanne 
Jespersen, Susanne Stubbe, Søs and also Anne (especially for her home baked cakes). 
 
I would also like to thank my external project collaborators Sun Yi, Minqiang Bu and Ivan from 
BioLabchip group at DTU- Nanotech and many thanks to Dr. Jesus Ruano-López and his 
colleagues at Ikerlan, Spain.  
  
My special thanks go to Jonas and Steen for being helpful from the day one of my Ph.D. I would 
like to express my sincere thanks to Cuong for his comments and proofreading the thesis. Also I 
thank my group members Xuan, Tram, Zoreah, Søren Peter, Morten, Joana, Huong, Yiping Li 
and Yuliang Liu for being cheerful colleagues. Thanks to colleagues from other groups and staff 
members in the department for their kindness and help.  
 
 
 
viii 
 
I would also like to express my thanks to all my friends and well-wishers in Aarhus and 
Copenhagen who offered help and support during several occasions. We had wonderful time 
together. 
 
I would like to express my loving thanks to my family, my sister, and friends for their constant 
moral support and encouragement in spite of being far away, without which I would not have 
made it this far. Finally, I would like to thank my wife Dhivyaa for her unwavering support and 
care, especially during the final months of my thesis.  
 
 
 
Raghuram Dhumpa 
January 2011 Aarhus, Denmark 
  
 
 
ix 
 
I. Table of content 
ABSTRACT ................................................................................................................................... iii 
SAMMENDRAG (Danish) ............................................................................................................. v 
I. Table of content ..................................................................................................................... ix 
II. List of publications ............................................................................................................... xii 
III. List of abbreviations ........................................................................................................ xiv 
1 Introduction and thesis outline ................................................................................................ 1 
2 Avian Influenza ....................................................................................................................... 4 
2.1 Terminology .................................................................................................................... 5 
2.2 Influenza virus replication .............................................................................................. 5 
2.3 Avian influenza pathogenicity ........................................................................................ 7 
2.4 Influenza virus variation ................................................................................................. 8 
2.5 AIV transmission ............................................................................................................ 9 
2.6 Pandemic ....................................................................................................................... 10 
2.7 Surveillance and control of AI ...................................................................................... 11 
3 Diagnosis of AIV .................................................................................................................. 12 
3.1 Specimens collection .................................................................................................... 12 
3.2 Isolation of influenza virus ........................................................................................... 13 
3.3 Haemagglutination assay .............................................................................................. 14 
3.4 Haemagglutination inhibition ....................................................................................... 15 
3.5 Neuraminidase inhibition assay .................................................................................... 16 
3.6 Agar gel immunodiffusion ............................................................................................ 17 
3.7 Enzyme-Linked Immunosorbent Assay ........................................................................ 18 
3.8 AIV Inactivation ........................................................................................................... 19 
3.9 Virus Quantification ...................................................................................................... 19 
 
 
x 
 
3.9.1 Plaque Assay ............................................................................................................. 19 
3.9.2 Infectious dosage determination ............................................................................... 20 
4 Molecular Diagnostics .......................................................................................................... 22 
4.1 RT-PCR......................................................................................................................... 22 
4.2 Real time RT-PCR ........................................................................................................ 24 
4.3 Subtyping AIV by RT-PCR .......................................................................................... 25 
4.3.1 Primer/probe adaptation ............................................................................................ 26 
4.4 Multiplex-RT-PCR ....................................................................................................... 26 
4.5 DNA Microarray ........................................................................................................... 27 
4.6 Sample preparation ....................................................................................................... 29 
5 Point-of-care diagnosis ......................................................................................................... 32 
5.1 Lab-on-a-chip ................................................................................................................ 35 
5.1.1 Microfluidics ............................................................................................................. 36 
5.1.2 Integrated system ...................................................................................................... 38 
5.1.3 Magnetic beads ......................................................................................................... 38 
6 Sample preparation for RT-PCR ........................................................................................... 42 
6.1 Rapid detection of avian influenza virus in chicken faecal samples by 
immunomagnetic capture RT-PCR assay ................................................................................. 43 
6.2 Rapid sample preparation for detection and identification of avian influenza virus from 
chicken faecal samples using magnetic bead microsystem ...................................................... 52 
6.3 On-chip sample preparation and RT-PCR for detection of avian influenza virus from 
chicken faecal sample ............................................................................................................... 57 
6.3.1 Introduction ............................................................................................................... 57 
6.3.2 SU-8 Chip ................................................................................................................. 58 
6.3.2.1 Materials and Methods .................................................................................... 59 
6.3.2.2 Results and discussions ................................................................................... 61 
 
 
xi 
 
6.3.2.3 Conclusion ....................................................................................................... 68 
6.3.3 RT-PCR to detect AIV using COC-chip ................................................................... 69 
6.3.3.1 Materials and Methods .................................................................................... 69 
6.3.3.2 Results and discussions ................................................................................... 70 
6.3.3.3 Conclusion ....................................................................................................... 71 
7 Solid-phase DNA microarray ............................................................................................... 72 
7.1 DNA Microarray Based Solid Phase RT-PCR for Rapid Detection and Identification of 
Avian Influenza Virus ............................................................................................................... 73 
7.2 A lab-on-chip device for rapid identification of avian influenza virus by solid phase . 82 
7.3 Development of simultaneous detection and haemagglutinin subtyping of Avian 
Influenza Viruses using solid-phase RT-PCR .......................................................................... 93 
7.3.1 Introduction ............................................................................................................... 93 
7.3.2 Materials and Methods .............................................................................................. 94 
7.3.3 Results and Discussions ............................................................................................ 95 
7.3.4 Conclusion .............................................................................................................. 101 
8 Immunoassays ..................................................................................................................... 102 
8.1 Detection of avian influenza virus by fluorescent DNA barcode-based immunoassay 
with sensitivity comparable to PCR ........................................................................................ 103 
8.2 Development of a fluorescent bead-based immunoassay for rapid detection of Avian 
influenza virus ......................................................................................................................... 111 
8.2.2 Materials and Methods ............................................................................................ 112 
8.2.3 Results and discussions ........................................................................................... 115 
8.2.4 Conclusion .............................................................................................................. 120 
9 Summary and Outlook ........................................................................................................ 121 
List of references ......................................................................................................................... 124 
  
 
 
xii 
 
II. List of publications  
 
Peer-review Journals 
 
i. Dhumpa, R., Handberg, K.J., Jørgensen, P.H., Yi, Sun., Wolff,A., Bang, D.D., (2011). Rapid 
detection of avian influenza virus in chicken faecal samples by immunomagnetic capture RT-
PCR assay. Diagnostic Microbiology and Infectious Diseases, 69,258-265. 
  
ii. Dhumpa, R., Bu,M., Handberg, K.J., Wolff,A., Bang, D.D (2010). Rapid sample preparation 
for detection and identification of avian influenza virus from chicken faecal samples using 
magnetic bead microsystem. Journal of Virological Methods, 169, 228–231  
 
iii. Yi, S., Dhumpa, R., Bang, D.D., Handberg, K.J., Wolff, A (2011). DNA Microarray Based 
Solid Phase RT-PCR for Rapid Detection and Identification of Avian Influenza Virus. 
Diagnostic Microbiology and Infectious Diseases, 69, 432–439. 
 
iv. Yi, S., Dhumpa, R., Bang, D.D., Handberg, K.J., Wolff, A. (2011). A lab-on-a-chip device 
for rapid identification of avian influenza viral RNA by solid-phase PCR. Lab chip, 11, 
1457-1463.  
 
v. Cao, C., Dhumpa, R., Bang, D.D., Ghavifekr, Z., Høgberg, J., and Wolff, A. (2010). 
Detection of avian influenza virus by fluorescent DNA barcode-based immunoassay with 
sensitivity comparable to PCR. Analyst, 135, 337-342. 
 
  
 
 
xiii 
 
 
International conference presentation and proceedings (*presenter) 
 Dhumpa, R.*, Handberg, K.J., Wolff, A., Bang, D.D., (2008). “Monoclonal antibody coated 
magnetic beads for rapid identification of Avian Influenza Virus (AIV) in Danish broiler”. 
Poster presentation at poster at Lab-On-a-Chip World Congress, Barcelona, Spain, May 
2008.  
 Dhumpa, R.*, Handberg, K.J., Wolff, A., Bang, D.D., (2008). “Monoclonal antibody coated 
magnetic bead microsystem for rapid identification of avian influenza virus (AIV)”. Oral 
presentation  at MED-VET-NET 4th Annual scientific meeting, St. Malo, France, June 2008  
 Dhumpa, R.*, Bu, M., Handberg, K.J., Wolff, A., Bang, D.D.,  (2009). “Rapid sample 
preparation using magnetic bead microsystem for detection and identification of avian 
influenza virus from chicken faecal samples”. Oral presentation at NanoBioTech-conference-
2009, Montreux, Switzerland, November 2009. 
 Dhumpa, R.*, Berganzo, J., Ruano-López, J.M., Wolff, A., Bang, D.D., (2010). 
“Microfluidic System for on Chip Sample Preparation and Immunodetection of Avian 
Influenza Virus”.  Poster presentation at Lab-on-a-Chip European Congress, Dublin, Ireland, 
May 2010.  
 Bang, D.D.*, Dhumpa, R., Cao, C., Florian, L., Berganzo, J., Walczak, R., Liu, Y., Bu, M., 
Yi, S., Dzuiban, J., Ruano, J.M. and Wolff, A. (2010). “A trip from a tube to a chip applied 
micro and nanotechnology in biotechnology”, veterinary and life sciences. Proceeding Series 
of the International Federation of Medical and Biological Engineering (ISSN 1680-0737), p: 
290-294.  
 Yi, S., Bang, D.D., Dhumpa, R., Handberg, K.J., Wolff,A.*(2009). A Lab on a chip device 
for rapid identification of Avian Influenza virus µTAS 2009 Vol. 1, p: 697-698.   
 Cao, C.*, Dhumpa, R., Bang, D.D., Ghavifekr, Z., Høgberg, J., and Wolff, A., (2009). 
“Detection of Avian Influenza virus with PCR like sensitivity by fluorescent DNA bare code 
based immunoassay” µTAS 2009 Vol.2. p:1614-1616.  
 Bang, D. D.*, Dhumpa. R., Cuong, C., Florian,L., Berganzo, J., Walczak, R., Liu, Y., Bu, 
M., Yi, S., Dzuiban, J., Ruano, J. M., and Wolff, A. (2010). "A trip from a tube to a chip 
applied micro and nanotechnology in biotechnology, veterinary and life sciences", 3rd 
Electronic System Integration Technology Conference, Brussels, Belgium. 
 
 
xiv 
 
III. List of abbreviations  
 
AGID Agar gel immunodiffusion  
AIV Avian influenza virus 
BSA Bovine Serum Albumin  
BSL-3 Bio safety level-3 
COC Cyclic-Olefin-Copolymer  
CP Capture probe 
CY5 Cyanine-5 
dNTP deoxynucleotide triphosphate 
EDC 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide  
EID50 50% Egg infectious dosage 
ELISA Enzyme linked immunosorbent assay  
FIA Fluorescent immunoassay 
FITC Fluorescein isothiocyanate 
HA Haemagglutination 
HA0 Haemagglutinin precursor 
HAU Haemagglutination Unit 
HPAI  Highly pathogenic avian influenza 
IVPI Intravenous pathogenicity index  
IVRD Influenza virus resource database 
LOC Lab-on-a-chip  
LPAI Low pathogenic avian influenza 
MDCK Madin-Darby canine kidney 
MMP Magnetic microparticle 
mRNA Messenger RNA 
NA Neuraminidase 
OIE Office International Des Epizooties 
PBS Phosphate buffered saline  
PCR polymerase chain reaction  
 
 
xv 
 
PD Primer dimmer 
PDMS polydimethyl siloxane  
PFU Plaque forming unit 
PMK Primary monkey kidney  
PMP Polystyrene microparticle 
POC Point of care 
RBC Red blood cell 
RNA Ribonucleic acid 
RNP Ribonucleoprotein 
RT-PCR Reverse transcription polymerase chain reaction 
SA Sialic acid  
SDS sodium dodecyl sulphate  
SNP Single-nucleotide polymorphisms  
SPF  Specific pathogen free 
SSC standard saline citrate 
SVR Surface to volume ratio 
TAQ Thermus aquaticus 
TCID50 50% Tissue culture infectious dosage 
WHO World health organization 
  
 
 
1 
 
Chapter 1 
1 Introduction and thesis outline 
Avian Influenza infection is caused by Influenza A virus belonging to the Orthomyxoviridae 
family. Avian influenza virus (AIV) have been affecting all types of wild birds and occasionally 
aquatic bird species [1]. The wild life species serve as a reservoir of all Influenza A viruses over 
a long period and have been the source of infection in domestic poultry and mammals. 
Transmission of AIV to domestic poultry is introduced primarily through direct or indirect 
contact with infected birds.  
Based on the ability of AIV to cause disease and mortality in experimental infection of four  to 
eight  weeks-old chickens, the AIV is classified as either highly pathogenic avian influenza 
(HPAI) or low pathogenic avian influenza (LPAI)[2;3]. The HPAI virus H5N1 which affected 
birds in Eurasia and Africa continues to spread and to pose a challenge to animal and human 
health. The first known instance of human infection with AIV H5N1 was reported in Hong Kong 
in 1997. Since then the pandemic started spreading around the world. So far a total number of 
507 cases of human Avian Influenza A/(H5N1) infection with 59.56% death ratio (302/507) was 
reported by Wold Health Organisation (WHO) on 18th October 2010 [4].  The pandemic could 
have resulted from either antigenic drift or avian viral strain re-assortment with a human strain 
(antigenic shift). Cross species infection between humans and other mammals continues to threat 
the world of a pandemic influenza. In poultry, several outbreaks of AIV caused culling of several 
millions birds and created a huge economic loss in poultry industry worldwide  [5]. The 
outbreaks of AIV have been characterized by the rapid spread of infection emphasizing the need 
for rapid diagnostic methods that would enable early detection and improve measures to control 
the AIV. This thesis aimed to development rapid diagnosis methods for the detection of avian 
influenza virus.  
 
The classical method for detection and identification of AIV is time consuming (3-10 days), 
laborious, requires high amount of virus for detection and also special laboratory facilities and 
trained staffs (Chapter 3). On the other hand, molecular diagnostic systems using reverse 
Introductio nd thesis outline 
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transcriptase polymerase chain reaction (RT-PCR) amplification have significantly improved the 
speed, sensitivity and specificity for the detection of AIV but are still cumbersome, expensive 
and time-consuming (1-2 days) (Chapter 4). In both classical and molecular diagnostics, the 
transportation of sample to the near-by reference or diagnostic laboratory is needed, which 
further increases the time for diagnostic result. A simple approach would be to have a point-of-
care (POC) diagnostic test at or near the site of sample collection which could provide result 
instantly or in a very short time and can improve medical decision-making. The available 
commercial POC tests are mainly based on immunoassays which detect influenza viral antigen 
and are used for screening of influenza A within 5-30minutes. However these POC poses low 
sensitivity and false negative results are a major concern. Ultimately, the miniaturization of the 
molecular diagnostics using Lab-on-a-chip (LOC) systems could provide the next-generation 
rapid POC diagnostics (Chapter 5).  
 
In order to develop such rapid diagnostic system, a simple and robust sample preparation for RT-
PCR is required (Chapter 6). In this study, a magnetic bead based system has been developed to 
separate, concentrate and purify AIV from faecal sample. The beads were conjugated with 
monoclonal antibodies against the AIV nucleoprotein, which is conserved in all the AIV. The 
bead captured virus was detected by RT-PCR without RNA extraction, due to effective removal 
of RT-PCR inhibitors. The developed bead-based assay showed a detection limit comparable to 
the RNA extraction and the classical virus isolation method. The advantage of using magnetic 
beads in sample preparation is that it can be automated using magnetic microfluidic system. The 
miniaturization of RT-PCR for AIV has been performed on a lab-on-a-chip system with a 
Cyclic-Olefin-Copolymer (COC) microfluidic chip. Using this system the entire process was 
detected in less than 2 h. 
 
Along with the detection and identification of AIV, it is important to be able to subtype AIV and 
understand the pathogenicity (Chapter 7). To address this, a DNA microarray based solid-phase 
PCR has been developed for rapid detection of influenza virus types A and simultaneous 
identification of pathogenic virus subtypes H5 and H7. This solid-phase RT-PCR method 
combines reverse-transcription amplification of extracted RNA in the liquid-phase with sequence 
specific nested PCR on the solid phase. A simple UV cross-linking method was used to 
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immobilize the DNA probes over an unmodified glass surface, which makes solid-phase PCR a 
convenient possibility for AIV screening. The testing of 33 avian faecal and tracheal swab 
specimens was completed in less than 2 hours with 94% accuracy. This work was extended to a 
LOC device for fast AIV screening by integrating DNA microarray-based solid-phase PCR on a 
microfluidic chip. Furthermore, by incorporating the microarray into a microchamber-based PCR 
chip, sample and reagent consumption was greatly reduced. The whole process for identifying 
and simultaneously subtyping AIV was reduced to 1h and the sample volume used in the 
microfluidic chip was at least 10 times less than specified in the literature. Subtyping of all the 
16 HA types is essential for the identification of circulating strains that could emerge as a 
pandemic influenza virus. This is addressed in the last part of the thesis where preliminary results 
on the development of primers and probes for detecting of AIV and simultaneous HA subtyping 
(H1-H16) are discussed. 
 
Apart from the PCR based detection, two immunological based methods; fluorescent DNA 
barcode based and fluorescent bead based methods for detection of AIV were presented (Chapter 
8). In both cases, the detection involves sandwiching of the target AIV between the monoclonal 
antibodies of nucleoproteins and matrix proteins. In the fluorescent DNA barcode-based 
immunoassay, fluorophore-tagged oligonucleotides are used as a detection signal whereas in the 
fluorescent bead-based immunoassay fluorescent beads were used as detection signals. The 
advantages of each method for rapid detection of are discussed.  
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Chapter 2 
2 Avian Influenza 
Influenza A viruses causes annual epidemics and occasional pandemics that have claimed the 
lives of millions. The three genera of Influenza viruses are classified by their antigenic 
differences as A, B and C. Among the three, Influenza A virus is known to be an infectious agent 
in birds (Avian) and some mammals.  
 
AIV is a spherically shaped virus with an average diameter of 100nm (Figure 2.1). The surface 
of AIV comprises distinctive peaks with two major glycoprotein’s: haemagglutinin (HA) and 
neuraminidase (NA) with a ratio of 4-5 to 1. Due to the antigenic drift of these two proteins, AIV 
is classified into 16 haemagglutinin subtypes (H1-H16) and 9 neuraminidase subtypes (N1-N9). 
The possible combinations of influenza A virus with both HA and NA form 144 sub-types and so 
far 103 have been found in wild birds [6;7]. The complete AIV genome is 13,588 nucleotides 
long and consists of 8 segments of single stranded, negative sense ribonucleic acid (RNA): 
haemagglutinin (HA) gene; neuraminidase (NA) gene; matrix (M) gene; nonstructural gene; 
nucleoprotein (NP) gene; and three polymerases: PA, PB1 and PB2 genes[6].  
 
 
 
 
 
 
 
 
 
Figure 2.1 Structure of Avian Influenza Virus (reproduced from ref [8])  
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The 11-13 nucleotides at the 3' end and 5' end of genome are conserved and are complementary 
to each other [9]. Each segment is encapsulated in a separate nucleocapsid and is surrounded by 
an envelope. The AIV genome encodes 11 proteins which include the structural and non-
structural proteins [9]. Virions (complete virus particle) are composed of 18-37% lipids by 
weight[10]. 
2.1 Terminology 
Isolates of AIV are termed by their source of isolation, location, year, etc. For example, the strain 
H16N3 – A/Gull/Denmark/68110/02 is identified as: 
A: stands for the species of influenza (A, B or C). 
Gull: the species in which the virus was found 
Denmark: the place where this specific virus was isolated 
68110: an identification number to differentiate the isolation from other AIV isolated at 
the same place 
02: represents the year 2002 
H16: stands for the sixteenth of sixteen known types of haemagglutinin. 
N3: stands for the third of nine known types of neuraminidase.  
Other examples include: H7N7-2 A/Chicken/Netherland/2993/03 and H5N1 
A/Chicken/Scotland/ 59 06.04/67. 
2.2 Influenza virus replication 
Replication of Influenza virus is divided into four phases: (1) virus attachment and penetration 
into the host cell; (2) transcription of the viral genome and translation of viral proteins; (3) 
replication of the viral RNA; and (4) assembly of the virions and subsequent release from the 
host cell [11](Figure 2.2).  
(1) Virus attachment and penetration: The Influenza virus is attaching to the host cell by HA 
glycoprotein, which is considered as a primary protein responsible for binding to receptor sites 
and activating virus infectivity[12]. HA is synthesized as a precursor (HA0) and is subsequently 
cleaved by a host cell trypsin-like protease to HA1 and HA2 subunits[13]. The infection process 
is initiated by HA1 binding to receptor sites i.e. sialic acid (N-acetylneuraminic acid) and 
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penetration of the virus particle into the cell by HA2 membrane fusion [14]. Due to the acidic 
environment of the host cell the adsorbed virus is internalized as an endosome and the viral 
capsid is degraded.  
(2)Transcription and translation: The eight segments of ribonucleoprotein (RNP) are transported 
into the host cell nucleus where messengerRNA (mRNA) synthesis and replication take place. 
As the segments enter the nucleus, the viral endonuclease cleaves the 5' end of the host capped, 
methylated mRNA about 13-15 bases from the 5' end. The cleaved part of the host mRNA is 
used as a primer by the virus to synthesize and to elongate leading to the formation of a 
complimentary plus strand of mRNA. These mRNA’s undergo a translation process in the 
cytoplasm resulting in the formation of polypeptides which are subsequently cleaved to form 
viral proteins[9].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 Replication of influenza A virus (from ref [15])  
 
3) Genome Replication: During the replication of viral RNA genome, a different type of 
complementary RNA (cRNA) is produced which is a positive strand of anti-genome. This cRNA 
strand serves as a template for the production of negative strand viral genomic segments with the 
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help of polymerase protein (PA). The newly synthesized negative stranded RNA’s are associated 
with NP and form ribonucleoprotein (RNP)[9].  
 
(4) Assembly and release: The RNP’s are transported into the host cell cytoplasm where other 
proteins are then assembled to form virons. On maturity the virus buds through the outer cell 
membrane and the NA protein cleaves terminal sialic acid from glycoproteins and the virus thus 
become free from the host cell[9]. 
 
2.3 Avian influenza pathogenicity 
Based on the ability to cause disease and mortality by the influenza A virus in poultry, the AIV  
is classified into two pathotypes: highly pathogenic avian influenza (HPAI) and low pathogenic 
avian influenza (LPAI)[2;6]. The laboratory criteria to evaluate the pathogenicity consist of an 
intravenous pathogenicity index (IVPI) test where the AIV strain is inoculated intravenously into 
6-week-old chicken. The IVPI is calculated based on the mortality of the birds, by following the 
protocols from the World Organization for Animal Health (Office International des Epizooties, 
OIE)[2]. The HPAI have an IVPI greater than 1.2 or alternatively cause at least 75% mortality 
within 10 days. The other criterion is the presence of multiple basic amino acids with minimum 
sequence motif R-X-R/K-R (R-Argenine, K-Lysine, X-variable amino acid) at the HA0 cleavage 
site found to be associated with HPAI viruses[16;17].  
 
During the viral infection the precursor HA0 is cleaved post-translationally at a conserved 
Arginine residue by host-produced proteases into two subunits HA1 and HA2 before the protein 
is functional and virus particles are infectious. The cleavage occurs by trypsin-like proteases 
which are present in tissue of respiratory and gastrointestinal tract of the host. However, with 
multiple basic amino acids (R or K) present at the HA cleavage site, the HA0 precursor becomes 
cleavable by a wide range of proteases. This allows the virus to replicate also in other organs 
than respiratory and gastrointestinal tract resulting in high mortality and leading to HPAI virus 
[1;13]. So far, the HPAI viruses have been restricted to two subtypes; H5 and H7, although not 
all viruses of these subtypes are HPAI. Table 2.1 shows the list of H5 and H7 subtype AIV 
viruses which are identified as both HPAI and LPAI viruses based on the presence of multiple 
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amino acids[18]. The viruses of subtype H1 to H4, H6, and H8 to H16 are all LPAI. Some H5 
and H7 subtypes which do not have IVPI greater than 1.2 and the absence of multiple R or K 
amino acids are considered as LPAI viruses (Table 2.1). 
 
Table 2.1: Few examples of H5 & H7 AI amino acid sequences across the cleavage site 
(HA1/HA2)[18]. The multiple basic amino acids for HPAI are shown in red.  
Virus Subtype Motif (HA1/HA2) Pathogenicity 
A/laughing gull/AK/296/75 H5N3 PSIGE----R/GLF LPAI 
A/chicken/Italy/RA9097/98 H5N9 PQKET----R/GLF LPAI 
A/duck/Ireland/113/83 H5N8 PQRKRKK--R/GLF HPAI 
A/chicken/Scotland/59 H5N1 PQRKK----R/GLF HPAI 
A/chicken/Italy/1487/97 H5N2 PQRRKKR-R/GLF HPAI 
A/chicken/Thailand/04 (1, 2, 3) H5N1 PQRERRRKKR/GLF HPAI 
A/avian/Texas/04 H5N2 PQRKKR/GLF HPAI 
A/ruddy turnstone/NJ/65/85 H7N3 PEKPK---TR/GLF LPAI 
A/duck/OH/10/88 H7N8 PESPK----TR/GLF LPAI 
A/duck/Victoria/76  H7N7 PEIPK----KRGLF LPAI 
A/finch/CA/28710-8/93  H7N8 PEIPK----ER/GLF  LPAI 
A/poultry/Chile/2002  H7N3  PEKPKTR/GLF  LPAI 
A/FPV/Brescia/02  H7N1  PSKKR---KKR/GLF HPAI 
A/turkey/England/63  H7N3  PETPK---RRRR/GLF  HPAI 
A/chicken/Leipzig/79  H7N7  PEIPK---KKGR/GLF  HPAI 
A/chicken/NL/2003  H7N7  PEIPKRRRR/GLF  HPAI 
 
2.4 Influenza virus variation 
During the viral replication cycle a high mutation rate of ≥ 7.3 x 10 -5 per nucleotide base per 
cycle of replication occurs, which corresponds to one nucleotide exchange per genome[19]. This 
error rate is due to the lack of proofreading by viral RNA polymerase in contrast to the DNA 
polymerase. The frequent mutations (substitutions, deletions, insertions) in the viral genes cause 
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changes to viral proteins resulting in antigenic drift. Some of these mutations occurring at the 
antigenic sites of the virus can reduce or inhibit the binding of neutralising antibodies.  This 
either increases the virulence of the strain or generate of a new strain that rapidly spread within a 
non-specific immune population[20]. In poultry, it was shown that the LPAI virus which was 
circulating in the natural wild birds for several months underwent antigenic drift and became a 
HPAI virus[21].  
  
Another major variation in viral proteins is called antigenic shift and is responsible for 
pandemics occurring at irregular intervals[22]. Antigenic shift occurs if the host cell is 
simultaneously infected by two or more strains of influenza A virus. A genetic exchange or re-
assortment takes place among the viruses and forms a progeny virus with a new HA (with or 
without a new NA)[23]. It has been shown that pigs are susceptible to both human and avian type 
influenza virus, and they are therefore considered to be the viral mixing vessel for genetic re-
assortment[24;25]. Another possibility of antigenic shift is the direct introduction of strain 
without re-assortment from animal reservoir to humans[22]. 
 
2.5 AIV transmission 
The wild life species serve as a reservoir of all Influenza A viruses over a long period and have 
been the source of infection in domestic poultry and mammals (Figure 2.3)[3;26-28]. Most of the 
influenza viruses, except the HPAI, cause mild primary respiratory infection in birds[3]. The 
introduction of H5 or H7 subtypes of LPAI viruses may adapt in poultry and cause a mutation at 
the HA cleavage site leading to the formation of a HPAI type. Transmission of AIV to domestic 
poultry is introduced primarily through direct or indirect contact with infected birds, movement 
of infected poultry, contaminated equipments, vehicles, etc. Other sources of infection 
transmission can be infected bird droppings, saliva, nasal secretions, faeces, or blood [26;29].  
 
It has been reported that AIV infective faeces may contain virus up to concentrations of 8.8 
log10 EID50 (50% Egg infectious dose) per gram and the virus can remain active over 30 days at 
0 °C with a five fold decrease in mean EID value [30]. The stability of the virus has also been 
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found to increase over the years. Transmission of AIV from wild birds to poultry depends upon 
the exposure interface where an adequate infectious dose for a given strain may be achieved[27]. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3 Scheme of avian influenza pathogenesis and epidemiology (dotted lines with arrows 
represent species barriers) (from ref[31]). 
 
In general the transmission of avian influenza to humans is limited and its replication is not 
efficient[32]. This species barrier is due to the variation of receptors for influenza viruses in birds 
and other species. The HA protein of AIV  binds to host (e.g. chicken) cell sialic acid (SA) 
linked to galactose by α-2,3 linkage (SA α-2,3) while in humans the binding site is α-2,6 linkage 
(SA α-2,6)[33]. Subtypes of the AIV such as H5 and H7 have acquired mutations in HA that can 
have affinity for both avian and human receptors and cause disease [1;34;35]. Human cases of 
AIV infection were acquired by close contact with infected birds, consumption of undercooked 
or raw poultry products and handling of sick or dead birds without proper protection[35;36]. In a 
few cases, there had been human to human transmission among family members[37] or health 
care workers[38].   
2.6 Pandemic 
Pandemic of AIV is the human infection caused by the appearance of a “new” influenza virus as 
a result of antigenic shift or antigenic drift[39]. The first known outbreak of HPAI occurred in 
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northern Italy in 1878 which caused extremely high mortality in chickens. The first confirmed 
outbreak of HPAI was reported in Scotland in 1959. Since then, more than 28 outbreaks have 
been recorded worldwide, of which half of them have occurred in the past 10 years[40]. The first 
known case of AIV H5N1 human infection was reported in Hong Kong in 1997. Since then the 
pandemic started to spread and affected birds in Eurasia and Africa and continued to pose a 
challenge to animal and human health[35]. So far a total number of 507 cases of human Avian 
Influenza A/(H5N1) infection with 59.56% death ratio (302/507) was reported by World Health 
Organisation (WHO) on 18th October 2010 [41]. Several outbreaks of AIV caused culling of tens 
of millions of birds and created a major economic loss in poultry industry around the world 
[3;40;42;43]. 
2.7 Surveillance and control of AI  
The AIV has crossed the species barrier and become more virulent over time. To inspect these 
changes in the behaviour of the virus, an efficient surveillance is necessary. The current 
surveillance studies are addressed in 4 major lines of investigation: 1) early detection of HPAI 
viruses; 2) ecology and epidemiology of LPAI virus in host populations; 3) diversity and 
evolution of viral strains within wild birds; and 4) identification of the pathogens that infect 
individual birds or population, often as part of multipathogen surveillance[44]. Improving 
pandemic surveillance additionally requires more research in secure laboratory settings to 
investigate the viral reassortment, biological  behaviour, and transmissibility[39]. 
 
The active surveillance for AIV in wild birds could act as an early warning system to identify 
areas of higher risk that can be controlled through vaccination. Surveillance can also provide the 
latest possible strains to determine the closest possible vaccine match. Although vaccines and 
antiviral drugs are key strategies to prevent severe illness and death from pandemic influenza, 
development of such vaccines and drugs have scientific barriers[45]: The diversities present in 
the HA and NA surface glycoproteins and its antigenic drift and antigenic shift pose a challenge 
in the development of such vaccine in advance of an outbreak[46]. At the same time,  the strong 
host immunity created by the vaccine could be a driving force to  antigenic drift in the AI [47].  
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Chapter 3 
3 Diagnosis of AIV 
 
Correct diagnosis of AIV provides information about the viral isolate and can reduce the spread 
of infection.  
 
3.1 Specimens collection 
The starting point of every diagnosis is collection of specimens and the successful detection 
depends on the sample type, the method to collect the sample, the quality of sample, and the 
handling conditions and time. Safety precautions must also be taken while collecting and 
handling the sample to avoid exposure to infectious agents. Therefore, care is taken from the 
time of specimen collection to the time of sample processing in the laboratory to provide valid 
results.  
 
The AIV infects both respiratory and intestinal tract of poultry and waterfowl. Birds infected 
with AI shed viruses in their faeces and these can be a source of transmission to other birds. Due 
to high replication of virus; swab of oropharyngeal, cloacal and faecal droping are the choice of 
specimens for AI culture isolation, nucleic acid based assays, and antigen immunoassays 
respectively. Other specimens such as blood, biopsies of lung, spleen, intestinal tract are also 
included. The collected specimens are placed in 1-3 ml plastic tubes with sterile isotonic 
transport medium containing antibiotics such as penicillin (2,000 units/ ml), streptomycin (2 mg/ 
ml), gentamicin (50 mcg/ ml) and mycostatin (1,000 units/ ml) and protein (Bovine Serum 
Albumin (BSA). During transportation, the antibiotics in the medium eliminate the growth of 
microflora and the protein prevents the degradation of live virus. The specimens are cooled to 
4oC and immediately transported to the laboratory for diagnosis. The specimens are not allowed 
to be freezed in order to avoid freezing and thawing of the virus which has been shown to  
reduce the viral titre value [48]. In case of long transportation, the specimens are frozen and 
transported on dry ice. The transportation of specimens has to follow the OIE guidance[2].   
Diagnos  of AIV 
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3.2 Isolation of influenza virus 
Virus isolation (VI) represents the gold standard and the official method for detection of AI 
viruses[2]. The method can be applied for all types of samples including clinical, laboratory, 
swabs, organs, faeces, and other organic and inorganic materials. The AIV are recovered from 
the specimens by one of the following methods a) classical culture of the AIV virus using 
specific pathogen free (SPF) egg; b) tissue culture based isolation. The classical culture method 
of AIV is viral propagation in embryonating SPF chicken eggs. The specimen with appropriate 
antibiotic medium is inoculated in the chorioallantoic sac (CAS) (Figure 3.1a) of 9-11 day-old 
fertilized egg and the infected eggs are incubated at 37°C for 4-7 days. After the incubation, the 
eggs are candled to test the survival of the embryos (Figure 3.1b). The allantoic fluid from the 
dead or dying embryos is harvested (about 10 ml) and used for further characterization of virus.  
 
a)                                                           b) 
 
 
 
 
 
 
Figure 3.1 a) Scheme of virus inoculation in to chorioallantoic sac of a embryonated chicken 
egg[49] b) Light shown over eggs to test their survival[50].  
 
For the tissue culture method, primary monkey kidney (PMK) or Madin-Darby canine kidney 
(MDCK) cells are widely used in the diagnostic laboratories for viral isolation. The cell lines 
support the growth of AIV (Figure 3.2). This method is simple and the cell lines are easy to 
maintain. In case of vaccine production for humans, the  propagation of the virus on MDCK cells 
is preferred since these cells resemble the original human isolate more closely than virus 
propagation in eggs[51]. Although the cell culture method can be performed in 24 hours, a 
superior growth of the AIV is achieved in embryonated eggs and therefore the method has been 
the choice for veterinary diagnostic[52].  
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Figure 3.2 A colorized transmission electron micrograph of Avian influenza A H5N1 viruses 
(seen in gold) grown in MDCK cells (seen in green)[53]. 
 
Virus isolation method is labour intensive and time consuming due to the handling of individual 
sample. Moreover, the method requires viable virus to be present in the sample. In some cases, 
the viral viability may be adversely affected by the sample collection, storage and transportation 
conditions which may lead to false-negative results[54]. Finally, virus isolation needs a higher 
level of biosafety level (BSL-3) laboratory facilities and special equipments.  
 
3.3 Haemagglutination assay 
Haemagglutination assay is commonly used to detect the propagation or presence of influenza 
virus in cell culture or SPF eggs by haemagglutinating activity. Haemagglutinin (HA) is one of 
the surface glycoprotein present on the envelope of Influenza virus particles. The HA binds to 
the erythrocytes through sialic acid receptors present on the cells surface forming a lattice. As the 
virus and erythrocytes contain multiple binding sites for each other, agglutination can be 
visualised and distinguished from other non agglutinated erythrocytes. The HA test is performed 
according to OIE standard method [55]. Initially, 25μl of PBS buffer is filled in every well of a 
microtitre 96-well V-bottomed plate. Then, 25μl of a virus sample is added in each well in the 
first row of the plate and a two fold dilution is made across each row for the entire plate. Finally, 
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25μl of 0.5% chicken red blood cells (RBC) is added to all the wells and the plate is incubated at 
room temperature for 30min. Results are read by tilting the plate 45 degrees and HA activity is 
determined by the formation of tear shaped streaming of RBC(Figure 3.3). The HA titre value is 
calculated as the highest dilution in which complete agglutination (no streaming) is observed and 
is represented as a HA units (HAU)[2]. The HA titre value can be used to describe the virus 
concentration[56;57]. The HA assay is relatively insensitive and requires a higher amount of 
virus (approx 107 particles) for one HAU[58].  
 
 
 
 
 
 
 
 
Figure 3.3 Haemagglutination assay(reproduced from ref[59]) 
  
3.4 Haemagglutination inhibition 
The HA subtype of the virus isolate is characterized by Haemagglutination inhibition (HI) assay. 
The HI test is also used to detect the specificity of antibodies of the HA subtypes which are 
produced in response to AIV infection. In the HI test, the antibodies bind to the virus/antigen and 
inhibit the formation of the agglutination with RBC’s (Figure 3.4)[60]. The HI titre is the 
reciprocal of the highest dilution of serum that inhibits the Haemagglutination completely. The 
HI assay is relatively easy and inexpensive to perform but the assay has low sensitivity. Since  
the HI titre depends on the virus antigen that can be highly variable within a subtype, the 
interpretation of the results is a challenge [61].  
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Figure 3.4 Haemagglutination inhibition assay[62]. A haemagglutination +ve reaction is formed 
when the blood cells and AIV bind to each forming a lattice. In the presence of antibodies 
specific to AIV subtype, the agglutination effect is inhibition (-ve reaction).  
3.5 Neuraminidase inhibition assay 
Like the HI assay, neuraminidase inhibition (NI) assay is performed to characterize the 
neuraminidase subtype of virus. Neuraminidase (NA) is a glycoprotein present on the surface of 
AIV that cleaves terminal sialic acid and releases AIV from the host cells. The viral 
neuraminidase activity is inhibited by antisera that are prepared against a NA antigen from 
reference strains [63]. In this method a fetuin substrate is added to the virus-antisera mixture and 
the released N-acetyl neuraminic acid (NANA) is determined by colorimetric assay of 
thiobarbituric acid (Figure 3.5). NI assay is cumbersome and requires large volume of multiple 
hazardous chemicals. The method is not suitable for large numbers of samples.  
 
 
 
 
 
 
 
Figure 3.5 Neuraminidase inhibition [64]. The inhibition of viral enzymatic acitivity by specific 
antibodies forms the basis of the neuraminidase inhibition assay. Interaction of free N-acetyl 
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neuraminic acid (NANA) with formylpyruvic acid and sodium arsenite for the formation of a 
pink chromophore. 
3.6 Agar gel immunodiffusion  
Agar gel immunodiffusion (AGID) is a serology test. The test is used to detect antibodies that are 
produced in response to an AIV infection. Unlike the HI assay, the AGID detects the antibodies 
against the AIV internal proteins; the NP and the matrix 1 (M1) protein. These proteins are 
antigenically similar in all AIV. The antigens (Virus) may be prepared by concentrating the virus 
from an AIV infective allantoic fluid or extracting the infected chorioallantoic membranes. 
These antigens are tested against known positive antisera [2].  
 
 
 
 
 
 
Figure 3.6 Agar gel immunodiffusion. Wells B and D are AGID negative reactions and all other 
wells are AGID positive reactions[65]. 
 
AGID is based on the formation of Immuno-precipitation. When an antibody and an antigen are 
placed proximity in agar wells; they diffuse and react with each other to form a visible white 
aggregate (Figure 3.6). A 1% agarose in 0.1M PBS buffer slide or plate is prepared and 
cylindrical wells with approximately 5mm in diameter and 2-5 mm apart are made in the agar. 
Fifty μl of sample, control and reference antibody are added to the cylindrical wells and the plate 
is incubated for 12 to 48h. After incubation, the formation of precipitin lines confirms the 
presence of the antibodies. AGID is a simple and inexpensive assay to perform but it is time 
consuming to detect some weak positive reactions. In addition, the amount of antibodies 
produced in immune response to AIV varies between species and this limits the sensitivity of the 
assay. Furthermore, the result of the assay only confirms the presence or absence of AIV rather 
than the subtype of the infected virus. The assay is therefore of less importance as a tool for AIV 
screening since several wild birds are known to be the natural reservoir of AIV[66].         
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3.7 Enzyme-Linked Immunosorbent Assay 
Enzyme-linked Immunosorbent Assay or ELISA is another serology test to detect antibodies, 
against AIV using colorimetric detection. In an antigen-capture ELISA, purified matrix or 
nucleoprotein antigens are attached to a 96-well microtitre flat-bottomed plate and the sample 
containing the antibody is applied over the surface so that it can bind to the antigen. A second 
enzyme linked antibody (the “detection” antibody) is added to the well to form a sandwich 
structure. Unbound products in each addition step are removed with a washing step. The assay is 
then quantified by measuring the amount of labelled antibody bound to the matrix, through the 
use of a colorimetric substrate (Figure 3.7).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7 Enzyme-linked Immunosorbent Assay[67] 
 
Antigen-capture ELISA is a fast, specific and inexpensive method that can be applied for large 
number of samples in routine diagnosis. Commercial ELISA kits are also available for the 
detection of influenza virus. The test of these kits are quick ( within 15 minutes) but are usually 
less sensitive  and are often for specific species [68;69]. An alternative to specific species 
antigen-capture ELISA is the competitive ELISA which can be applied  in case to detect diverse 
species such as chicken, ducks, swan, etc. [70;71].   
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3.8 AIV Inactivation 
Inactivation of AIV, especially HPAI viruses, is required to avoid the potential health hazard. 
The inactivated viruses are often used as materials in a development of methods for diagnosing 
AIV. As the AIV is a low thermal stable virus [72], the inactivation can be performed at 
temperatures above 50 °C [73]. Chemicals such as beta propiolactone or formaldehyde are 
commonly used for inactivation of the AIV. A combined effect of  heat and high hydrostatic 
pressure have also been reported to inactivate the AIV[74]. After the inactivation, the sample is 
often tested for infectious activity by inoculating in to SPF egg. The allantoic fluid from infected 
egg is harvested and tested for any AIV growth using HA assay and the AIV virus is considered 
inactive by a negative HA assay. Inactivation of virus is a critical requirement in the production 
of vaccine. 
 
3.9 Virus Quantification  
Quantification of viral particles in a sample is critical for investigations of their ecological role 
and the viral infection. The ability of virus to spread must, to some extent relate to the amount of 
virus released by the respiratory or intestinal route. The viral quantification can be classified in to 
two types: physical and biological assays[75]. The physical assays can only quantify the 
presence or absence of virus but  not the nature of infection; such methods are 
Haemagglutination tests, electron microscopic particle counts, optical density measurements or 
immunological methods[75]. The biological assays can quantify the viral infectious particles 
such methods are plaque assay, cell culture or in vivo (SPF eggs) virus cultivation. 
 
3.9.1 Plaque Assay  
The plaque assay is a standard method for determining and representing the quantification of the 
AIV in terms of infectious dose. The assay is based on the ability of a single infectious virus 
particle to produce a macroscopic area of cytopathology on a cultured cell monolayer called a 
plaque. Figure 3.8 shows the plaque assay used to quantify the virus from a sample. The sample 
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with unknown viral concentration is serially diluted in an appropriate medium and a known 
dilution volume is seeded onto confluent monolayer cell culture. 
 
Figure 3.8 Plaque assay method (reproduced from [76]) 
 
The infected cells are covered with a mixture of semisolid nutrient of the growth medium and 
agar and the plate is incubated at 37oC for several h. The semisolid medium prevents the 
secondary plaque formation through indiscriminated spreading of infection. In order to visualize 
the plaques formed, the monolayer cell culture is stained with dyes such as neutral red and 
subsequently enumerated (Figure 3.8). The concentration of virus is calculated from the dilution 
factor using the formula: 
No. of plaques  
d x V 
= pfu/ ml 
d= dilution factor 
V = volume of diluted virus added to the well 
 
The resulting plaque forming unit (pfu) per milliliter is the number of the infectious particles 
present in the sample. The plaque assay measures only the infectious particles and this can be a 
fraction of particles such as 1 in 10 to 1 in 10,000 from a given sample. This difference of 
infectious particle in sample could be due to a) damage of the virus particles while purification, 
b) presence of empty or defective particles or c) the virus requires a specific metabolic state of 
cell for infection. Errors are also inherent while performing a serial dilution of the sample[77].  
 
3.9.2 Infectious dosage determination 
This method can be performed using a cell culture (50% tissue culture infective dosage, TCID50) 
or an embryonated chicken egg (50% egg infective dosage, EID50). In both cases the sample 
Plaque 
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containing virus is serially diluted. Each dilution with multiple replicates is inoculated in to the 
cell culture or the egg at 37oC and incubated for 3 or 4 days. The results of the tests are 
calculated based on the observation of the cytopathic effect in the cultured cells or the death of 
the embryonic in the viral inoculated eggs. An index is calculated from the observation of 
percentage for positive and negative infection above 50% of dead embryo’s using Reed-Muench 
formula[78]:   
 
Index  =                 (% of positive infection above 50%) – 50%                                                                                                      
               (% of positive infection above 50%) - (% of positive infection below 50%) 
 
This index number is applied to the dilution of virus that produced positive infection 
immediately above 50 percent. For e.g., if the 10-6 dilution cause positive infection immediately 
above 50 percent, the index number say 0.7 is applied to this dilution and expressed as 
106.7EID50/ ml or TCID/ ml. 
 
Several research groups working with virus use different quantification method to express the 
amount of viruses used in their studies. Although a one-to-one correlation between the various 
quantitative assays is not possible, the difference in magnitude of detection between the assays is 
as below[77]. 
 
 
  
 
 
 
 
 
  
Method Amount (per milliliter) 
Egg infectious dosage method 109 EID50 
Plaque formation method 108 PFU 
Haemagglutination assay 103 HA units 
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Chapter 4 
4 Molecular Diagnostics 
Classical methods for detection and identification of AIV samples are time consuming (4-10 
days), laborious, expensive, and require special laboratory facilities and trained staff. Over the 
last decade, the use of molecular methods based on nucleic acid amplification for genetic 
identification have improved the sensitivity and speed for diagnosis of AIV [79].  
 
4.1 RT-PCR 
Polymerase chain reaction (PCR) is a powerful molecular technique, which is widely used to 
amplify a single or few copies of DNA to several-million-fold or more copies (Figure 4.1). To 
utilize the technique for AIV detection, a copy of DNA, complimentary (cDNA) to viral RNA is 
synthesised using a reverse transcriptase (RT) enzyme and random hexanucleotides or a 
sequence specific primer. The sequence of interest located within the cDNA is amplified using a 
heat stable polymerase enzyme from the bacterium Thermus aquaticus (TAQ) and primers. The 
sequence is selected by these primers which binds to the target region and serves as a starting 
point (3'-end of the primer) for DNA synthesis. 
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Figure 4.1. Reverse transcriptase polymerase chain reaction (from ref [80]). a)The first strand of 
cDNA is synthesized using RT enzyme, which adds complementary nucleotide bases to the RNA 
strand at the primer annealing site creating a strand of cDNA (b). In the PCR reaction (c), Taq 
polymerase adds complementary nucleotides beginning at the primer annealing site and a double 
stranded cDNA is produced (d). The three step process of denaturation, primer annealing and 
extension are repeated for 30-40 cycles (e) to yield over billion copies of double stranded DNA 
molecules identical to the initial template RNA fragment.  
 
The RT step can be performed either as a separate reaction (two-step PCR) [81] or along with 
PCR reaction in one tube (one-step PCR) using a temperature between 45 °C and 60 °C 
depending on the properties of the reverse transcriptase. The amplification of a DNA sequence 
typically involves 30-40 PCR cycles and each cycle requires three steps: denaturing, annealing 
and extension. In the first denaturing step, the double stranded DNA (dsDNA) is melted at 
approximately 94ºC to form single strands DNA (ssDNA). In the annealing step the specific 
primers binds (anneal) to the single strands of the target DNA. The annealing temperature is 
normally between 50 ºC to 65 ºC depending on the length and on the guanine/cytosine (GC) 
content of the selected primers. Finally, the extension step where the TAQ polymerase adds 
deoxynucleotide triphosphate bases (dNTP’s) to the primer on the 3' side takes place. The 
extension occur around 72ºC at 50-100 nucleotides per sec.  
 
Depending on the aim of the study to detect, different genes of AIV are selected as the target for 
RT-PCR to detect AIV.  The presence of AIV can be confirmed by targeting highly conversed 
genes in all influenza A viruses such as matrix (M) [82] or  nucleoprotein (NP) [83;84]. Fouchier 
et al., [82] first designed  a  set of primers, M52C and M253R, of matrix gene and used for 
diagnosis purpose. The PCR end point analysis was performed by gel electrophoresis. The 
method was used for clinical diagnostic and was found to be about 100-folds more sensitive than 
the classical virus isolation method. This increased sensitivity of 100-fold is likely due to the 
detection of RNA from incompletely packaged virus particles or viral RNA from infected 
cells[85].  
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4.2 Real time RT-PCR  
Conventional end-point RT-PCR has several disadvantages such as time consuming, non-
automated method with risk of cross-contamination. In order to overcome these disadvantages, a 
real-time RT-PCR (rRT-PCR) approach was introduced to detect AIV. The rRT-PCR eliminates 
the post-amplification steps increasing the reliability and reproducibility of the assay. In rRT-
PCR the amplified DNA is detected by monitoring the fluorescence emitted as the reaction 
progresses in real time. The two common methods used for detecting PCR product are a) non-
specific intercalating dye (e.g. SYBR green) which becomes fluorescent when binding to double 
stranded DNA and b) sequence specific approach using TaqMan probes. The TaqMan probes are 
oligonucleotides longer than the primers and are designed to anneal to an internal region of a 
PCR product to increase the specificity of real-time PCR assays. TaqMan probes contain a report 
dye on the 5' base and a quenching dye on the 3' base.  
 
 
Figure 4.2 Real time RT-PCR with TaqMan probe (from ref[86]) 
 
While the probe is intact, the close proximity of the reporter and quencher prevents the emission 
of fluorophore via fluorescence resonance energy transfer (FRET). During the primer extension 
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step, the 5' exonuclease activity of Taq polymerase cleaves the 5’ end of probe which contains 
the reporter dye. This separates the reporter from the quencher and the reporter starts to emit 
fluorescence. The flurescence intensity increases in each cycle and is proportional to the amount 
of amplified DNA (Figure 4.2). The rRT-PCR assay is characterized by a wide dynamic range of 
quantification of 7 to 8 logarithmic decades, a high technical sensitivity (< 5 copies) and a high 
precision (< 2% standard deviation)[87;88]. A single-step RT-PCR method also greatly reduces 
the risk of cross contamination since it is a closed system once the template is added. 
The application of real-time RT-PCR detection for identifying the AIV  based on TaqMan probe 
chemistry was first described by Spackman et al.,(2002) [89]. The limit of detection in the assay 
is 1000 copies of target RNA, which is equivalent to 0.1 EID50 of virus. The matrix gene rRT-
PCR was evaluated as highly sensitive, specific for AIV and selected as a method for 
surveillance by Avian influenza reference laboratories [90].  
4.3 Subtyping AIV by RT-PCR 
The molecular basis for subtyping of AIV is the antigenic differences of HA and NA. The amino 
acid sequence between H1 and H12 subtypes varies from 20% to 74% compared to 0-9% 
variation among the same subtypes [91]. As the amino acid sequences are determined by the 
nucleotide sequences, the presence of wobble in the codon usage (for e.g., Arginine can be CGU, 
CGC, CGA, CGG, AGA or AGG) will increase the difference in nucleotide sequences between 
HA subtypes to more than 20–74% [83]. Using conventional RT-PCR, Lee et al.,(2001)[83] 
designed the first subtype specific primers that were able to differentiate fifteen subtypes (H1–
H15) of the AIV viruses. It has been showed that this method had a 100% correlation with the 
results of serological methods. The major advantage of this method is the reduction of testing 
time from one week (HI typing) to one day. Additionally, the PCR product could be used for 
sequence comparison and phylogenetic analysis which provide important information on the 
origin of the studied strain.  
 
Among the sixteen HA subtypes of the AIV (H1-H16), H5 and H7 are the two known subtypes 
which are responsible for high pathogenicity. So the identification of these subtypes in the 
sample has been prioritised in AIV diagnosis. The detection and differentiation of H5 and H7 
have been developed using both conventional RT-PCR (Starick et al.,(2000)[81], Munch et al., 
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(2001))[84] and  real-time RT-PCR (Spackman et al.,(2002) [92]. The developed rRT-PCR has 
been used for the quantification and competitive replication studies of AIV H5 and H7 subtypes 
[93]. The quantitative rRT-PCR demonstrated high correlation between the amount of viral RNA 
determined by quantitative rRT-PCR and the virus titre determined by virus isolation method 
using SPF eggs. The use of rRT-PCR for AIV quantification greatly reduces the risky handling 
of infectious materials. However, the rRT-PCR can only quantify the presence or absence but not 
the viability of the virus.  
4.3.1 Primer/probe adaptation  
The phylogenetic analysis of HPAI viruses of H5 and H7 subtype showed two geographically 
distinct lineages of North American and Eurasian viruses[94;95]. The primers and probe 
sequences designed by Spackman et al., (2002) were optimally designed to detect North 
American H5 and H7 and failed to detect some of Eurasian H5 and H7 subtypes[90]. So 
modifications have been made to originally design, validate and shown to sensitively detect all 
H5 Eurasian lineages[96]. Adaption of primers and probe are also needed if some new AIV’s 
emerge with genetic variation that could affect the primer and/or probe binding sequences[97]. 
Such a case has been observed with H7 American lineage, when the 2002 H7 test does not have 
adequate specificity [98].  So a new test, the 2008 Pan-American H7 test, was developed by 
using recently available H7 nucleotide sequences. These data highlight the importance of 
continued monitoring of rRT-PCR primers and probes to ensure that sensitivity and specificity 
are maintained. It is important to employ validated and updated methods from the OIE (world 
organisation for animal health) reference laboratories in the diagnosis of a HPAI outbreaks[97]. 
 
4.4 Multiplex-RT-PCR 
Multiplexing RT-PCR consists of simultaneous amplifications of more than one target using 
multiple primer sets in a single reaction. The produced RT-PCR amplicons vary in sizes that are 
specific to different DNA sequences. The advantages of the multiplex RT-PCR are rapid, 
sensitive, specific, and cost effective detection. Several multiplex RT-PCRs have been developed 
in the past decade. A two step reaction of a multiplex conventional RT-PCR for identification of 
influenza AIV and simultaneous subtyping of H1N1 and H3N2 subtypes were developed  
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(Stockton et al.,1998) [99] and  further utilized for a one step detection of H1N1, H3N2 and 
H5N1 subtypes (Poddar et al. 2002) [100]. Other multiplex conventional RT-PCR for subtyping 
of H5, H7 and H9 subtypes have been reported[101;102]. 
 
The multiplex rRT-PCR assay using TaqMan probes labelled with two or three different reporter 
dyes for the simultaneous detection of combination of H5-H7[103], Matrix-H5-H9 [104] and 
Matrix-H5-N1 [105;106] genes have been developed. Recently,  Hoffmann et al., (2008) 
developed a new rRT-PCR for rapid detection of H5 specific subtype and also for pathotyping of 
HPAI H5N1 of the Qinghai lineage[107]. In that study, a set of primers and two probes were 
designed for the amplification and detection of a fragment spanning the cleavage site HA0 
sequence of the HA gene of H5 subtype. One probe was designed to target a sequence 
reasonably conserved among various H5 strains and the second probe was specific for the 
cleavage site sequence of H5N1 isolates of the Qinghai lineage. This assay offers an alternative 
method to conventional sequencing for identifying HPAI H5 virus.  
 
Overall the methods based on rRT-PCR multiplexing offer rapidity and accuracy and are 
therefore attractive for large-scale screening of suspected cases of influenza A virus subtype of 
H5, H7 or H9 in order to control potential outbreaks. However, the use of two or three 
fluorophore dyes increases the complexity in the detection system and it become more 
expensive[108].   
 
4.5 DNA Microarray  
The molecular detection of AIV by RT-PCR always needs an extra step to confirm the desired 
target, which has been amplified, by methods such as gel electrophoresis, fluorogenic PCR or 
DNA sequencing. However, such methods are difficult to use for multiplex purposes [109].  
Another approach for identification of PCR amplicon in multiplex assays is the use of DNA 
microarray. It consists of a solid support onto which arrays of spots from hundred to many 
thousands of oligonucleotides or capture-probes are fixed in an area of 1–2-cm2[110]. These 
spots contain multiple copies of capture-probes (CP) and the spots can range in size from 10 to 
500 microns. The CP can bind specifically to the target and the binding is detected using a 
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reporter molecule (e.g. fluorescent dye) of the target DNA sequence (Figure 4.3). The successful 
implementation of microarray technologies has required the development of many methods and 
techniques for fabricating the microarrays and spotting the CP, target preparation, hybridization 
reactions, and data analysis [110]. The DNA microarray enhances the assay capabilities by 
detecting multiple targets in parallel, and being more sensitive and specific. 
 
Figure 4.3 DNA microarray (reproduced from ref[111]) 
The first study on microarray for AIV detection was reported by Wang et al.,(2008) [112]. In that 
method the detection of H5 and H7 of AIV and NewCastle Disease virus (NDV) was made using 
PCR products of a multiplex RT-PCR. Using this method, the viruses were both detected and 
type classified. No cross-reactions were found and the sensitivity of the oligonucleotide 
microarray was ten to 100 times higher than the PCR end-point analysis by agarose gel 
electrophoresis. The hybridization signals on the microarrays were determined by colorimetry 
and identified using the naked eyes without any additional imaging equipment. Using DNA 
microarrays, Han et al., [113] reported simultaneous subtyping of all influenza A viruses i.e., 
sixteen serotypes of HA (H1–16) and nine (N1–9) of NA that have been identified in mammalian 
and avian species. In that study, an asymmetric multiplex PCR with 25 sets of primers was 
carried out in four separate reactions (50 µl each) and the amplified target cDNA’s (fluorophore 
labelled) were hybridized over the immobilized capture-probes.  By this approach, all subtypes 
were identified with high sensitivity (2.47 PFU/ ml) and the results were consistent with that of 
the virus isolation method. However, the hybridization procedure used in that method involved 
several steps and it was time consuming (3h)[114]. Moreover, considering the variability 
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between and within different HA and NA gene subtypes among the lineages, the designed 
capture-probe and oligonucleotide needs further optimization.  
 
Recently, an electronic DNA microarray system (NanoChip 400 system (Nanogen Inc.)) San 
Diego, USA) has been used for fast detection of AIV as well as HA subtyping, and pathotyping 
[115]. In the assay, one-step amplification of HA0 cleavage site of all the 16 HA subtypes and 
matrix gene-specific of AIV were performed.  The developed microarray comprised of 97 CP 
designed for HA subtyping. These CP targeting the HA0 cleavage site are conserved within a 
given subtype and have variation between subtypes. These CP can also distinguish between 
HPAI and LPAI viruses. One CP was designed to target the M-gene to identify AIV. The method 
was extensively validated with a high specificity and a high sensitivity (of 101 to 102 copies). 
This low-density microarray can be an approach to the problem of AIV classification and could 
be used as a diagnostic tool for the detection and typing of AIV.  However, the method uses 
expensive equipment and it involves long processing steps. So far there had been no rapid, and 
inexpensive assay reported for subtyping using microarray. 
 
4.6 Sample preparation 
Nucleic acid amplification methods based on RT-PCR need a preparation of AI viral RNA from 
clinical samples suitable for detection. The different types of samples used for AIV diagnostics is 
mentioned earlier (Section 3.1) which includes swab, either oropharyngeal or cloacal, and faecal 
dropping. Among them, faeces are more accessible and often the only specimens available for 
routine surveillance work[116]. The faecal sample contain complex mixtures of host cells, 
microflora, bile salts, complex polysaccharides and other materials that have been show to be  
PCR inhibitors[117;118]. The presence of these inhibitors that either inactivates the Taq 
polymerase or degrades the nucleic acid in the sample limits the detection and the efficiency of 
the test [119;120].  Sample preparation is therefore an important step which is always required 
for removing inhibitors and to obtain reliable diagnosing results. Other important objectives of 
sample preparation are to reduce the sample volume, to concentrate the total RNA into a 
workable volume and to homogenize sample for a reproducible and repeatable test[118].   
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The extraction of RNA from samples is more difficult than that of DNA, as RNA is considerably 
less stable than DNA. Samples such as tracheal/oropharyngeal swabs contain low cellularity and 
RNA can easily be extracted. In contrast, cloacal swabs, tissue and faecal samples contain higher 
level of organic materials, cells, bacteria and tissues containing ribonuclease (RNase) enzymes 
that can rapidly degrade RNA into smaller components [121;122].  
The most widely used method for extraction of RNA from AIV is based on a silica column 
extraction kits that are commercially available as shown in Figure 4.4. The advantages of column 
based extraction are removal of PCR inhibitors and a homogenous RNA with high quality. The 
drawback of the method however, is laborious and has a limited throughput capacity and batch-
to-batch variation may exist in quality and quantity of the template[118].   
 
 
 
 
 
 
 
 
Figure 4.4 Scheme representing RNA extraction using RNeasy Kit, Qiagen [123] 
 
A magnetic bead based RNA extraction has been introduced with automated platforms for 
pathogen detection[124;125]. Magnetic carriers prepared from a biopolymer exhibiting affinity 
to the target nucleic acid are used for the extraction process as shown in Figure 4.5.  The 
magnetic bead based extraction method is a simple and efficient way to separate the RNA from 
PCR inhibitors.  It also takes less time compared to column based extraction method due to the 
fewer manipulation steps and no centrifugation. Magnetic beads can be used for larger volume of 
sample up to 10 ml (with working volume upto 50 ml) and the purified RNA can be down scaled 
to 5 to 50μl.  
 
 
 
 
 
 
 
Figure 4.5 Magnetic bead based extraction method (reproduced from ref[126]) 
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Tewari et al., (2007) used silica-based magnetic beads with robotics for extraction of RNA from 
AIV and obtained a sensitivity and specificity comparable to virus isolation and manual silica 
column extractions[127]. The main advantages of the automated robotic viral nucleic acid 
extraction are high throughput processing; hands-free operation; and reduction in human and 
technical errors. However, the robotic system is expensive and for laboratories with limited 
resources and/or lower sample volumes, the column extraction kits are required. The robotic 
method was only demonstrated for easily extractable sample such as tracheal swabs and allantoic 
fluid (virus isolation) and not for faecal sample. 
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Chapter 5 
5 Point-of-care diagnosis 
In both classical and molecular diagnosis, transportation of sample to the nearest reference or 
diagnostic laboratory is needed, and this will increases the time for diagnostic result. The 
continuing spread of Asian avian influenza H5N1 since 2003 highlights the need for a point-of-
care (POC) diagnosis. The POC is defined as a diagnostic testing at or near the site of patient, 
and the test results will be available instantly or in a very short time that can improve medical 
decision-making[128]. A list of commercially available POC tests for influenza virus is shown in 
Table 5.1[129]. These tests are largely immunoassays which detect influenza viral antigen and 
are used for screening of influenza A and B virus infections within 5-30minutes. The accuracy of 
these POC test is determined by the sensitivity and specificity which is percentage of “true 
influenza cases” and “true non-influenza cases” detected as positive and being negative by a test 
respectively. In general, the sensitivity of POC tests is variable (29 -100 %) and in some cases 
the sensitivity is lower than that of the cell culture, while their specificity is a little higher (80%). 
A major concern for  using these tests is the possibility of  false negative results due to the low 
sensitivity of the tests [68;69]. Miniaturization of the molecular diagnostics using Lab-on-a-
chip’(LOC) systems could provide the next-generation point-of-care diagnosis with a high 
sensitivity and specificity [128;130;131].  
 
Table 5.1 A list of commercially available point-of-care test for influenza virus[129] 
Test 
Name*  
Manufactu
rer  
Influe
nza 
Type  
Differen
tiate 
Between 
A and 
B?  
Storage 
Requirement; 
Storage Life  Acceptable Specimens  
Assay 
Time  
 
 
General 
Ease of 
Use  
Sensitivity  Specificity  
Binax 
NOW Flu 
A and Flu 
B  
Binax Inc., 
Portland, 
ME. 
www.binax
.com  
A and 
B  Yes  
15-30 º C, 1 
year  
Nasal wash, 
nasal aspirates, 
nasopharyngeal 
swabs  
15 
min  Easy  
A: 52-82%  
B: 54- 
100%  
A:92-94%  
B: 58-71%  
  
Binax Now 
Influenza A 
& B  
Binax Inc., 
Portland, 
ME.  
A and 
B  Yes  
15-30 º C, 1 
year  
Nasal wash, 
nasal aspirates, 
nasopharyngeal 
swabs  
15 
min  Easy  
A: 100%  
B:92-100%  
A: 92-93% 
B:94-99%  
Point-of-care diagnosis 
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Directigen 
Flu A  
Becton 
Dickinson, 
Franklin 
Lakes, NJ. 
www.bd.co
m  
A  Detects A only  
15-30 dgrs C, 
twelve months  
Naso-
pharyngeal 
wash, 
nasopharyngeal 
aspirate, 
nasopharyngeal 
swab, 
pharyngeal 
swab  
 15 
min  
Moderat
e  67- 100%  88-100%  
Directigen 
Flu A+B  
Becton 
Dickinson, 
Franklin 
Lakes, NJ. 
www.bd.co
m  
A and 
B  Yes  
2-25 º C, 
twelve months  
Naso-
pharyngeal 
wash, 
nasopharyngeal 
aspirate, 
nasopharyngeal 
swab, lower 
nasal swab, 
throat swab, 
bronchoaveolar 
lavage  
 15 
min  
Moderat
e  
A: 55-
100%  
B: 29-88%  
A: 99.6%  
B:93100%  
Flu OIA  
Biostar, 
Inc., 
Boulder, 
CO 
www.biosta
r.com  
A and 
B  No  2-8 º C, 1 year  
Throat swabs, 
nasopharyngeal 
swabs, nasal 
aspirates, 
sputum  
20 
min  
Moderat
e  46-100%  52-97%  
QuickVue 
Influenza 
Test  
Quidel, San 
Diego,CA. 
www.quide
l.com  
A and 
B  No  
15-30 º C, 2 
years  
Nasal swab, 
nasal wash, 
nasal aspirate  
 10 
min  Easy  AB:55-91%  AB:83-99%  
QuickVue 
Influenza 
A+B  
Quidel, San 
Diego, CA. 
www.quide
l.com  
A and 
B  Yes  
15-30 º C, 2 
years  
Nasal swab, 
nasal wash, 
nasal aspirate  
 10 
min  Easy  
A:72-77%.  
B: 73-82%  
A: 96-99%.  
B: 96-99%.  
Influ AB 
Quick  
,Denka 
Seiken Co., 
Ltd Japan 
www.denka
seiken.co.jp  
A and 
B  Yes  
2-30 º C, 10 
months  
Nasal swab, 
nasal aspirate  
 15 
min  Easy  
   
A:55-93%. 
 B: 63-93%  A: 98-99%.  B: 98-99%.  
Quick S-
Influ A/B 
"Seiken"  
,Denka 
Seiken Co., 
Ltd Japan 
www.denka
seiken.co.jp  
A and 
B  Yes  
2-30 º C, 10 
months  
Nasal swab, 
nasal aspirate  
 25 
min  Easy  
A: 81-93%.  
B: 88-93%.  A: 96-99%.  
B: 98-
99%..  
Xpect Flu 
A & B  
Remel Inc., 
Lenexa, 
KS, USA 
www.remel
inc.com  
A and 
B  Yes  
2-25 º C, 12 
months  
Nasal wash, 
Nasopharyngeal 
swabs, throat 
swabs, tracheal 
aspirates, 
sputum,   
 15 
min  
Moderat
e  
A: 89-
100%  
B: 93-
100%  
 
A: 100%  
B:  100%  
 
Wampole 
Clearview 
Flu A/B  
Fisher 
Scientific, 
USA 
www.fisher
sci.com  
A and 
B  Yes  
 2-25 º C, 12 
months  
(1) Nasal wash, 
Nasopharyngeal 
swabs, throat 
swabs  
 15 
min  Easy  
A:92%  
B:98%  
A:100% 
B:100%  
ZstatFlu-II 
test  
Zyme Tx, 
Inc., 
Oklahopma 
City, OK. 
www.zyme
tx.com  
A and 
B  No  
 
Throat swab   30 min  Easy  
A:76%  
B: 41%  7798%  
Influ-A 
Respi-Strip  
Coris 
BioConcept
, Belgium 
www.coris
bio.com  
A  No   4-37 º C, 12 months  
Nasopharyngeal 
swabs  
 5-15 
min  
Moderat
e  A: 91%  A: 86%  
Influ-A&B 
Respi-Strip  
Coris 
BioConcept
, Belgium 
A and 
B  Yes   4-37 º C  
Nasopharyngeal 
aspirates, 
washings or 
 5-15 
min  
Moderat
e  
A: 99%  
B: 72.2%  
A:88% 
B:100%  
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www.coris
bio.com  
swabs  
Espline 
Influenza 
A&B-N  
Fujirebio 
Inc., 
Tokyo, 
Japan 
www.fujire
bio.co.jp  
A and 
B  Yes  
 
Nasal aspirates/ 
swabs, Throat 
swabs  
 15 
mins  
Moderat
e  
A:85100%  
B:72-91  
A/B:98-
100%  
Capila 
FluA,B  
Tauns Co., 
Ltd., Japan  
A and 
B  Yes  
 Nasal 
aspirate/swab, 
pharyngeal 
swab  
 15 
mins  Easy  
A:69-94%  
B: 81-96%  
A:93-95%  
B: 96-99%   
RapidTesta 
FLU AB  
Daiichi 
Pure 
Chemicals 
Co., Tokyo, 
Japan  
A and 
B  Yes  
 2-30 º C, 12 
months  
Nasal aspirates/ 
swabs  
 10 
mins  Easy  
A:82-83%  
B:80-83%  
A:98-99% 
B:98%  
SAS 
Influenza A 
Test  
SA 
Scientific 
Inc, USA  
A and 
B  Yes  
 Nasal 
wash/aspirate  
 30 
mins  Easy  
  
ImmunoCa
rd STAT! 
Flu A&B  
Meridian 
Bioscience,
Inc  
A and 
B  Yes  
 2-25 º C, 12 
months  
Nasal wash, 
Nasopharyngeal 
aspirate/swabs,
nasal swabs  
15-20 
min  Easy  
A:83%  
B:100%  
 A:98% 
B:100%  
Wampole 
Clearview 
Flu A/B  
Fisher 
Scientific, 
USA 
www.fisher
sci.com  
A and 
B  Yes  
 2-25 º C, 12 
months  
(1) Nasal wash, 
Nasopharyngeal 
swabs, throat 
swabs  
15 
min  
 
A:92%  
B:98%  
A:100% 
B:100%  
ZstatFlu-II 
test  
Zyme Tx, 
Inc., 
Oklahopma 
City, OK. 
www.zyme
tx.com  
A and 
B  No  
 
Throat swab  30 min  Easy  
 A:76% 
 B: 41%  77-98%  
Influ-A 
Respi-Strip  
Coris 
BioConcept
, Belgium 
www.coris
bio.com  
A  No   4-37 º C, 12 months  
Nasopharyngeal 
swabs  
 5-15 
min  Easy  A: 91%  A: 86%  
Influ-A&B 
Respi-Strip  
Coris 
BioConcept
, Belgium 
www.coris
bio.com  
A and 
B  Yes   4-37 º C  
Nasopharyngeal 
aspirates, 
washings or 
swabs  
 5-15 
min  Easy  
A: 99%  
B: 72.2%  
A:88% 
B:100%  
Espline 
Influenza 
A&B-N  
Fujirebio 
Inc., 
Tokyo, 
Japan 
www.fujire
bio.co.jp  
A and 
B  Yes  
 
Nasal aspirates/ 
swabs, Throat 
swabs  
 15 
mins  
 
A:85100%  
B:72-91  
A/B:98-
100%  
Capila 
FluA,B  
Tauns Co., 
Ltd., Japan  
A and 
B  Yes  
 Nasal 
aspirate/swab, 
pharyngeal 
swab  
15 
mins  Easy  
A:69-94%  
B: 81-96%  
A:93-95%  
B: 96-99%  
 
RapidTesta 
FLU AB  
Daiichi 
Pure 
Chemicals 
Co., Tokyo, 
Japan  
A and 
B  Yes  
 2-30 º C, 12 
months  
Nasal aspirates/ 
swabs  
10 
mins  
 
A:82-83%  
B:80-83%  
A:98-99% 
B:98%  
SAS 
Influenza A 
Test  
SA 
Scientific 
Inc, USA  
A and 
B  Yes  
 Nasal 
wash/aspirate  
30 
mins  
Moderat
e  
  
ImmunoCa
rd STAT! 
Flu A&B  
Meridian 
Bioscience,
Inc  
A and 
B  Yes  
 2-25 º C, 12 
months  
Nasal wash, 
Nasopharyngeal 
aspirate/swabs,
nasa l swabs  
15-20 
min  Easy  
A:83%  
B:100%  
 A:98% 
B:100%  
  
 
 
35 
 
5.1 Lab-on-a-chip 
Lab-on-a-chip (LOC) is an integrated microfluidic device that contains one or several laboratory 
functions on a single chip of only millimetres to a few square centimetres in size. The integrated 
microfluidic system with active or passive fluid control components for sample valving, 
pumping, mixing, etc., improves the functionality and reliability of LOC devices. The ability of 
these devices to conduct measurements from small volumes of complex fluids with efficiency 
and speed, without the need for a skilled operator, has been regarded as the most powerful 
application of LOC technologies[131].  
 
The different steps of a molecular diagnostic LOC device are sample preparation, amplification 
and detection. Conventional PCR amplification is performed in a thermocylers that is based on 
Peltier element technology (Figure 5.1a). A 96- or 384-well plastic PCR plate is thermally cycled 
in a heating block made of thermal conductive metals and the reaction volume is between 10 and 
50μl. Cycling is achieved by heating and cooling the massive metal block with a maximum 
temperature ramp of 1–3 oC/s. A large heat capacitance is required for homogeneity across the 
whole plate, resulting in slow PCR cycles.  
 
     a)                                                b)  
   
 
:  
 
 
 
Figure 5.1: PCR thermocyclers a) A conventional PCR thermocyclers (MJ Research Inc., 
Waltham, MA, USA) and b) A miniaturized PCR thermocyclers[132].  
 
By shrinking the sample volume, the over all heating and cooling rate becomes faster [133].   A 
variety of miniature PCR systems have been developed with fast heating (>10 oC/s) for efficient 
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amplification [134].  These miniaturized devices (Figure 5.1b) have the following 
advantages[135]: 
 Shorter diagnosis times due to faster heating/cooling times, a high surface-to-volume 
ratio and a smaller thermal capacitance. 
 Lower sample and reagent consumption (usually <10 μl) 
 Improved resolution and higher sensitivity: massively parallel processing steps can be 
integrated into a microchip, which allows high-throughput analysis and more sensitive 
analytical results at the molecular level. 
 Lower per unit cost: lower fabrication cost based on mass production allowing for cost-
effective, disposable chips (single-time use). 
 High-throughput automated analysis 
 Minimum variability 
 
Several comprehensive reviews were made on miniaturized PCR devices covering the 
fabrication techniques, PCR reaction speed, PCR inhibition and carryover contamination 
[134;136-138]. Over the years the fabrication material for PCR chambers or channel has been 
changing from glass and silicon to polymers due to the effort to minimize the fabrication cost 
(disposable chips). The commonly used polymers are SU-8, polydimethylsiloxane (PDMS), 
polycarbonate (PC) and polymethylmethacrylate (PMMA) and cyclic olefin copolymer (COC).  
5.1.1 Microfluidics 
Microfluidics deals with the behaviour, precise control and manipulation of fluids that are 
geometrically constrained to a small, typically sub-millimetre scale. The down scaling of the 
dimensions in the fluidic system increases the surface-to-volume ratio (SVR) and changes the 
behaviour of the fluids. The large SVR of a microfluidic chip permits rapid thermal cycling and 
also increases the interaction possibility between the analyst molecules and the surface of 
receptor molecules. The large SVR also increseases the non-specific binding and often causes 
inhibition of PCR reaction[139].  
 
In microfluidic channels, mass transport is dominated by viscosity with inertial effects becoming 
negligible. As inertia is responsible for most of the instabilities and chaotic behaviour observed 
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in fluids, its reduced influence within micron scale systems leads to a simplified flow regime. 
The Reynolds number (Re), defined as the ratio of the inertial properties of the fluid to the 
viscous (η) properties of a fluid flow describes the flow regime as either laminar or turbulent.  
 
Re = ρ ν D 
       η 
 
where ρ is the density of the fluid, ν is the velocity of the fluid and D is the hydraulic diameter of 
the flow channel. Re < 2300, as calculated by the above formula, generally indicates a laminar 
flow. As Re approaches 2300, the fluid begins to show signs of turbulence, and at Re greater 
than 2300 the flow is considered to be turbulent. For the microfluidic channel, with at least one 
characteristic dimension in the micrometer range and with fluid flow velocities in the millimetre 
to centimetre per second, the flow is generally in the low Reynolds number regime (Re <<1). 
The laminar flow provides a means by which molecules can be transported in a relatively 
predictable manner i.e., the position of a particle in the fluid stream as a function of time[140]. 
 
The common method used for fluid actuation through microfluidic channel is pressure driven 
flow. This is done via positive displacement pumps, such as syringe pumps. The pressure driven 
laminar flow produces a no-slip boundary condition where the fluid velocity at the walls is zero 
and a maximum flow velocity at the channel centre. This condition results in Poiseuille-type 
flow, characterised by a parabolic velocity profile across the channel (Figure 5.2)[141]. 
 
 
 
 
 
 
Figure 5.2  A parabolic fluid velocity profile in a microfluidic channel resulting from pressure-
driven fluid[141].  
 
Pressure driven flow can be a relative inexpensive and quite reproducible approach to pumping 
fluids through microdevices.  
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5.1.2 Integrated system 
Although partially integrated PCR chips have been successfully developed, the total integrated 
PCR-based LOC still requires further development. Two main challenges that delay the 
realization of a truly and highly integrated PCR chip are on-chip sample preparation and on-chip 
detection steps. The on-chip sample preparation with crude sample such as faeces is more 
complex than for detecting purified analytic targets, because of the multiple preparing steps that 
should be required for complex crude sample. The miniaturization of sample preparation and 
functionalities on a chip remain a challenge in the development of point-of-care nucleic acid 
based assay for resource limited settings[137;142;143].  Many PCR chips have been developed 
for rapid amplification but in most of those studies the PCR product were analyzed off-chip by 
gel electrophoresis or fluorescence microscopes [144]. Although few reports on miniature real 
time PCR on chip have been made, significant advances are needed to reduce the cost, physical 
size and power requirement of the conventional detector suitable for integration and multiplex 
detection.  
 
5.1.3 Magnetic beads 
The challenge in the integration of sample preparation has been addressed using magnetic bead-
labelled with biomolecules to enhance the specific separation and purification of the target [145].  
In molecular diagnostics, magnetic beads have been applied in sample preparation and nucleic 
acid purification for PCR. The benefits of using magnetic beads in these steps are the  removal of 
PCR inhibitors and concentration of target pathogen from  a large sample volume (up to 10 ml) 
to workable volume (10-50μl)[146]. The use of magnetic beads allows high sample throughput 
and automation with reduced reagent costs and elimination of labour intensive steps. Magnetic 
beads have several advantages that include, simple and fast with only a few handling steps in 
comparison with standard separation procedures.  
 
A number of magnetic beads are commercially available on the market with different 
characteristics such as surface chemistry, size, and the binding properties to ligands and target 
molecules [126;147].  The magnetic bead consists of a magnetic core (single or multiple) 
encapsulated in a polymer shell (Figure 5.3a and b). The core provides the magnetic 
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characteristics of the bead while the polymer (typically polystyrene) prevents the direct contact 
of biomolecules with the magnetic material and provides the beads with a biocompatible surface.   
 
   a)                                                  b)                                  c) 
  
 
 
 
 
 
Figure 5.3 Configuration of magnetic beads: a) single-core and b) multi-core (reproduced  from 
ref[148]). (c) Scanning electron microscopy picture of magnetic beads from Dynabeads, 
Invitrogen [149]. 
 
The commonly used magnetic cores are inorganic nanoparticles such as iron oxide (maghemite 
or magnetite) or other more complex metal-iron oxide alloys (e.g. Nicol or Cobalt-iron-oxide). 
The diameter of these nanoparticles (magnetic core) varies between 20nm to 200nm. There are 
different functional groups such as -COOH, -OH or -NH2 available on the surface of magnetic 
particles (polymer shell). These functional groups are used for immobilization of ligand such as 
antibody, protein or antigen, and DNA/RNA capture-probe to capture the desired target. In some 
cases, the magnetic beads  are available in the activated form (e.g., tosylactivated, carboxyl, 
epoxy, amine)[150]. 
 
A response of magnetic beads to an external magnetic field is characterized by hysteresis loop. A 
typical hysteresis loop of a ferromagnetic material is shown in Figure 5.4a [151]. In the presence 
of an external magnetic field (H), the material exhibits a magnetic moment or magnetization 
(M).The magnetization of the material increases the total induced magnetic flux density (B), 
which is expressed as: 
 
B = μ0 (M + H)   
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where μ0 is the permeability of a free space or vacuum. An increase in external magnetic field 
increases total flux density and reaches a saturation value Bs. The material will retain the 
magnetic moment (remanence R) even in the absence of the external field. After the application 
of a coercitive field HC, the net magnetic moment of the material will return to zero.  
 
a)                                                                    b)  
 
 
 
 
 
 
 
 
Figure 5.4 Hysteresis curve for the bead platform: magnetization as a function of magnetic field 
strength. The loop is generated for a) ferromagnetic or ferrimagnetic material [151] and b) 
super-paramagnetic beads (Myone Dynabeads (Invitrogen)) [152]. 
 
When the diameter of magnetic core decreases (<25 nm), the magnetic moment is increasingly 
affected by thermal fluctuations and the system becomes superparamagnetic[153].   The 
hysteresis curve for the superparamagnetic beads such as MyOne Dynabeads (Invitrogen) is 
shown in Figure 5.4b, where the magnetisation is linear with both increasing and decreasing the 
external magnetic fields[152]. The total magnetic field increases at the bead position as the bead 
is attracted towards the external field. When the external magnet is removed, the beads 
immediately lose all their magnetic remanence (HC = 0 and so B=0) and are easily resuspended. 
The prevention of aggregation and clumping of the magnetic particles during the reaction results 
in a monodispersity and ensures a uniform reproducibility. 
 
Using magnetic beads for sample preparation, an integrated RT-PCR microfluidic system has 
been developed for Dengue fever viruses [154-157]. Figure 5.5 shows such approach using 
immunomagnetic separation and amplification of target in microfluidic environment[157]. The 
sensitivity of the system for detection of dengue-virus serotype-2 is 102 PFU/ ml. However, in 
this case, the samples were purified dengue-virus serotype-2 and not a crude sample such as 
faeces. The RT-PCR product was also analyzed off-chip using gel-electrophoresis.  
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Figure 5.5 Schematic illustration of an operating process of a miniature RT-PCR system with 
sample preparation. (a) Mixing clinical biosamples with the antibody-conjugated magnetic 
beads. (b) Binding of the targeted analyte on the surfaces of the beads by specific antibodies. (c) 
Magnetic separation of the beads and the targeted analyte conjugates and washing of the non-
target entities (d) Release of RNA by thermal lysis is performed by the on-chip microheaters. (e) 
Synthesizing and amplification of cDNA by the RT-PCR process [157].  
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Chapter 6 
6 Sample preparation for RT-PCR 
 
This chapter focuses on the development of an immunomagnetic bead-based assay for rapid 
sample preparation that could be used for on chip RT-PCR to detect AIV. The developed method 
was further investigated in a magnetic microfluidic system for high throughput. In the later part 
of this chapter, the experimental results for on chip sample preparation using SU-8 chip and on 
chip RT-PCR for rapid detection of AIV using SU-8 and COC chips are highlighted. 
  
Sample p aration for RT-PCR 
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6.1 Rapid detection of avian influenza virus in chicken faecal samples by 
immunomagnetic capture RT-PCR assay 
Manuscript published in Diagnostic Microbiology and Infectious Diseases (2011), 69, 258-265. 
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Abstract
Avian influenza virus (AIV) causes great economic losses for the poultry industry worldwide and threatens the human population with a
pandemic. The conventional detection method for AIV involves sample preparation of viral RNA extraction and purification from raw
sample such as bird droppings. In this study, magnetic beads were applied for immunoseparation and purification of AIV from spiked
chicken fecal sample. The beads were conjugated with monoclonal antibodies against the AIV nucleoprotein, which is conserved in all the
AIV. The bead-captured virus was detected by reverse transcriptase–polymerase chain reaction (RT-PCR) without RNA extraction because
of effective removal of RT-PCR inhibitors. The developed bead-based assay showed a similar detection limit comparable to the RNA
extraction and the classic virus isolation method. Using ready-to-use antibody-conjugated bead, the method requires less than 5 h.
Furthermore, the method has potential to integrate into a Lab-on-a-chip system for rapid detection and identification of AIV.
Crown Copyright © 2011 Published by Elsevier Inc. All rights reserved.
Keywords: Avian influenza virus; Magnetic beads; Fecal sample; Immunoassay; Real-time RT-PCR
1. Introduction
Avian influenza is a disease caused by influenza A virus.
Outbreaks of Avian influenza virus (AIV) caused great
economic loss in the poultry industry and are threats to
human health (IMF Report, 2006; Peiris et al., 2007). To
prevent the emergence of a human pandemic, improved
measures for controlling of AIV are crucial (de Wit and
Fouchier, 2008; Editorial, 2008).
AIV belongs to the Orthomyxoviridae family—an
enveloped and negative-sense single-stranded RNA virus.
On the AIV surface, 2 glycoproteins [hemagglutinin (H)
and neuraminidase (N)] are presented, and these have been
used to classify the AIV into 16 H subtypes (H1–H16) and
9 N subtypes (N1–N9), respectively (Alexander, 2007).
Based on the ability to cause disease and mortality of the
virus in experimental infection of 4 to 8 week-old chickens,
the AIV is classified as either highly pathogenic avian
influenza (HPAI) or low pathogenic avian influenza (LPAI)
[Alexander, 2007; World Organization for Animal Health
(OIE), 2009].
Classic method for detection and identification of AIV is
the isolation of virus in embryonated specific pathogen-free
(SPF) chicken eggs. If successful, the virus is used for further
typing (Charlton et al., 2009), but the method is time-
consuming (3–10 days), laborious, expensive, and requires
special laboratory facilities and trained staff. A faster method
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for detecting AIV based on reversed transcriptase–polymer-
ase chain reaction (RT-PCR) was developed (Fouchier et al.,
2000). Although RT-PCR is a sensitive method for detection
of AIV, the presence of any inhibitors in the sample limits
the detection and the efficiency (Ginny and Helen, 1999;
Peter et al., 2004). A sample preparation step for removing
inhibitors is therefore always required to obtain reliable
diagnosis results.
A number of commercial kits, especially column-based
nucleic acid purification, are available for viral RNA
extraction from raw samples such as feces. Recently,
magnetic microspheres (beads) have been introduced to
enhance AIV viral RNA extraction and purification (Tewari
et al., 2007), and to detect antibodies against AIV in
immunoassays (Deregt et al., 2006). Magnetic beads
conjugated with anionic polymer have been utilized to
capture H5 AIV from allantoic fluid sample (Sakudo and
Ikuta, 2008). The beads can be used to catch H5 AIV strain
from allantoic fluid or other virus suspension but cannot be
used to catch the virus from raw samples because of the lack
of specificity that may be due to unspecific hydrophobic
interaction. Silica-based magnetic beads have been applied
to extract AIV viral nucleic acid using robotics (Tewari et al.,
2007). This method is sensitive, specific, and comparable to
the conventional RNA extraction method. However, the
method can isolate total RNA only from a small sample
volume (up to 400 μL); therefore, it can be cumbersome pre-
processing step for larger volumes of samples (up to 1 mL).
Moreover, the robotic system is also very expensive.
In this study, a novel method for selective separation and
purification of AIV from chicken fecal sample using
monoclonal antibody (mAb)-conjugated magnetic beads
without RNA extraction step is described. The applied
mAb interacts with a protein conserved in all AIV strains.
Subsequently, the AIV-captured mAb-conjugated magnetic
beads were identified by RT-PCR. The method was
evaluated using chicken fecal samples spiked with 16
different AIV subtypes and compared to the RNA extraction
method and the virus isolation (VI) method.
2. Materials and methods
2.1. Viruses
Sixteen different AIV strains that belong to 16 H and 9 N
subtypes were used to evaluate the method, and a Newcastle
disease virus (NDV) was used to check the specificity of the
AIV mAb. Table 1 shows a list of the AIV strains with
different phenotypes, sources of isolation, and HA titers. All
the strains except the H16N3 were kindly supplied by the
Veterinary Laboratories Agency (VLA, Weybridge, UK).
The viruses were prepared by propagation in 9- to 11-day-
old embryonated chicken SPF eggs. The allantoic fluid
containing the viruses was harvested from the eggs and kept
at −80 °C until testing. The HPAI viruses (H5 and H7) were
inactivated using β-propiolactone at a concentration of
1:1200. To determine the antigenic titer value for the viruses,
hemagglutination (HA) test was performed using a 96-well
microtiter V-bottomed plate according to standard method
(OIE, 2009).The HA titer value is represented in HA unit
(HAU), which is the reciprocal of the highest dilution
causing complete HA per 50 μL. The 50% egg infectious
dose (EID50) was calculated for H16N3 strain using Reed–
Muench formula (Reed and Muench, 1938).
2.2. Antibody
Monoclonal antibody against the nucleoprotein (NP) of
AIV was selected for conjugation onto the surface of the
beads. The NP is conserved in different AIV strains, and
different detection methods targeting NP have been
developed successfully (Jin et al., 2004; Yang et al., 2008).
The mAb (HYB 340-05) was purchased from Statens Serum
Institut (Copenhagen, Denmark). The mAb was obtained in a
purified solution with a concentration of 1 mg/mL.
2.3. Conjugation of antibody to magnetic beads
Anumber of magnetic beads are commercially available in
the market with different characteristics such as surface
chemistry, size, and the binding properties to the ligand and
target molecules. Super-paramagnetic polystyrene beadswere
selected for the bead-based assay as it has a large surface, high
capacity for target isolation, and excellent properties for
automation (Andreassen, 2005). Super-paramagnetic poly-
styrene beads with a diameter of 1.08 μm (Dynabeads,
MyOne-Tosylactivated; Invitrogen, Copenhagen, Denmark)
were used for the assay. The beads were supplied in a
concentration of 100mg beads/mL. ThemAbwas conjugated
Table 1
List of different strains used in this study and their HAU titer value
No. AIV strains Titer
(HAU)
Limit of
detection
A B
1. H1N1 A/Duck/Alberta 35/76 16 10−6 10−5
2. H2N3 A/Duck/Germany/1215/73 64 10−5 10−5
3. H3N2-A/Turkey/England/384/79 256 10−5 10−5
4. H4N6 A/Duck/Czech/56 512 10−6 10−6
5. H5N1 A/Chicken/Scotland/ 59 06.04.67 256 10−4 10−4
6. H6N8 A/Turkey/Canada/63 256 10−5 10−5
7. H7N7-2 A/Chicken/Netherland/2993/03 128 10−4 10−4
8. H8N4 A/Turkey/Ontario/6118/68 128 10−6 10−6
9. H9N2 A/Turkey Wisconsin/66/3577 64 10−7 10−7
10. H10N4-A/Turkey/England/384/79 512 10−5 10−5
11. H11N6 A/Duck/England./56 1024 10−6 10−6
12. H12N5 A/Duck/Alberta/60/76 1024 10−5 10−5
13. H13N6 A/Gull/Maryland/704/77 256 10−5 10−5
14. H14N5 A/Mallard/Gurjev/263/82 256 10−5 10−5
15. H15N9 A/Shearwater/Australia/2576/1979 256 10−6 10−6
16. H16N3-A/Gull/Denmark/68110/02 128 10−5 10−5
17. Newcastle diseases, Ulster strain 128
All strains except H16N3 virus were supplied by VLA. The end-point
dilution of each strain detectable by both (A) RNA extraction and (B) bead-
based method is mentioned.
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covalently to magnetic beads according to manufacturer's
instructions. Briefly, 3 mg (30 μL) of beads were suspended
in 1 mL of coating buffer (0.1 mol/L sodium borate buffer).
The beads were mixed by vortex and placed on a magnetic
separator (Dynal MPC, Invitrogen) to separate the beads
from the suspension. The supernatant (1.2 mL) was removed
and the beads were washed once in coating buffer. The mAb
was conjugated to the beads by adding 100 μg of
immunoglobulin G (IgG) mAb in 685 μL of the coating
buffer and 415 μL of 3 mol/L ammonium sulfate. The
mixture was incubated at 37 °C for 24 h on a slow mixing
rotor. Later, the supernatant was removed and saved for
determination of the efficiency of antibody conjugation. The
beads were resuspended in 1.2 mL of blocking buffer
containing phosphate-buffered saline (PBS) with 0.5%
bovine serum albumin (BSA) and 0.05% Tween 20 and
incubated overnight at 37 °C. After the incubation, the mAb-
conjugated beads were washed 3 times with 1 mL of storage
buffer containing PBS with 0.1% BSA and 0.05% Tween 20
and finally resuspended in 300 μL of the storage buffer and
stored at 4 oC for up to 3 months without loss of activity.
2.4. Antibody conjugation determination
The conjugation of antibodies to the surface of the beads
was verified by 2 methods: enzyme-linked immunosorbent
assay (ELISA) to determine the presence of mAbs on the
bead surface and UV spectrophotometric method to
measure the amount of mAbs in the liquid phase before
and after conjugated to beads. The ELISA was performed
according to the method described previously (Sakhalkar
et al., 2005) with modification. Briefly, a 96-microwell
plate was coated with blocking buffer to reduce the
background signal. Fifty micrograms of either mAb-
conjugated or unconjugated beads were placed in separate
wells and 45 ng of horseradish peroxidase-conjugated
rabbit antimouse IgG (Dakocytomation, Glostrup,
Denmark) was added to each well and incubated for 1 h.
For washing, magnets (IKEA, Aarhus, Denmark) were
placed beneath the microwell plate to immobilize the beads
on the bottom of the wells. The beads were washed 3 times
with 300 μL of washing buffer (PBS 10 mmol/L and
0.05% Tween 20). After the washing steps, 100 μL of
substrate solution (hydrogen peroxide) was added to each
well. The plate was wrapped with aluminum foil and kept
at room temperature for 20 min. Finally, 100 μL of 0.5
mol/L sulfuric acid was added to each well to stop color
procedure. The optical density (OD) was measured using
ELISA plate reader (MTX Lab Systems, Vienna, VA) by
dual wavelength mode at 492 nm and reference wavelength
at 620 nm. In the latter method, the amount of mAb
conjugated to beads was determined by calculating the
difference between total mAbs applied (100 μg) and the
free remaining mAbs after conjugation by UV-visible
spectrophotometer (Pharmacia Biotech, Uppsala, Sweden).
The concentration was calculated using an extinction
coefficient of 1.4 for IgG (A280/1.4 = concentration in
milligrams per milliliter).
2.5. Preparation of chicken fecal sample
A fresh chicken fecal stock was prepared by suspending
1 g of chicken feces in 1 mL of PBS (10 mmol/L). The fecal
mixture was homogenized by vortex. To prepare the AIV-
spiked chicken fecal sample for testing, a sterilized cotton
swab was dipped into the chicken fecal stock sample and
approximately 235 mg was introduced into 2 mL of PBS to
release fecal material. The solid fecal content was removed
by centrifugation at 13 000 rpm for 5 min at room
temperature and the supernatant was tested for the presence
of AIV by RT-PCR (Fouchier et al., 2000). The AIV RT-
PCR negative fecal suspension was used to prepare the AIV-
spiked fecal sample for the assays. To mimic the natural AIV
infectious fecal sample, 100 μL of each AIV virus (listed in
Table 1) diluted at 1:100 in PBS was spiked and mixed with
900 μL of the prepared feces and used as AIV-spiked
samples for the assays. AIV was spiked into the sample after
centrifugation to ensure a uniform starting material for both
the RNA extraction and the bead-based assay.
2.6. Bead-based assay
For the bead-based assay, 3 different volumes (5, 25, and
50 μg) of the beads were tested and evaluated. Fifty
micrograms of beads were selected for the assay to have an
efficient capturing. Fifty micrograms of mAb-conjugated
magnetic beads were added to each of the 16 AIV subtypes
spiked fecal samples. The mixture was mixed by slow
rotation for 30 min at room temperature. The mixture was
then placed in a magnetic particle concentrator (MPC-1,
Invitrogen) to separate the bead-captured virus from the
Table 2
List of primers and probes for RT-PCR and rRT-PCR used in this study
Description Sequence (5′ to 3′) Reference
RT-PCR forward (M52C) CTTCTAACCGAGGTCGAAACG Fouchier et al. (2000)
RT-PCR reverse (M253R) AGGGCATTTTGG ACAAAKCGTCTA
rRT-PCR forward (M+25) AGATGAGTCTTCTAACCGAGGTCG Spackman et al. (2002)
rRT-PCR reverse (M-124) TGCAAAAACATCTTCAAGTYTCTG
rRT-PCR probe (M+64) FAM-TCAGGCCCCCTCAAAGCCGA-TAMRA
NDV-2 CTGCCACTGCTAGTTGBGATAATCC Jørgensen et al. (1999)
NDV-3 GTYAAYATATACACCTCATCYCAGACWGG
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solution containing potential PCR inhibitors in feces and
unbound virus. The supernatant was removed and the beads
were washed 5 times with 1 mL of washing buffer (PBS
10 mmol/L and 0.05% Tween 20). Finally, the beads (with
captured virus) were resuspended in 50 μL of washing buffer
to have same volume with the RNA extraction method and
5 μL of the bead suspension was used as template for RT-
PCR. To study whether lysis of AIV by heat has any
influence on the efficiency of the bead-based assay, the bead-
captured AIV suspension was tested by both nonheating and
preheating at 95 °C for 5 min and was chilled to 5 °C before
the addition of RT-PCR mixture.
Pilot experiments for bead-based assays were conducted
with H5N1 virus in feces suspension to verify the washing
procedure. In these experiments, the fraction of each wash
was collected and tested for the presence of unbound free
virus after each wash by RT-PCR.
2.7. RNA extraction
Extraction of RNA from allantoic fluid and spiked fecal
sample was performed using the RNeasy Kit (Qiagen,
Copenhagen, Denmark) according to the manufacturer's
instruction. RNA was also extracted from bead-captured
virus to observe any loss of signal after the washing steps.
The RNA was finally eluted using 50 μL of RNase-free
water. All the extraction steps were performed in biosafety
level 3 laboratory facilities.
2.8. RT-PCR reaction
Both conventional RT-PCR and real-time RT-PCR (rRT-
PCR) were performed using one-step RT-PCR kit (Qiagen).
All the primers and probes were synthesized by DNA
technology A/S (Aarhus, Denmark). The sequences of
primers, probes, and references used in this study are
shown in Table 2. The RT-PCR was performed according to
the manufacturer's instruction with minor modification.
Briefly, 5 μL of template was used in 25 μL of RT-PCR
reaction mixture with 2 primers, namely, M52C and M253R,
targeting the matrix gene of AIV (Fouchier et al., 2000). The
RT-PCR conditions consist of a reverse transcription at
56 °C for 30 min and an enzyme activation step at 95 °C for
15 min, 40 cycles of 94 °C for 30 s, 58 °C for 1 min, and
72 °C for 1 min, and finally, a primer extension step at 72 °C
for 7 min using a thermal cycler (Biometra, Goettingen,
Germany). The obtained PCR product was analyzed using
agarose gel (1.5%) electrophoresis and a 100-bp DNA ladder
(Invitrogen, Taastrup, Denmark) was used as a marker. The
rRT-PCR was performed according to a method described
previously (Spackman et al., 2002) with 2 μL of template in
20 μL master mix using a Stratagene Mx 3000 real-time PCR
machine (AH-Diagnostics, Aarhus, Denmark). The RT-PCR
for NDV virus was performed using 2 primers specific for
NDV, namely, NDV-2 and NDV-3, as reported previously
(Jørgensen et al., 1999).
2.9. Agglutination test
The HA test and the latex (LAT)-based agglutination test
were performed to detect AIV. The HA test was performed
by mixing 20 μL of 0.5% chicken red blood cells (CRBC)
with 20 μL of the bead-captured virus on a white ceramic
tile. Two minutes after the mixing, the agglutination was
observed. The LAT-based agglutination test is a technique to
detect antibodies that are capable to react with antigen coated
on latex bead. The reaction of antibodies and antigen forms
an agglutination that can clearly be seen with naked eye.
When no specific antibodies are present, the latex suspension
will remain homogeneous (negative result). In this study, the
LAT-based agglutination test was performed to detect AIV
as described by Chen et al. (2007), with modification by
using magnetic beads conjugated with mAb instead of latex
beads. Briefly, 10 μL of mAb beads was placed on a
microscopic glass slide and 10 μL of virus (allantoic fluid)
Fig. 1. A schematic representation of sample preparation of AIV using mAb-
conjugated magnetic beads. The magnetic beads and fecal sample are mixed
in a tube. The beads were separated using a magnetic stand and the inhibitors
were removed. The AIV-captured beads were used for RT-PCR directly
without further treatment.
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was added. The slide was then manually rotated for 30 s and
agglutination event was observed.
2.10. Sensitivity
The sensitivity of the bead-based assay was determined
and compared with the viral RNA extraction method and the
VI method. Both the AIV-infected allantoic fluid and the
AIV-spiked fecal samples were used. A 10-fold serial
dilution of an AIV H16N3 strain (allantoic fluid) was
made and 200 μL of each dilution was used as starting
material for the 3 different methods: (1) For the VI method,
200 μL of each virus dilution was injected into the allantoic
cavity of 9 to 11 day-old SPF eggs according to a standard
method (OIE, 2009). The allantoic fluid was harvested from
the eggs after 5 days of inoculation and the HA agglutination
test was carried out to observe the agglutination. (2) For the
viral RNA extraction method, the RNA was extracted from
200 μL of virus dilution series and 5 μL was used as template
for RT-PCR. (3) For the bead-based method, 50 μg of bead
was added to 200 μL of each virus dilution and the assay was
performed as described in the earlier section. To determine
the sensitivity of the bead-based assay, the H16N3 virus was
spiked, chicken fecal sample was prepared by mixing 20 μL
of virus with 180 μL of fecal suspension, and 50 μg of beads
was added. The sensitivity of the bead-based assay was
determined for all the 16 AIV viruses using 1 mL spiked
sample and compared with the RNA extraction method.
The limit of detection of the bead-based method was
determined by rRT-PCR and was compared to the RNA
extraction method. In rRT-PCR, the bead-captured virus was
heated at 95 °C for 5 min to separate the virus from the beads
before used as a template. This heat step was performed to
avoid the possible light scattering from the beads in rRT-
PCR. The rRT-PCR was performed in duplicates.
2.11. Specificity
The specificity of the bead-based assay to capture AIV
was tested using NDV. The assay was performed similar to
the bead-based assay for AIV, except that the sample in this
case was allantoic fluid containing NDV virus. After the
assay, the presence of virus in beads and supernatant of each
wash was tested by RT-PCR with NDV-specific primers.
3. Results
3.1. HA titer value
HA test was performed on allantoic fluid, and the titer value
for the 17 viruses varied from 16 to 1024 HAU (Table 1). The
EID50 for the AIV H16N3 was 6.7 log10 EID50/mL.
3.2. Conjugation of mAb to magnetic beads
The efficiency of the conjugation of the antibody on the
surface of the beads was determined by ELISA and UV
spectrophotometer. Using ELISA, the OD values of the
unconjugated and the mAb-conjugated beads were 0.37
(±0.347) and 2.73 (±0.063), respectively, while using UV
spectrophotometer of 100 μg of mAb used for conjugation,
approximately 80 μg (80%) was conjugated to 3 mg
of beads.
3.3. Development of a bead-based method
Fig. 1 shows a schematic of sample preparation of AIV
using the mAb-conjugated magnetic beads. Pilot experi-
ments were performed to determine the optimal washings for
the assay. Fig. 2A shows the results of one of such
experiments. A positive RT-PCR was observed for the
bead-captured virus (Fig. 2A, lane 1), while a negative RT-
PCR was observed at the wash 5 (Fig. 2A, lane 4). Positive
RT-PCRs were also seen at the first to the third wash with
reduction in intensity (Fig. 2A, lanes 2–3). No signal was
observed when the bead-based system was performed using
NDV and tested by RT-PCR (Fig. 2B, lane 1). To test the
ability of mAb-conjugated beads to catch different AIV
subtypes (Table 1), chicken fecal samples spiked with 16
different AIV subtypes were tested twice with the bead-
based assay, and all subtypes were detected from the spiked
fecal sample using the assay. No significant difference was
observed when the beads (with captured virus) were used
Fig. 2. Agarose gel electrophoresis images of the bead-based assay to determine (A) the optimal washing steps for the assay. On gel: lane 1, the bead-captured
virus (H5N1); lanes 2–4, washing steps 1, 3, and 5, respectively. Controls: master mix (5), negative control (H2O) (6), and positive control (AIV) for RT-PCR
(7). (B) The specificity of the mAb-conjugated beads using NDV. On gel: Lane 1 shows no signal from the beads used to capture NDV virus. Lane 2, 3, and
4 represent supernatant washing numbers 1, 3, and 5. Lane 5 represents master mix, and 6 and 7 are the negative (H2O) and positive control for NDV
virus, respectively.
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directly for RT-PCR, or preheat and lysis using a lysis buffer
from RNA extraction kit (data not shown).
3.4. Agglutination test
Detection of AIV by agglutination was performed with
HA- and LAT-based tests. No agglutination was observed
with the HA test, whereas the LAT-based test clearly
showed agglutination.
3.5. Sensitivity for the bead-based system
The sensitivity of bead-based system was determined and
compared with both the VI and viral RNA extraction
methods. The VI method showed a positive HA test for virus
(H16N3) dilution up to 10−5 or equivalent to 1 log10 EID50/
mL. Similar detection limit was obtained for viral RNA
extraction method (Fig. 3A) and the bead-based method for
both allantoic fluid (Fig. 3B) and AIV-spiked fecal sample
(Fig. 3C). A similar limit of detection was achieved when
rRT-PCR was used to detect AIV from both the bead-based
assay and the RNA extraction method with end-point Ct
value of 36.21 ± 0.92 and 35.28 ± 0.62, respectively. The
detection limits of all the 16 viruses for both the bead-based
assay and the RNA extraction method are listed in Table 1.
4. Discussion
Detection and identification of AIV by RT-PCR is a faster
method recommended by OIE for AIV diagnosis, and it has
replaced the VI method (OIE, 2009). Conversely, the PCR-
based approaches require sample pretreatment and enrich-
ment, which is time-consuming and laborious. The approach
to use magnetic beads for sample preparation in rapid assays
has not only removed inhibitors from the sample but also
concentrated the pathogen from a large sample volume
(Bidawid et al., 2000; Gilpatrick et al., 2000). A number of
immunomagnetic capture RT-PCR assays for the viral
detection have been reported for hepatitis A virus (López-
Sabater et al., 1997), ampeloviruses (Gambley et al., 2009),
and Norwalk virus (Gilpatrick et al., 2000). In this study, a
rapid bead-based method was developed to catch, to
concentrate, and to purify the AIV from feces for detection
by RT-PCR.
Two different agglutination tests, the HA and the LAT-
based, were performed to confirm the presence of AIV on the
surface of the beads. Using the HA test, no agglutination was
observed. This could be due to the steric hindrance of beads,
which was not able to provide enough room for the virus
particles to agglutinate with other CRBCs. However,
agglutination was observed through LAT-based test that
confirmed the presence of AIV virus on the surface of the
beads. The virus and beads contain multiple binding sites for
each other that forms lattice (agglutination). The LAT-based
test has been reported as a detection method for H5N1
subtype (Chen et al., 2007).
The development of the bead-based assay revealed that
washing step is one of the factors that influence the
performance of the bead-based system. In another study, it
has shown that washing is an important step to remove PCR
inhibitors (Nilsson et al., 1996). In this study, when the AIV-
spiked sample was used directly as a template for RT-PCR,
great inhibitions were observed, whereas positive RT-PCRs
were obtained when purified RNA or purified AIV-captured
beads were used (data not shown). Furthermore, the pilot
experiments to define the optimal washing step for the assay
revealed that no unbound virus was detected after 5 times of
washing (Fig. 2A, lane 4); therefore, at least 5 times of washing
was included in the bead-based method. Because of the
effective removal of inhibitors during the bead-based assay,
the AIV-captured beads were used directly as template for the
RT-PCR without RNA extraction step and no preheat step
Fig. 3. The sensitivity of RT-PCR with H16N3 virus as target purified by RNA extraction method for allantoic sample (A), by bead-based method using allantoic
sample (B) and spiked fecal sample (C). On gel, the number above each lane corresponds to the AIV dilutions. Lanes marked with 1, 2, and 3 represent master
mix, negative, and positive PCR controls, respectively.
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before RT-PCR was required to release the RNA as reported
earlier with Chikungunya virus (Pastorino et al., 2005), which
is advantageous compared to RNA extraction method.
A number of different methods such as ELISA (Jin et al.,
2004; Velumani et al., 2008; Yang et al., 2008), microsphere
immunoassay (Deregt et al., 2006), and anionic magnetic
beads (Sakudo and Ikuta, 2008) have been developed to detect
AIV in allantoic fluid. Although these immunocapture assays
are simple and quick, these methods were not able to apply for
the fecal material. Furthermore, these methods posed a lower
sensitivity in comparison to the RT-PCR assay and the use of
VI method to prepare allantoic fluid introduces tediousness.
The detection limit of all the AIV strains except H1N1
achieved in this study is comparable to the RNA extraction
method. The strain H1N1 that exhibited 10 times low
detection limit (10−5 dilution) also demonstrated a low HA
titer value (16 HAU) indicating that presence of incomplete
AIV (Carter and Mahy, 1982) was detected by extraction
method (10−6 dilution). The immunomagnetic capture RT-
PCR assays have been reported in previous studies (Gambley
et al., 2009; Gilpatrick et al., 2000); however, data on the
specificity of the assays were not reported. In this study,
NDV virus is used to confirm the specificity of the bead-
based system, and the use of NDV for testing the specificity
of the assays has been described previously (Chen et al.,
2009; Deregt et al., 2006).
The developed bead-based system was able to capture,
concentrate, and purify AIV from 16 different AIV-spiked
fecal samples, demonstrating the efficiency of mAb-
conjugated beads. As the bead-based system separates the
AIV virus rather than the viral RNA from samples, the attack
of nucleases leading to false-negative results can be avoided
as long as the protein (+/− lipid) coat is not disrupted
(Anderson et al., 2003). The time required for sample
preparation by the bead-based system (35 min) is similar to
that for the RNA extraction method (45 min) with the
advantage of fewer manipulation steps, which reduces the
probability of obtaining false-positive result. Other obvious
advantages are (i) the bead-based method works with higher
volume (1 mL in this study), (ii) the method eliminates the
use of hazardous chemical involved in the extraction
method, and (iii) the cost of analysis for each sample
preparation for the bead-based assay without considering the
labor charge (€1.46) is less than half of that for the RNA
extraction method (€3.97).
A big challenge for applying the bead-based system to
clinical sample could be the variation and uncertainty of the
concentration of AIV in the clinical samples and the
degradation of the sample, which can affect the sensitivity of
the assay. These depend on how the sample is treated while
transportation to the reference laboratory (Forster et al., 2008).
For safety reasons, if the sample is inactivated without
destroying the RNA, it can be detected by the bead-based
assay as observed in this study with the HPIV strains such as
H5 and H7. It has been reported that AIV-infected feces may
contain virus up to concentrations of 8.8 log10 EID50 infectious
particles per gram and the virus can remain active over 30 days
at 0 °C with decrease in mean EID value by 5-fold (Webster
et al., 1978). At this AIV concentration, the developed
bead-based assay may able to detect as demonstrated in this
study with a number of AIV-spiked fecal samples.
In conclusion, the bead-based system presented in this
study is a simple and powerful technique for immunosepara-
tion and identification of AIV virus directly in fecal sample
using RT-PCR. This AIV bead-based system could be
potentially further integrated into a microsystem to obtain a
rapid automated detection system with a high sensitivity.
Moreover, using antibody-conjugated bead as ready to use,
the entire detection required less than 5 h. The bead-based
system has a potential to be an alternative sample preparation
for surveillance of epidemic outbreaks caused by AIV in
wild bird and poultry production.
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a b s t r a c t
Avian inﬂuenza virus (AIV) is an infectious agent of birds andmammals. AIV is causinghuge economic loss
and can be a threat to human health. Reverse transcriptase polymerase chain reaction (RT-PCR) has been
used as a method for the detection and identiﬁcation of AIV virus. Although RT-PCR is a sensitive method
for detection of AIV, it requires sample preparation including separation and puriﬁcation of AIV and
concentrate viral RNA. It is laborious and complex process especially for diagnosis using faecal sample. In
this study,magnetic beadswereused for immunoseparationofAIV in chicken faecal sampleby amagnetic
microsystem. Using this system, all the 16 hemagglutinin (H) and 9 neuraminidase (N) subtypes of AIV
were separated and detected in spiked faecal samples using RT-PCR, without an RNA extraction step.
This rapid sample preparation method can be integrated with a total analysis microsystem and used for
diagnosis of AIV.
© 2010 Elsevier B.V. All rights reserved.
Avian inﬂuenza virus (AIV) in wild and domestic birds, causes
an abundant economic loss and continues to threat a pandemic
in human (Peiris et al., 2007; Subbarao and Katz, 2000). AIV is
an enveloped RNA virus with eight-segmented single-stranded,
negative-sense genome that belongs to the family Orthomyxoviri-
dae. The virus is classiﬁed into 16 H and 9 N types based on the
antigenic properties of two surface glycoproteins; the hemagglu-
tinin (H) and the neuraminidase (N) (Alexander, 2007). The gold
standard method used for diagnosis of AIV is virus inoculation. In
this method, the sample is inoculated into speciﬁc pathogen free
(SPF) eggs and incubated for a week or two (Charlton et al., 2009).
Conventional RT-PCR (Fouchier et al., 2000) and real-time RT-PCR
(Spackman et al., 2002) have beenused for ampliﬁcation anddetec-
tion of AIV viral RNA. These methods are more rapid and more
sensitive than virus inoculation. However, RT-PCR requires sample
preparation that involves isolation of virus and extraction of RNA.
This sample preparation is a crucial step for removing substances
that cause the inhibition of RT-PCR (Peter et al., 2004). To avoid
inhibition, extraction of AIV RNA from samples can be performed
using commercial kits.
The micro electro mechanical system (MEMS) has been applied
at different stages of sample preparation that added in miniatur-
ization and automation of the sample preparation unit (Huang et
∗ Corresponding author. Tel.: +45 35886892; fax: +45 35886901.
E-mail address: ddba@vet.dtu.dk (D.D. Bang).
al., 2002). The application of magnetic bead-labeled biomolecules
inside the microﬂuidics system enhanced the target speciﬁc sep-
aration (Gijs, 2004). Different approaches have been applied for
the automation of sample preparation using magnetic beads. One
such system has been developed to purify and concentrate Dengue
viruses and detected using RT-PCR (Lien et al., 2007). Conversely,
the system was used only for puriﬁed analytic target and not a
crude sample such as faeces. Faecal sample contains a mixture of
complex components which could inhibit the detection of virus
if used directly in RT-PCR. A magnetic bead based microsystem is
described for rapid sample preparation andpuriﬁcation of AIV from
chicken faecal samples and was used directly for RT-PCR.
For immunoassay separation, magnetic beads were coated with
monoclonal antibody (mAb) raised against the nucleoprotein of
AIV, which is a conserved part in all AIV subtypes. The pro-
tein A puriﬁed mAb was purchased from Staten Serum Institute
(Copenhagen, Denmark). The mAb was conjugated to the magnetic
beads covalently, according to the manufacturer’s instructions.
Brieﬂy, 3mg of super-paramagnetic polystyrene beads (Ø1.08m)
(MyOneTM Tosylactivated, Invitrogen, Taastrup, Denmark) were
washed twice with 1ml of 0.1M sodium borate (coating buffer)
using a magnetic separator (Dynal MPC, Invitrogen, Taastrup, Den-
mark). The beads were re-suspended in a mixture of 685l of
coating buffer, 415l of 3M ammonium sulphate and 100g of
mAb (1mg/ml). The bead suspension was incubated at 37 ◦C for
24h using a slow mixing rotor. Later, the beads were blocked by
incubation overnight at 37 ◦C in a blocking buffer of phosphate
0166-0934/$ – see front matter © 2010 Elsevier B.V. All rights reserved.
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Table 1
List of different subtypes of AIV used for the bead based assay.
No. AIV strains HA titre
1. H1N1 A/Duck/Alberta 35/76 1:16
2. H2N3 A/Duck/Germany/1215/73 1:64
3. H3N2 – A/Turkey/England/384/79 1:256
4. H4N6 A/Duck/Czech/56 1:512
5. H5N1 A/Chicken/Scotland/ 59/67 1:256
6. H6N8 A/Turkey/Canada/63 1:256
7. H7N7-2 A/Chicken/Netherland/2993/03 1:128
8. H8N4 A/Turkey/Ontario/6118/68 1:128
9. H9N2 A/Turkey wisconsin/3577/66 1:64
10. H10N4 – A/Turkey/England/384/79 1:512
11. H11N6 A/Duck/England./56 1:1024
12. H12N5 A/Duck/Alberta/60/76 1:1024
13. H13N6 A/Gull/Maryland/704/77 1:256
14. H14N5 A/Mallard/Gurjev/263/82 1:256
15. H15N9 A/Shearwater/Australia/2576/79 1:256
16. H16N3 – A/Gull/Denmark/68110/02 1:128
based saline (PBS)with 0.5% bovine serumalbumin (BSA) and0.05%
Tween 20. Finally, the beads were captured and re-suspended in
300l of storage buffer containing PBS with 0.1% BSA and 0.05%
Tween20andused for theassay. ThepresenceofmAbon the surface
of magnetic beads was tested by enzyme linked immunosorbant
assay (ELISA) as described by Sakhalkar et al. (2005) and conﬁrmed
(unpublished data).
A microﬂuidic magnetic microsystem was used for the bead
based sample preparation. The design and the manufacture details
of the microsystem was described previously (Bu et al., 2007;
Smistrup et al., 2008). The microsystem consists of a 200m high
SU-8 separation chamberwith a volumeof 10l. Themagnetic sys-
tembeneath the separation chamber consists of twoparts: The ﬁrst
part is an array of external Nd–Fe–B permanent magnets each with
a dimension of 2mm×2mm×2mm and a ﬂux density of about
0.3 Tat the surface. The secondpart is anarrayof integratedpermal-
loy soft magnetic elements buried at the bottom of the separation
chamber. These elements are magnetized by the external perma-
nentmagnet and the totalmagnetic force increasesup to twoorders
of magnitude (Smistrup et al., 2008).
To mimic the natural AIV infectious faecal sample, 100l of
avian inﬂuenza virus diluted at 1:100 in PBS was spiked to 900l
of chicken faecal swab sample that was tested negative for AIV by
RT-PCR. Table 1 shows a list of 16 different AIV strains with all AIV
subtypes (from H1 to H16 and N1 to N9) that were used for the
assays. The list includes both AIV high and low pathogenic viruses.
The titres of the 16 viruses using hemagglutination assay (HA) var-
ied from1:16 to 1:1024HAunits. Fiftyg ofmagnetic beads coated
with mAb was added into 1ml of the AIV-spiked-faecal sample and
the mixture was mixed at room temperature for 30min.
The magnetic microsystem (Fig. 1) consists of two inlets
connected to syringe pumps (model 540060, TSE Systems, Bad
Homburg, Germany) and an outlet. For the bead based assay, 1ml
mixture of the bead and faecal sample was introduced into the
chip through the inlet 1 at a ﬂow rate of 0.5ml/min. As the liquid
passes through the chamber, the magnetic beads were captured
by the magnetic ﬁeld created in the magnetic microsystem. Fig. 1B
shows the microscopic image of the microsystem after magnetic
beads were introduced. Three ml of washing buffer (PBS and 0.05%
Tween 20) were introduced into the microchamber via inlet 2 at
0.5ml/min to remove PCR inhibitors and other complex material
that were in the faecal sample (Fig. 1A). Finally, the microsys-
tem was de-magnetised by removing the permanent magnets. The
removal of the permanent magnets reduced the total magnetic
force of attraction to the beads to a great extend. The magnetic
beads were collected in 50l of washing buffer by pumping out at
a ﬂow rate of 1ml/min (Fig. 1C).
Fig. 1. Sample preparation of AIV using magnetic microsystem. (A) Faecal swab
samplewasmixedwithmonoclonal antibodycoatedmagneticbeadsand introduced
into the chip and later washing buffer used to remove inhibitors. (B) Microscopic
image showing internal permalloy magnets and the captured magnetic beads. (C)
External magnet was removed and beads were eluted using washing buffer.
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Fig. 2. RT-PCR results for 16 different strains of AIV performed using magnetic bead
based microsystem. Lanes 1–16 (number corresponds to Table 1). A, B and C are
RT-PCR’s master-mix, negative and positive controls, respectively. Marker (M) is a
100bp DNA ladder (Invitrogen, Taastrup, Denmark).
To avoid cross-contamination after each assay, themicrosystem
was washed by pumping 4ml of washing buffer into the chamber
at a ﬂow rate of 2ml/min. The last 50l of the washing liquid was
collected and tested for the presence of AIV using RT-PCR.
A 25l AIV speciﬁc RT-PCR with 5l of template was used
to perform with one step RT-PCR kit (Qiagen, Copenhagen, Den-
mark). Two primers; the forward primer M52C with sequence
5′-CTTCTAACCGAGGTCGAAACG-3′ and the reverse primer M253R
with sequence 5′-AGGGCATTTTGGACAAAKCGTCTA-3′ speciﬁc for
the matrix gene of AIV reported previously (Fouchier et al., 2000).
The templates used for RT-PCR include AIV-captured collected
beads; collected washing liquid as well as RNA extractions. The
RT-PCR program: 56 ◦C for 30min, 95 ◦C for 15min, following 40
cycles of 94 ◦C for 30 sec, 58 ◦C for 1min and 72 ◦C for 1min and
ﬁnal extension step at 72 ◦C for 7min was performed on a thermal
cycler (Biometra, Goettingen, Germany). The RT-PCR product was
analysed using agarose gel (1.5%) electrophoresis.
The limit of detection for sample preparation of AIV-spiked
faecal was determined using magnetic bead based microsystem
method and compared with RNA extraction method. A 10-fold
serial dilution of H16N3 virus spiked faecal sample was prepared
and thedilutionswereused for samplepreparation in the tube (RNA
extraction) and in the magnetic microsystem. The RNA extraction
was performed using an RNeasy Kit (Qiagen, Copenhagen, Den-
mark) in accordance with manufacturer’s instruction. Puriﬁed RNA
was eluted using 50l of RNase free water and used as a template
for RT-PCR. The RT-PCR results of the assays performed with 16
different AIV strains using the magnetic bead based microsystem
method are shown in Fig. 2. The detection limit of sample prepara-
tion was determined using the bead based microsystem method as
10−3 dilution of H16N3 virus (Fig. 2, lane 16) and it was 100 times
lower than the RNA extraction method (10−5 dilution).
The bioanalytical microsystems with microﬂuidics have been
developed more than a decade ago but have not yet been suc-
cessfully applied to the clinical sample due to the requirement of
multiple preparing steps (Chen and Cui, 2009). The clinical sample
for example, a faecal swab, consists of complex faecal composition,
with a fragile target (virus particles) which sometimes insufﬁcient
for detection. The extraction and puriﬁcation of viral RNA of such
sample is a big challenge. Tewari et al. (2007) described an automa-
tion method for extraction and puriﬁcation of AIV viral RNA from
treacle swab samples using a commercial robotic system (BioRobot
M48, Qiagen; Valencia CA) with magnetic beads. Although the use
of the robotic system for AIV sample preparation is rapid with no
cross-contamination and as good as the use of commercial RNA
kit method; the commercial robotic system is expensive (approxi-
mately D50,000). In this study, a simple and portable microsystem
made by photoresist SU-8 was used with magnetic beads coated
with mAb to separate and concentrate AIV in faecal samples.
Nilsson et al. (1996) reported that washing step plays an impor-
tant role for the effective removal of PCR inhibitor in the bead based
assay. In this study, three different ﬂow rates of 0.5, 2 and 4ml/min
were selected for washing. The ﬂow rate of 0.5ml/min was deter-
mined as optimal ﬂow rate and was selected for the assay. At this
ﬂow rate the loss ofmagnetic beads due to the shear forcewasmin-
imized, while a higher ﬂow rate of 1ml/min was used for eluting
the beads from the chip chamber. Using the magnetic microsys-
tem described in this study, all the subtypes of AIV were separated,
concentrated and puriﬁed from chicken faecal samples.
The AIV-captured magnetic beads was detected using RT-PCR,
without using a viral RNA extraction step (Noroozian et al., 2007) or
a pre-heat step to release the viral RNA (Gambley et al., 2009). This
could due to the low thermal stability of AIV (Shahid et al., 2009) or
the presence of non-ionic detergent (Tween20) which may further
enhanced the releasedof theviral RNA (Singh, 1999). Similar results
havebeenobservedwithChikungunyavirus (Pastorinoet al., 2005).
The speciﬁcity of themonoclonal antibodywasdeterminedwith
two viruses which are infectious to avian species: Infectious bur-
sal disease virus (IBDV) and Newcastle disease virus (NDV). In
both cases no RT-PCR signal was observed (unpublished data).
The robustness of the method was demonstrated by assays with
16 different AIV strains which cover all the 16 H and 9 differ-
ent N subtypes with varying HA titre. In all cases, the method
was completed within 5h without RNA extraction and puriﬁca-
tion steps. The microsystem was reused for all the viruses and no
cross-contamination occurred after each assay, when a washing
step combined with the RT-PCR was performed as control test.
The sensitivity of sample preparation step using the magnetic
microsystem is 10−3 dilution of the virus (H16N3) for both faecal
and allantoic ﬂuidic samples and is lower than the RNA extrac-
tion method for faecal sample (in this study) and for allantoic
ﬂuid (Cao et al., 2010). Recently, Lien et al. (2007) developed an
integrated microRT-PCR system using magnetic beads coated with
monoclonal antibody for rapiddetectionofDenguevirus.Using that
system, a sensitivity limit of 102 plaque forming unit was obtained
for Dengue virus and was comparable to conventional RNA extrac-
tion kit. The magnetic bead based microsystem used in this study
for virus separation and concentration showed a lower sensitivity
than the RNA extraction method. This could be due two reasons
(i) after the immuno-magnetic capture step the bead was collected
and transferred to the tube to perform RT-PCR, which could have
caused the loss of targets during the transportation and (ii) free
RNA from disrupted virus in the sample may have contributed to a
higher detection limit by the RNA extractionmethod andmight not
have been captured in the magnetic bead based method. Therefore,
an alternative to increase the detection limit could be to integrate
the RT-PCR step in the sample preparation platform and research
is in progress.
In conclusion, a rapid, robust and simple method developed for
the sample preparation of AIV from chicken faecal samples using a
magneticbeadmicrosystem.Themethod testedandevaluatedwith
16 different AIV strains and themicrosystem can be reusedwithout
cross-contamination. A higher detection limit could be achieved
by sample preparation and RT-PCR inside the microsystem. The
method can be integrated in a total analysis microsystem and used
for diagnosis of AIV.
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6.3 On-chip sample preparation and RT-PCR for detection of avian influenza virus from 
chicken faecal sample 
 
6.3.1 Introduction 
The magnetic bead based sample preparation has been 
developed successfully both in-tube and in a magnetic 
microsystem. However, the RT-PCR amplification 
steps are performed using a conventional thermocycler 
which is time consuming (3h 15min). This project 
aimed to reduce total amplification time by using 
integrated microfluidic devices for both sample 
preparation and RT-PCR amplification (Figure 6.3.1). 
As discussed in Chapter 5, there is an expanding use 
of polymers in microfabrication, due to its simplicity 
in fabrication methods and low cost, making it popular 
for various applications. 
 
In this project, two microfluidic chips made of a) SU-8 
and b) Cyclic olefin copolymers (COC) were tested 
for RT-PCR amplification of the AIV. The SU-8 chip 
was also tested for sample preparation.  These chips 
were from the EU projects, OPTOLABCARD [158] 
and LABONFOIL [159]. The performance of a 
miniaturized RT-PCR was first developed in-tube and 
later transferred to the chips. The biocompatible effects 
of the surface of the SU-8 chips on RT-PCR reaction 
have been addressed and characterized.  
Figure 6.3.1 Scheme of 
integrated microfluidic system 
for sample preparation of AIV 
from chicken faecal swab sample 
using magnetic beads followed 
by RT-PCR on chip. 
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6.3.2 SU-8 Chip 
SU-8 is an epoxy-based negative photoresist polymer that has been commonly used to transfer a 
pattern in a thin film during photolithography. It is also being used recently as structural 
materials in micro and nanotechnologies[160]. The SU-8 chip used in this study was fabricated 
based on a method applying bonding and releasing of photo-patterned SU-8 layer that creates 
multilayer microfluidic structures [161]. The microfluidic or PCR chamber is 3x5.4x0.2 mm 
(WxLxH) and has a chamber volume of 3 µl. The chamber was bonded on a Pyrex substrate 
which consists of an integrated resistive Ti/Pt sensor and heaters with parallel heat elements 
(Figure 6.3.2 right). 
 
 
 
 
 
 
 
 
 
 
Figure 6.3.2 Pictures of the OPTOLABCARD LOC system; capsule (left) and the SU-8 PCR 
chip (right)[162] 
 
The PCR chip is placed into a reusable package or capsule establishing full electric and fluidic 
connections to the macro world without the need of adhesives or wirebonding. This allows an 
easy replacement of the used chips, forming a disposable portable LOC device. The package is 
connected to a PCR controller, which acts as a data acquisition system, and the controller is 
connected to a computer. The computer with specific software controls the parameters of the 
thermocycling on the chip.  
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6.3.2.1 Materials and Methods  
Sample preparation on SU-8 chip: The sample preparation step was performed using magnetic 
beads(1 µm) coated with mAb as described previously (See section 6.2 Conjugation of antibody 
to magnetic beads). To 100 µl of allantoic fluid containing H16N3 virus, 50 µg magnetic beads 
coated with mAb were added and mixed for 30 min at room temperature using a rotor.  The 
magnetic particles in the mixture were concentrated to 5 µl volume using a magnetic particle 
concentrator (MPC-1, Invitrogen, Taastrup, Denmark). The mixture of beads and viruses were 
transferred into the chamber of the chip by a pipette.   Magnetic elements were placed at the top 
and bottom of the chip. The chip was placed into the chip holder (fig 6.3.3 a) with an inlet 
connected to a syringe pump containing washing buffer (10 mM PBS and 0.05% Tween 20) 
(Figure 6.3.3.b).  
 
 a)                                                    b)        
 
 
 
 
 
Figure 6.3.3 Set up for sample preparation using SU-8 chip a) SU-8 placed in a chip holder with 
a magnet placed on top to capture magnetic beads[158]. b) The chip holder was connected to a 
syringe pump system for the washing step. 
 
For the SU-8 chips; optimal flow rate of washing step for removing unbounded virus and other 
PCR inhibitors was determined. Three different flow rates of 0.25 ml/min, 0.5 ml/min and 1 
ml/min were tested. For each wash, a total of 2 ml of the washed buffer was collected in 8 
aliquots of 250 µl each. After the wash, the magnetic elements were removed. The mixture of 
liquid containing beads inside the chamber was collected and tested for AIV using RT-PCR in-
tube. 
RT-PCR reaction: A one-step RT-PCR mixture of 25 µl with 5 µl of template was used as 
described in Section 6.2. A  primer set namely M2  consisting of  a forward primer with 
sequences  5’-CY5-AGA TGA GTC TTC TAA CCG AGG TCG-3’ and a reverse primer with 
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sequence 5’-TGC AAA AAC ATC TTC AAG TCT CTG-3’ specific for the matrix gene of the 
AIV was used.  
 
Miniaturization in-tube: For miniaturization of the RT-PCR, a commonly used RT-PCR 
volume of 25 μl containing 5 μl of AIV RNA (H16N3) was reduced to 3 μl volume and tested 
for in-tube RT-PCR amplification using conventional thermal cycler (Biometra, Goettingen, 
Germany). The required time for each step in the PCR thermocycler was reduced and tested for 
the performance of the miniaturization.  The miniaturization was first tested with RNA (AIV) 
and later with the magnetic bead captured virus.  The sensitivity of the in-tube miniaturized RT-
PCR (3 μl) was determined using a 10-fold serial dilutions of the AIV. Due to the small volume 
of the RT-PCR amplified products, the end point analysis of the RT-PCR was performed on a 
Bioanalyzer 2100 (Santa Clara, CA, USA) using DNA1000 chip. 
In addition, different final volumes of 50 µl to 25 µl and 5 µl of the bead suspension in the 
sample preparation step were also tested for RT-PCR in 3 µl in-tube.  
 
RT-PCR on SU-8 chip  
The SU-8 chip was loaded with RT-PCR reaction mixture with template (RNA from H16N3 
virus) and introduced into a capsule. This capsule is connected to a small device capable of 
generating the thermocycling steps (Figure 6.3.4). 
a)                                                  b) 
 
 
 
 
 
Figure 6.3.4 The experimental setup for RT-PCR. a) SU-8 chip in a capsule[158] and (b) the 
capsule connected to a computer controlled thermocycling system. 
 
Preliminary results for RT-PCR on-chip showed no PCR amplification (inhibition) while the 
same reaction mixture was amplified in-tube. To address this inhibition effect the following 
studies were performed. 
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Surface treatment: The surface of SU-8 chip was treated with BSA before RT-PCR reaction. 
BSA solution (10 mg/ml) was made from crystallized BSA dissolved in PBS buffer and filtered 
using 0.22µm filter. Two approaches: static and dynamic were performed to reduce the effect of 
inhibition. In the static approach, various concentrations of BSA solution of 10 mg/ml, 1 mg/ml 
and 0.1 mg/ml were prepared. The BSA was introduced into the chip and incubated at room 
temperature for 1 h. The BSA was removed and the chip was dried at 37oC for 1h. Later the chip 
was used for RT-PCR. In the dynamic approach, 1 μl of BSA (1 mg/ml) was added to the RT-
PCR reaction mixture and tested.  
 
RT-PCR conditions: The concentration of enzyme mix for RT-PCR was doubled in the RT-PCR 
reaction mixture and tested for amplification on both tube and chip. To test the inhibition by 
ribonucleases, 1 μl of RNAse inhibitor (Invitrogen, Taastrup, Denmark) was added to the 
reaction mixture of RT-PCR and tested.  
 
To further investigate the mechanism by which RT-PCR amplification was inhibited, the 
components of the RT-PCR reaction such as RNA and enzyme mix (RT & TAQ) were tested 
individually. Chip control:  
a) RT-PCR reaction mixture was incubated inside the chip for 1min at room temperature 
and the mixture was transferred to a tube and RT-PCR amplification was performed in-
tube. 
b) RNA from H16N3 virus was incubated inside the chip for 1 min at room temperature and 
used as a template for RT-PCR. 
c) RT-PCR enzyme mix (without template) was incubated inside the chip for 1 min at room 
temperature and RNA was added later and tested for amplification 
 
6.3.2.2 Results and discussions  
Sample preparation on SU-8 chip 
Figure 6.3.5 shows results for sample preparation on SU-8 using three flow rates a) 0.25 ml/min, 
b) 0.5 ml/min and c) 1 ml/min. The RT-PCR signals for the aliquots collected from the washing 
step shows a decrease in the intensity of signals indicating the efficient removal of unbounded 
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virus from the chip, while a positive signal was observed from the elution of beads (Figure 6.3.5 
a, b, c lane 6). The rate at which the unbound viruses were removed was dependent upon the 
flow rate of the washing buffer. At the flow rate of 0.25 ml/min (Figure 6.3.5 a, lane 6), there 
were still some unbound viruses present in the final washing aliquot, indicating the need for 
additional washing step where as at the higher flow rate of 1 ml/min (Figure 6.3.5 c) the unbound 
viruses were totally removed after a few washing steps (Figure 6.3.5 c lane 3, 4). Similar with 
the flow rate of 0.5 ml, the unbound viruses were totally removed after 7 washing steps (Figure 
6.3.5 b lane 5).  
 
a)                                    b)                                            c) 
 
 
 
 
Figure 6.3.5 RT-PCR results for sample preparation on SU-8 using three flow rates a)0.25 
ml/min, b) 0.5 ml/min and c) 1 ml/min. Lanes number 1 to 5 represent the washed buffer aliquot 
(250 µl) of 1, 3, 5, 7 and 8. Lane 6 corresponds to extracted beads from the chip. Marker (M) is a 
100 bp DNA ladder (Invitrogen, Taastrup, Denmark). 
 
Determination of shear forces in SU-8 Chamber 
The fluidic flow inside the chamber generates a parabolic laminar flow profile which removes 
inhibitors and unbound virus in the sample and also creates a fluidic drag forces on the virus- 
bound bead (Figure 6.3.6).  In the parabolic flow profile, the flow velocity (Vf) is characterized 
by a parabolic velocity distribution where the centerline velocity is 1.5 x the linear flow velocity: 
 
𝑉𝑓 =  1.5 𝑄𝑤ℎ �1 − �𝑑−ℎ/2ℎ/2 �2�   (1) 
 
where Q is the volumetric flow rate, w and h are the width (3mm) and height (0.2 mm) of flow 
chamber, d distance(1.05μm) between the center of the virus particle to the wall of the chamber. 
As the magnetic bead are close to the channel wall (d<<h) the quadratic term in Eqn (1) can be 
linearly approximated[163;164], resulting a velocity profile known as plane shear flow: 
1     2     3     4     5    6 
M 
1    2     3     4    5    6          
M 
1    2    3    4    5    6          
M 
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(2) 
   
For the three flow rates of 0.25, 0.5 and 1 ml/min, the flow velocities inside the chamber at the 
virus-bead position were 0.88, 1.75 and 3.5, mm/sec.  
 
 
 
 
 
Figure 6.3.6 shows the cross section side view of the flow channel (not to scale). 
 
The shear force on the virus particle can be calculated with equation (2) according to a model by 
Goldman and co-workers[165]. The force depends on the viscosity (η) of the buffer (1mPa s), 
radius(r) of virus particle (0.05μm) and the flow velocity (Vf) at the level of the particle center.  
 
                                                          Fs=Fs*6πηr Vf   (3) 
 
Fs* is a function (Tabulated in [165]) of the ratio of distance between the center of the virus 
particle above the wall(d)  and the radius of the particle. Since the ratio is high (21), the Fs* 
value taken as 1 for the calculation.  The shear force on the virus-bead bound for the three flow 
rates of 0.25, 0.5 and 1 ml/min were 0.85, 1.7 and 3.4 pN respectively. Although the calculated 
shear force (3.4pN) for the highest flow rate (1ml/min) was approximately 10times lower than 
the single-bond rupture forces for IgG and protein (35pN)[166], the effective bond strength of 
virus on the surface of bead can be much lower (56 times) due to the applied tangential or shear 
forces[167]. So an optimal flow rate of 0.5 ml/min was selected for the sample preparation to 
minimize the shear force on the virus-bound bead.  
 
In-tube RT-PCR miniaturization 
Figure 6.3.7 shows the result of 3 μl RT-PCR reaction.  The quantity of PCR product for the 3 μl 
volume was determined as 14.12±1.83 ng/µl and that was similar to the result (14.41±3.1 ng/µl) 
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of the RT-PCR 25 μl volume. Two peaks (double band)of PCR products of 107 bp and 116 bp 
were observed in the Bioanalyzer graph probably due to CY5 (dye) conjugation to the DNA and 
this effect was studied earlier by Carisson et al. 1995[168] by gel electrophoresis and later by Tu 
et al. 1998[169] by capillary electrophoresis. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3.7: Bioanalyzer graph of RT-PCR amplification of 3 µl reaction volume 
 
In-tube miniaturized RT-PCR with magnetic bead captured virus   
As a first step toward on-chip RT-PCR, the developed miniaturized RT-PCR with magnetic bead 
captured virus as template was performed in-tube. Although with a high volume of the magnetic 
beads in the RT-PCR reaction mixture, a PCR amplicon of 110bp was observed. Furthermore, 
there is no significant difference in the RT-PCR amplification efficiency when the miniaturized 
RT-PCR performing with the three different re-suspension volumes of 5 µl, 25 µl and 50 µl of 
the beads.  
 
Table 6.3.1 shows a comparison of the required time of a conventional RT-PCR and the 
miniaturized RT-PCR using one-step RT-PCR kit from Qiagen (Germany). Using the 
miniaturized RT-PCR, the total time was reduced from 3h 15min to 1h 20min (Table 6.3.1). The 
fast thermocycling was possible because of the low reaction volume (3 µl) and thus better 
heating/cooling rates. During this process, the time required for the activation step was critical 
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since a decrease of 5 min in this step was drastically reduced the amplification efficiency up to 
20%.  
Table 6.3.1: Comparison of amplification time required for RT-PCR using one-step Qiagen kit 
with conventional and miniaturized. 
 Conventional Miniaturized 
Temperature Time Temperature Time 
RT 56oC 30min 56oC 15min 
Activation 95oC 15min 95oC 15min 
Denature 94oC 30sec 94oC 1sec 
Annealing 58oC 1min 54oC 5sec 
Extension 72oC 1min 72oC 5sec 
Number of cycles 40 
Final extension 72oC 7min 72oC 3min 
Total time  3h 15min  1h 20min 
 
A sensitivity test of the miniaturized RT-PCR (3 μl) in-tube was performed with the miniaturized 
thermocycling time and the results are shown in Figure 6.3.8. The sensitivity for the 3 μl 
miniaturized RT-PCR was determined as low as 10-5 dilution corresponding to H16N3 virus and 
was found to be similar to the larger volume (25 μl).  
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Figure 6.3.8: The sensitivity of RT-PCR with RNA from H16N3 virus as template. Lanes 
number 1 to 7 represent dilution of series of virus from 100 to 10-6 of virus and ‘L’ corresponds 
to the ladder. 
 
RT-PCR on SU-8 chip  
Figure 6.3.9 shows a measured temperature profile of a SU-8 chip during the PCR cycles  using 
the OPTOLABCARD Lab-on-a-chip system. It took 4 s for heating from 54oC to 72oC with a 
4.5oC /s heating rate. For raising temperature from 72 oC to 94 oC, generally 6 s are needed, with 
a rate of 3.66oC /s. Thus, the average heating rate for the two steps was 4.08oC/s while the 
cooling rate from 94 oC to 54oC was 1.52oC/s. The cooling rate of the chip was slower than the 
heating rate due to passive cooling process, and can be improved by connecting an additional 
cooling fan to the microcontroller. 
 
 
 
 
 
 
 
Figure 6.3.9:  Measured temperature profile of the RT-PCR during the PCR thermocycles using 
OPTOLABCARD lab-on-a-chip system. 
 
The entire RT-PCR amplification was performed within 45 min. However, preliminary results of 
on-chip RT-PCR amplification showed PCR inhibition effects i.e., no PCR amplification product 
was observed. It has been shown that miniaturization of RT-PCR or PCR often causes  PCR 
inhibition due to the high surface-to-volume ratio (SVR) that increases the significance of the 
surface chemistry in RT-PCR[139].  In addition, the components of RT-PCR such as Taq 
polymerase often adsorb non-specifically on the surface of the chip and cause no 
amplification[170]. To avoid the PCR inhibition effects, the chip surface is treated chemically or 
pre-coated with a bio-compatible substance during fabrication process or immediately before use 
[134] . The substances such as bovine serum albumin (BSA), polyethylene glycol (PEG) or 
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silanizing agents (for example dichlorodimethy-lsilane (DCMDS), or trimethylchlorosilane) 
[139;171] are the most common substances that were used to obtain the bio-compatible of the 
chips. In this study, BSA was selected  for the surface treatment as it has been proved to 
significantly improving the PCR efficiency for SU-8 material [171].  
 
Figure 6.3.10 shows the results for different approaches (see Materials and Methods) used to 
study the PCR inhibition effect. PCR inhibitions were observed when an untreated surface SU-8 
chip was used and also when increasing the concentration of enzyme mix (2X) to encounter its 
adsorption on the chip surface. Similar PCR inhibition effects were observed when the surface 
was treated with BSA according to the static approach where three different concentrations of 10 
mg/ml, 1 mg/ml and 0.1 mg/ml and as well as the dynamic approach was applied. A total number 
of 6 SU-8 chips tested and 3 chips (50% 3/6) showed primer dimmer (PD) (Figure 6.3.10, lane 
4).  
 
 
Figure 6.3.10: Gel Chart of Bioanalyzer showing the different approaches used to study RT-PCR 
inhibition study. Lane 1 positive control (in-tube). RT-PCR performed on SU-8 chip 2) untreated 
surface, 3) untreated surface with 2X enzyme mix, 4) BSA treated, 5) RT-PCR reaction with 
RNase inhibitor and BSA (1 mg/ml) and 6) chip control. RT-PCR in-tube with 7) RNA 
incubated on-chip and 8) RT-PCR master mix incubated on-chip. ‘L’ corresponds to the marker. 
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The PD’s are formed due to the weak interactions occurring between the primers and in the 
absence of template (cDNA), the inter-primer extension takes place due to the highly 
processivity of Taq polymerase[172;173]. The formation of PD is used as an internal control of 
amplification[174] and the failure to amplify the PD have been identified as the presence of 
inhibitors[175]. This phenomenon of PD formation was observed when chips were treated with 
BSA indicating the existence of amplification step and the presence of cDNA synthesis. When 
further testing was made by adding RNase inhibitor to the PCR mixture  a weak PCR positive 
signal  with a reduction of PCR efficiency (Figure 6.3.9 lane 5) compared to the positive control 
(Figure 6.3.10 lane 6) was observed. This indicates that the RT-PCR reaction mixture inside the 
SU-8 chip chamber quickly deteriorates by an unknown factor.   
 
Since RT-PCR giving a positive band when performed with RNA as template pre-incubated 
inside the chip and a negative band (only PD) while using the RT-PCR master mix pre-incubated 
inside chip, this results confirms the instability of RT enzyme presence inside the SU-8 chip. 
 
6.3.2.3 Conclusion  
The miniaturization of RT-PCR in-tube to detect AIV has been performed successfully. 
However, the attempt to miniaturize on SU-8 chip using OPTOLABCARD lab-on-a-chip system 
has failed due to the PCR inhibition that caused by the SU-8 chip surface-effect. The efforts to 
address the inhibition for improving the RT-PCR efficiencies were often inconsistent and not 
always comparable to those of conventional in-tube RT-PCR. Conversely, the same system has 
been applied for PCR rapid detection of Campylobacter spp. directly from chicken faeces with 
high sensitivity (0.7 – 7 pg DNA /µl)[176]. An improvement in the system can be made with the 
availability of sufficient information on chip fabrication chemical materials and the reduction of 
the batch-to-batch variation.  
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6.3.3 RT-PCR to detect AIV using COC-chip  
Cyclic-Olefin-Copolymer is a new group of polymers that has been introduced as a promising 
plastic substrate for microfluidic devices[177]. The fabrication of COC devices is inexpensive 
and compatible with mass production. In this study, COC chips were fabricated by milling and 
thermal bonding.  The chips were used to test the ability of the chip for performing AIV RT-PCR 
amplification steps. The chip has dimensions of 4x6x0.42mm (WxLxH) with a volume capacity 
of 10 µl. For thermocycling, the chip was placed on the miniaturized thermocycler-chip holder 
made of Pyrex substrate with integrated resistive Ti/Pt sensor and heat elements (Figure 6.3.11). 
 
 
 
 
 
 
 
Figure 6.3.11 Pictures of COC PCR chip (left) and the capsule (right). 
 
6.3.3.1 Materials and Methods  
RT-PCR reaction  
The one-step RT-PCR reactions were carried out using SuperScript III Platinum One-Step-PCR 
(Inivtrogen, Taastrup, Denmark). A 20 µl reaction mixture was prepared containing 6 µl of 
nuclease-free water, 12.5 µl of RT-PCR buffer, 0.5 µl of each primer (50 pmole) and 0.5 µl of 
Superscript III/Platinum Taq enzyme mix.  To the reaction mixture 5 µl of RNA extracted from 
H16N3 was added. The primer set M1 targeting matrix gene of AIV that was described 
previously in section 6.2 was used.  The RT-PCR cycling conditions were:  56°C for 15min, 
95°C for 2 min followed by 40 cycles of 94°C for 2 s, 58°C for 5 s, and 72°C for 5s and finally 
72°C for 3min. The RT-PCR product was analyzed with 1.5% (w/v) agarose gel electrophoresis.  
 
RT-PCR on COC chip 
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The RT-PCR reaction was performed on COC chips using the miniaturized thermocycler-chip 
holder with integrated heaters and microcontroller (see figure 6.3.4) and compared with COC 
chips using a flat-bed thermocycler (MJResearch, MA, USA). The inlet/outlet of the COC chips 
used in flat-bed was sealed with PCR-tape (Abgene House, Surrey, UK). For positive control, a 
miniature in-tube (10μl) RT-PCR was used. 
 
6.3.3.2 Results and discussions 
The RT-PCR on COC-chip using miniaturized thermocycler-chip holder showed a 
heating/cooling rate similar to that of the SU-8 chip. The RT-PCR reaction was completed in 45 
min using miniaturized thermocycler and the results are shown in Figure 6.3.12.  
 
  
 
.  
 
  
Figure 6.3.12: Gel electrophoresis image of RT-PCR performed with RNA (H16N3) as template. 
On gel: lane 1) RT-PCR on-COC chip using miniaturized thermocycler, lane 2) chip control; 
lane 3) positive control miniaturized in-tube and lane and lane 4) Negative control (tube). Marker 
(M) is a 100bp DNA ladder 
The RT-PCR was performed successfully on COC chip (Figure 6.3.12, Lane 1). To compare the 
efficiency of RT-PCR amplification on-COC chip and in tube, their fluorescent intensity was 
quantified using ImageJ software (National Institute of Health, USA). The on-chip RT-PCR 
showed a weak signal 43.52%, (6812.64) compared to positive control (15652).  
To investigate the reason for the weak signal from the on chip RT-PCR using the miniaturized 
thermocycler, the on COC chip RT-PCR was performed using flat-bed thermocycler and the 
results of this test are shown in Figure 6.3.13.  
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Figure 6.3.13: Gel electrophoresis of on COC chip RT-PCR results. On gel:  Lane 1)on COC 
chip RT-PCR using flat bed thermocycler, Lane 2) on COC chip RT-PCR using  miniaturized 
thermocycler 3) RT-PCR positive control (in-tube)  and 4) negative control (in-tube). 
For the same RT-PCR reaction mixture, the COC chip on flat-bed showed stronger signal 
72.71% (12671.95) than miniaturized thermocyler 50.87% (8865.30) and in all cases the RT-
PCR in-tube showed superior results (17425.05). The difference in the efficiency of RT-PCR 
could be due to the low thermal conductivity of COC material and the heating system.  
 
6.3.3.3 Conclusion 
The preliminary results of on COC chip RT-PCR show the possibility of using the system for 
rapid detection of AIV in less than two hours. However the system needs to be optimized further 
for efficient amplification and integration of sample preparation. 
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Chapter 7 
7 Solid-phase DNA microarray 
 
This chapter focuses on the development of a DNA microarray based solid-phase PCR platform for sub-
typing of AIV. This approach overcomes a limitation of real-time RT-PCR in sub-typing a number of 
targets, e.g. H5&H7 subtypes of the AIV, simultaneously. The developed solid-phase RT-PCR method 
was incorporated into a microchip to reduce the sample volume and detection time from 2h to 1h. 
Subtyping of all the 16 HA types of the AIV is essential for identification of circulating AIV strains that 
have recently emerged as a pandemic influenza virus. The development of a method for sub-typing of all 
the 16 HA types of the AIV is presented in the last part of this chapter where preliminary results in 
designs of primers and probes for simultaneous HA subtyping (H1-H16) and the use of the designed 
probes and primers for AIV subtyping are presented and discussed. 
 
  
Solid-ph  DNA microarray 
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7.1 DNA Microarray Based Solid Phase RT-PCR for Rapid Detection and Identification 
of Avian Influenza Virus 
Manuscript published in Diagnostic Microbiology and Infectious Diseases (2011), 69, 432–439. 
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Abstract
Endemic of avian influenza virus (AIV) in Asia and epizootics in some European regions have caused considerable public concern on a
possible pandemic of AIV. A rapid method for virus detection and effective surveillance in wild avian, poultry production as well as in
humans is required. In this article, a DNA microarray-based solid-phase polymerase chain reaction (PCR) approach has been developed for
rapid detection of influenza virus type A and for simultaneous identification of pathogenic virus subtypes H5 and H7. This solid-phase
RT-PCR method combined reverse-transcription amplification of RNA extract in the liquid phase with sequence-specific nested PCR on the
solid phase. A simple ultraviolet cross-linking method was used to immobilize the DNA probes over an unmodified glass surface, which
makes solid-phase PCR a convenient possibility for AIV screening. The testing of 33 avian fecal and tracheal swab specimens was completed
in less than 2 h with 94% accuracy.
© 2011 Published by Elsevier Inc.
Keywords: Avian influenza virus; Solid-phase RT-PCR; DNA microarray
1. Introduction
Avian influenza virus (AIV) belongs to the virus family
Orthomyxoviridae. It is an infectious disease and has caused
great economic losses in poultry and started to threaten
human life (WHO, 2010). The AIV genome consists of
8 segments of negative-sense single-stranded RNA. Based
on antigenic differences in the hemagglutinin (HA) and
neuraminidase (NA) proteins, AIV is divided into 16 HA and
9 NA subtypes, and is classified as either highly pathogenic
avian influenza virus (HPAIV) or low pathogenic avian
influenza virus (LPAIV) based on the ability to cause disease
and mortality (Alexander, 2007).
Although virus cultivation combined with hemagglutina-
tion inhibition (HI) and neuraminidase inhibition (NI) tests is
still the standard for influenza virus detection (Knipe and
Howley, 2001), many nucleic acid amplification techniques,
such as reverse transcriptase PCR (RT-PCR) (Lee et al.,
2001), real-time RT-PCR (Spackman et al., 2002), and real-
time NASBA (van Aarle et al., 2006), have been developed
for more sensitive and rapid diagnosis.
PCR amplification products can be analyzed in parallel by
using high-density oligonucleotide microarrays. Several
studies about microarray for AIV identifications have been
reported (Gall et al., 2009a; Han et al., 2008; Kessler et al.,
2004; Li et al., 2001; Wang et al., 2008). In these studies, the
AIV viral RNA was amplified through RT-PCR and the
resulting product was hybridized on the spotted probes and
detected through fluorescent labeling. Although differentia-
tion of all 16 HA subtypes of AIV has been demonstrated
(Gall et al., 2009b), hybridization as a post-PCR process
inevitably increased the complexity of the assay.
To enable multiplex amplification and sequence detection
done in one step, microarray-based solid-phase PCR was
developed (Huber et al., 2001). This approach combined
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liquid-phase PCR with simultaneous nested amplification
using oligonucleotide primers attached to a glass slide. The
PCR amplicons remained covalently bound to the solid
surface and could be identified by fluorescence scanning.
This method was further applied for single nucleotide
polymorphism detection (Huber et al., 2002; Pemov et al.,
2005; Shapero et al., 2001), bacteria identification (Mitterer
et al., 2004), and disease genotyping (Khodakov et al.,
2008). Solid-phase PCR has shown its advantages of high
throughput, ease of operation, and specific detection;
however, protocols for attaching probes on the glass surface
were complicated and the method has never been applied for
a fragile material like viral RNA.
In this article, we extended the strategy and developed a
DNA microarray platform where RT-PCR of viral RNA
occurred in the liquid solution and nested amplification
occurred on the microarray elements with specific oligo-
nucleotide probes for interrogating different influenza
types. A very simple ultraviolet (UV) cross-linking
immobilization procedure was used to immobilize TC-
tagged oligonucleotide probes on a bare glass slide. With
this method, AIV can be quickly detected with subtypes of
H5 and H7 simultaneously identified. Thirty-three speci-
mens from wild birds and experimentally infected chicken
were tested. The microarray-based platform can be a good
tool for rapid detection of AIV and could be widely
employed for on-site screening of potential AIV carriers in
wild and domestic poultry.
2. Materials and methods
2.1. Virus strains
Four inactivated AIV strains, namely, H1N1 A/DK/ALB
35/76, H5N1 A/CK/Scotland/59 06.04.67, H16N3-A/Gull/
Denmark/68110/02, and H7N5 A/Chick/Nether/2993–17/03
AV 506/03, were used in this study. Two strains, a
Newcastle diseases virus and an infectious bursal disease
virus (IBDV), were used to check the specificity of the PCR.
All the strains were kindly supplied by the National
Veterinary Institute, Technical University of Denmark.
2.2. Sample collection from wild birds for method validation
A total of 33 samples which include cloacal (n = 24) and
tracheal (n = 9) swabs were collected and used to validate the
solid-phase RT-PCR method. The samples were originating
from a national surveillance program for AIV in wild birds
(n = 20) and chickens experimentally infected with AIV (n =
13). The swabs were dipped in 2 mL phosphate-buffered
saline to release the fecal or tracheal materials from the
swabs. Nine hundred microliters of the mixture sample was
subjected to a centrifugal force of 18,894×g for 5 min
(Eppendorf, Hamburg, Germany) to remove debris, and the
supernatant was collected for isolating viral RNA.
2.3. Isolation of RNA from AIV virus
Isolation of RNA from AIV virus was performed using
the RNeasy Kit (Qiagen, Hilden, Germany) according to the
manufacturer's instruction. The RNA was eluted using
50 μL of RNase-free water. The isolated RNA was used as a
template for evaluation of the solid-phase RT-PCR.
2.4. Primers and probes
Table 1 shows a list of primers and probes used for
amplification. The matrix (M) gene was selected for AIV
screening as it has been found to be conserved across all type
A influenza viruses (Starick et al., 2000). Primers and probes
for H5 and H7 subtypes were targeted at the HA gene of the
influenza virus with avian origin. Each forward primer was
Cy5 labeled at the 5′ end so that the solid-phase RT-PCR
results could be directly visualized on the microarray. The
probes (immobilized primers) were modified at the 5′ end
with a poly(T)10-poly (C)10 tail to facilitate the attachment
to the solid substrate as previously described (Gudnason
Table 1
List of specific primers and probes used in this study
Type or subtype Target gene Primers and probes Sequences (5′–3′) Amplicon (bp)
A Matrix Forward DB-MF (24–47, sense) CY5-AGA TGA GTC TTC TAA CCG AGG TCG 100a
Reverse DB-MR (101–124, antisense) TGC AAA AAC ATC TTC AAG TCT CTG
M gene probe (74-93, sense) TTTTTTTTTTCCCCCCCCCC TCA GGC CCC CTC
AAA GCC GA
H5 HA Forward DB-H5LH1 (1508-1532, sense) CY5-ACA TAT GAC TAC CCA CAR TAT TCA G 151b
Reverse DB-H5RH1 (1640-1659, antisense) AGA CCA GCT AYC ATG ATT GC
H5 Probe (1613-1636, sense) TTTTTTTTTTCCCCCCCCCC TCW ACA GTG
GCG AGT TCC CTA GCA
H7 HA Forward DB-LH6H7 (1477-1503, sense) CY5-GGC CAG TAT TAG AAA CAA CAC CTA TGA 131c
Reverse DB-R4H7 (1586-1608, antisense) GCC CCG AAG CTA AAC CAA AGT AT
H7 Probe (1545-1574, sense) TTTTTTTTTTCCCCCCCCCC CCG CTG CTT AGT
TTG ACT GGG TCA ATC T
a Based on GenBank accession no. CY015082 (A/chicken/Scotland/1959 [H5N1]).
b Based on GenBank accession no. CY015081 (A/chicken/Scotland/1959 [H5N1]).
c Based on GenBank accession no. AB438941 (A/chicken/Netherlands/2586/2003 [H7N7]).
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et al., 2008). All the oligonucleotide primers and probes were
synthesized at DNA Technology, Denmark.
2.5. In-tube RT-PCR conditions
The in-tube multiplex RT-PCR was performed using a
RT-PCR kit (Qiagen). The RT-PCR conditions were based
on the manufacturer's instruction with minor modifications.
Briefly, a 25-μL RT-PCR reaction mixture contained 5 μL of
5 × RT-PCR buffer, 1 μL of 10 mmol/L DNTP mix, 1 μL of
enzyme mix, 5 μL of RNA sample, and three pairs of
primers, each at a final concentration of 0.2 μmol/L. RT-
PCR was carried out in a thermal cycler (MJ Research,
Massachusetts, USA) and the cycling protocol consisted of
reverse transcription for 30 min at 50 °C; enzyme activation
for 15 min at 95 °C; followed by 40 cycles of 10 s at 95 °C,
30 s at 54 °C, and 10 s at 72 °C; and, finally, extension of 5
min at 72 °C. The PCR amplicons were analyzed
quantitatively using the Agilent Bioanalyzer 2100 system
(Agilent, California, USA) with a DNA 500 chip kit
according to the manufacturer's instruction.
2.6. Preparation of DNA microarrays for solid-phase
RT-PCR
Microarray was produced on the glass slides by a simple
method using TC-tagged probes. Briefly, normal Super Frost
glass microscope slides were purchased from Menzel
(Braunschweig, Germany) and the glass slides were used
without any pretreatment or modification. The three oligonu-
cleotide probes with poly(T) 10-poly(C) 10 tails were diluted
in 150 mmol/L sodium phosphate buffer (pH 8.5) to a final
concentration of 50 μmol/L and spotted using a noncontact
array, Nano-Plotter 2.1 (GeSim, Dresden, Germany). The
array layout is shown in Fig. 1A. Spots had a diameter of
150 μm and the spot-to-spot distance was 300 μm. The spots
were allowed to dry and the probes were immobilized by UV
irradiation at 254 nm for 10 min using Stratalinker 2400
(Stragtagene, California, USA). Subsequently, the slides were
washed under agitation in 0.1× standard saline citrate (SSC)
with 0.1% (w/v) sodium dodecyl sulfate (SDS) (Promega,
Wisconsin, USA) solution for 10 min and then rinsed in
deionized water and dried by nitrogen.
2.7. On-slide solid-phase RT-PCR
The on-slide solid-phase RT-PCR method consists of two
phases: liquid phase and solid phase. The extracted RNA of
AIV strains was used directly on the array to develop the
method. Briefly, 25 μL of reaction master mix for solid-
phase RT-PCR containing 10 μL of 5× RT-PCR buffer, 1 μL
of 10 mmol/L DNTP mix, 1 μL of enzyme mix, 5 μL of
RNA sample, three pairs of primers each at a final
concentration of 1 μmol/L, 2.5 μL of 2.5 μg/μL bovine
serum albumin (BSA), and 6 μL self-sealing reagent (MJ
Research). The self-sealing reagent polymerizes upon
contact with air at high temperature and thereby seals the
reaction mixture at the edges to prevent evaporation during
RT-PCR. Immediately before use, the glass slides were
rinsed in BSA (2.5 μg/μL) at room temperature. This step
was to block the surface and reduce the absorption of
enzymes during reaction. The slides were then washed with
deionized water and dried using compressed air.
Ten microliters of the reaction master mix was loaded
directly on the oligonucleotide microarrays and coverslips
were mounted to seal the reaction droplets. The glass slides
were transferred to a twin-tower PTC 200 slide thermocycler
(MJ Research). PCR was carried out according to the
following program: 15 min at 50 °C for reverse transcription,
10 min at 95 °C for enzyme activation, followed by 40 cycles
of 10 s at 95 °C, 30 s at 54 °C, and 10 s at 72 °C, and, finally,
5 min at 72 °C for extension. After cycling, the slides were
washed with agitation in 0.1× SSC/0.1% SDS for 10 min,
followed by a short rinse in deionized water.
The microarrays were scanned by ScanArray Lite (Packard
Bioscience, MA), with appropriate laser power and photo-
multiplier tube settings. ScanArray software (Packard Biosci-
ence) was used to quantify the spots by calculating the average
pixel intensity inside the defined spots.
2.8. Sensitivity of the solid-phase RT-PCR
The sensitivity of the solid-phase RT-PCR was evaluated
and compared analytically with in-tube multiplex RT-PCR.
Fig. 1. (A) Microarray layout. The spotted solid-phase PCR probes for M,
H5, and H7 are represented as gray circles. Each dot is 150 μm in diameter
with a spot-to-spot distance of 300 μm. Green circles in the top and bottom
corners are guide dots used for orientation and grid alignment during
analysis. (B–D) Fluorescent images after 40 cycles of multiplex SP/RT-PCR
amplification of three different viral RNA strains, (B) H1N1, (C) H5N1, and
(D) H7N5.
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Ten-fold serial dilution of the AIV strain H16N3 ranging
from 100 to 10−9 was prepared. The HA titre value for the
AIV strains was measured to be 1:64. The 50% egg
infectious dose (EID50) calculated for the H16N3 strain
was 6.7log10 EID50 per milliliter. RNA was isolated from the
viral dilution series according to the method described
above, and 5 μL of each dilution was used as a template for
both in-tube RT-PCR and solid-phase PCR.
2.9. Specificity of the solid-phase PCR
The specificity for both the solid-phase RT-PCR and in-
tube multiplex RT-PCR was tested using RNA extracts of
avian pathogens with different subtypes, as well as RNA
isolated from NDV and IBDV virus strains.
3. Results
3.1. Development of in-tube multiplex RT-PCR
With an aim to develop a solid-phase method for rapid
detection and identification of AIV, an in-tube multiplex RT-
PCR was first carried out. In this multiplex PCR, three pairs
of primers were used to amplify the AIV conserved region on
the M gene and H5 and H7 regions on the HA gene. In-tube
RT-PCR was carried out to amplify three PCR amplicons
with expected lengths of 100, 151, and 131 bp for the M, H5,
and H7 fragments, respectively. Fig. 2 shows a bioanalyzer
figure of the results of amplifications where the RNA of three
AIV virus strains (H1N1, H5N1, H7N5), as well as of NDV
and IBDV, was used as a template. A fragment of 100 base
pairs (bp) from the M gene was detected in PCR products
from all of the three AIV viral RNAs: H1N1, H5N1, and
H7N5 (Fig. 2, lanes 1, 3, and 5). PCR amplicons with lengths
of 151 and 131 bp were only observed from H5N1 and
H7N5 viral RNA, respectively (Fig. 2, lanes 1 and 3). No
PCR product was observed when the RNAs of other
infectious viruses such as NDV and IBDV were used
(Fig. 2, lanes 2 and 4).
3.2. Solid-phase RT-PCR using RNA isolated from
AIV virus
A microarray-based solid-phase multiplex PCR was
developed to identify AIV at subspecies level as shown in
Fig. 3. During the reaction, the RNA was firstly reverse
transcribed to cDNA in the liquid sandwiched between the
glass slide and the cover lid. cDNA was then amplified
with three pairs of freely moving PCR primers as described
above (Fig. 3A). Simultaneously, the newly amplified PCR
amplicons in the liquid phase interacted with the nested
probes immobilized in the solid phase (Fig. 3B). If the
probes matched the bases in the template DNA, they were
extended by the polymerase, which served as the template
for the second-strand elongation primed by the liquid-phase
primers, thus generating new templates for the solid-phase
amplification. After the reaction, PCR products remained
on the glass slide through covalent binding and could be
directly visualized as the liquid-phase primer was labeled
with Cy5 dyes.
Fig. 1B–D shows the fluorescent images of the micro-
array after the solid-phase RT-PCR using RNA templates
from three different strains, H1N1, H5N1, and H7N5,
respectively. The three types of viruses were unambiguously
identified by the distinct patterns. For H1N1, only the probe
for the M gene was amplified (Fig. 1B), while with RNA
from the H5N1 strain, both the M and H5 probes were
positive (Fig. 1C), indicating that the virus belonged to
influenza type A and H5 subtype. With RNA from the AIV
H7N5 strain, both the M and H7 probes lightened up
(Fig. 1D). Despite the presence of all the primers and probes,
nonspecific amplification was negligible.
3.3. Analytical sensitivity of solid-phase RT-PCR
The sensitivity of the solid-phase RT-PCR system was
investigated and compared to multiplex RT-PCR in tubes. A
10-fold serial dilution (from 100 to 10−9) of the AIV H16N3
strain (HA 1:64) was prepared and the extracted RNA was
used as a template. For the multiplex RT-PCR in tubes, the
100-bp PCR amplicon of the M gene was observed up to
10−5 or equivalent to 1 log10 EID50/mL (Fig. 4A). A similar
detection limit was obtained for solid-phase RT-PCR on
slides where the lowest concentration of template at which
positive fluorescence signals could be detected was also 10−5
(Fig. 4B).
Fig. 2. In-tube multiplex RT-PCR for different virus strains. Three sets of
primers specific to influenza virus type A and two important HA subtypes
H5 and H7 were added into a single tube. Forty cycles of PCR were
performed and the results were obtained using the bioanalyzer. Lane 1:
H5N1; lane 2: NDV; lane 3: H7N5; lane 4: IBDV; lane 5: H1N1.
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3.4. Validation of solid-phase RT-PCR using real samples
To validate the performance of the method, 33 samples
from a national surveillance program for AIV in wild birds
were analyzed both by solid phase RT-PCR on slides and by
multiplex RT-PCR in tubes. Five microliters of the isolated
RNA was used as templates and the results are compared in
Table 2.
Of 33 samples, 14 (42.4%) were identified as AIV at
subspecies level using conventional culture and the rest of
the 19 samples (57.6%) were negative (Table 2, column 3).
With the use of multiplex RT-PCR in tubes, 14 (42.4%)
positive samples were recognized (Table 2, column 7),
whereas for the solid-phase RT-PCR method, 12 (39.4%)
samples were found to be AIV positive (Table 2, column 11).
Two samples, namely, 063234C and 063234T [cloacal (C)
and tracheal (T) swabs from the same bird], which were
identified as AIV H5N3 by conventional culturing and
inhibition tests as well as by RT-PCR in tubes, were shown
to be negative using solid-phase RT-PCR. In contrast, two
samples (0753794T and 0753594C) that could not be
subtyped by RT-PCR in tubes were correctly identified as
AIV H7 subtype by solid-phase RT-PCR. Four chicken
samples that were experimentally infected with different
non-AIV avian viruses (new cattle virus, IBD, and avian
penury virus) were all correctly identified as negative by
both methods. Overall, 31 (94%) of 33 samples were
identified accurately using the solid-phase RT-PCR.
4. Discussion
In recent years, HPAIV has caused massive economic
losses for the poultry industry and has been the cause of
death for hundreds of millions of birds around the world
(Rushton et al., 2005; WHO, 2005). Strong evidence
suggests that all known outbreaks of HPAIV have been
preceded by transmission of LPAIV of H5 or H7 subtypes
that was circulating in feral birds and transmitted to domestic
poultry (Ito et al., 2001). So far, RT-PCR has been applied
for the regular diagnosis of AIV (WHO, 2007). Therefore,
development of a mobile and automated method based on
RT-PCR would be a great advantage for rapid detection and
early warning of AIV infection.
Multiplex RT-PCR involves simultaneous amplification
of several PCR products; however, the formation of primer
dimers due to the presence of more than one primer pair in
the multiplex PCR increases the chances of undesirable
nonspecific RT-PCR products. Such products could be
avoided by optimizing primer design and RT-PCR condi-
tions. In this article, three sets of primers were carefully
chosen to target general influenza virus type A and two
highly pathogenic virus subtypes H5 and H7. Experiments
performed in tubes show that the three sets of primers
designed for the multiplex amplification were very specific
and did not interfere with each other.
Using the specific primers and probes designed for
multiplex RT-PCR, we developed a DNA microarray-based
solid-phase PCR platform for rapid identification of AIV.
Despite the great potential of solid-phase PCR, the
widespread use of the technology is limited. One of the
major causes lies in the tedious and time-consuming
procedures for surface treatment and DNA immobilization.
It took days to derivatize the glass surface and incubate the
slides after spotting (Huber et al., 2001; Mitterer et al., 2004).
In this study, a much faster and easier immobilization
method was developed by us where DNA probes with poly
Fig. 3. DNA Microarray-based solid-phase RT-PCR. (A) In the liquid phase, the RNA is firstly reverse transcribed to cDNA and then amplified with freely
moving PCR primers. (B) Simultaneously in the solid phase, the probes matched to the templates in solution are extended by the polymerase, which served as
templates primed by the liquid-phase primers, thus generating strands complementary to the extended probes.
436 Y. Sun et al. / Diagnostic Microbiology and Infectious Disease 69 (2011) 432–439
(T)10-poly (C)10 tails were immobilized over an unmodified
glass surface by simple UV cross-linking. The probes
modified with TC tails offer up to 70% cost reduction
when compared to the commonly used amino group
modifications of the probes and make solid-phase PCR a
convenient possibility for AIV screening. Another advantage
of our immobilization method is that the probes are thermally
stable. For other immobilization methods, it can be a
problem if the primer detaches during thermocycling. A 60%
loss of grafted primers during thermocycling was reported
(Fedurco et al., 2006). This is, however, not a problem with
our method. No significant decrease in fluorescence signal
was observed after 20 min of incubation in water at 100 °C
(Gudnason et al., 2008).
Fig. 4. Detection of H16N3 AIV by on-tube RT-PCR and solid-phase RT-PCR. Serial 10-fold dilutions of the extracted viral RNA templates, ranging from 100 to
10−9 were tested. (A) Sensitivity of on-tube RT-PCR. Amplified products (100 bp target for M gene) with different template concentrations are shown. One gel,
lane 1: 100 bp DNA ladder; lanes 2–9: 10-fold dilutions of the virus pool ranging from the original HA titre to 10−7, respectively; lane 10: negative control (virus
free); lane 11: positive control. The virus strain was not recognized at dilutions higher than 10−5. (B) Sensitivity of solid-phase RT-PCR. Fluorescence intensities
of probes specific to the M gene were measured. The detection limit was 10−5.
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The DNA microarray platform described in this article
combines liquid-phase amplification and specific solid-
phase PCR in 1 step. As probes are spatially separated,
nonspecific amplification is minimized. Moreover, apart
from array scanning, no other post-PCR steps are needed.
Solid-phase PCR is also advantageous when compared to the
more advanced real-time multiplex PCR as the latter suffers
from the interference of absorption and fluorescence spectra
and no more than four reactions can be reliably detected in
one assay (Khodakov et al., 2008).
The solid-phase PCR method was used to test 33
cloacal and tracheal swabs samples collected from wild
birds. Two (6%) of 33 samples showed a false-negative
result. This is probably because of the insufficient binding
of the probe and its target due to low viral concentration.
However, two samples that were not able to be subtyped
by in-tube RT-PCR were identified as AIV H7 subtype by
solid-phase RT-PCR, showing that solid-phase PCR has
higher specificity. In all, the testing of 33 avian fecal and
tracheal swab specimens was completed in less than 2 h
with 94% accuracy.
Last but not least, the small footprint of the microarray
makes it easily adaptable to a microfluidic chip format.
Various functional modules such as sample pretreatment
(virus concentration and purification), on-chip virus lysis,
and solid-phase RT-PCR typing array can be integrated on a
single device so that detection of AIV can be obtained in a
rapid and automated way. Research works in this direction
are in progress.
5. Conclusion
We have developed a DNA microarray-based solid-phase
RT-PCR method for rapid detection of AIV and simulta-
neous identification of the HA subtypes H5 and H7.
Oligonucleotide probes were immobilized on bare glass
surface by a much simpler and faster UV cross-linking
method. This is an important step forward towards the
development of a rapid and cost-effective test for AIV
screening in the laboratory or on-site. Compared to in-tube
multiplex PCR, the solid-phase PCR method involves fewer
Table 2
Detection and identification of AIV from 33 real samples by in-tube multiplex RT-PCR and solid-phase RT-PCR
No. Specimen ID Known
subtypea
In-tube RT-PCR Identification Solid-phase RT-PCR Identification
M H5 H7 M H5 H7
1 0853404T − − − − − −
2 0853404C − − −
3 781347C H5N2 + + − AIV, H5 type + + − AIV, H5 type
4 0853405T − − − − − −
5 0853405C − − − − − −
6 7860366C H6N8 + − − AIV + − − AIV
7 065341T − − − − − −
8 065393C − − − − − −
9 0653130T H5N3 + + − AIV, H5 type + + − AIV, H5 type
10 0653234 T H5N3 + + − AIV, H5 type − − − False negative
11 0653234 C H5N3 + + − AIV, H5 type − − − False negative
12 0850406 T − − − − − −
13 0850406 C − − − − − −
14 0753594T AIV + − − AIV + − + AIV, H7 type
15 0753594C AIV + − − AIV + − + AIV, H7 type
16 0853407T − − − − − −
17 0853407C − − − − − −
18 7860295T H5N1 + + − AIV, H5 type + + − AIV, H5 type
19 H5N2 H5N2 + + − AIV, H5 type + + − AIV, H5 type
20 0853408T − − − − − −
21 0853408C − − − − − −
22 H5N2 H5N2 + + − AIV, H5 type + + − AIV, H5 type
23 Lasota NDV − − − − − −
24 APV type C − − − − − −
25 IBV m41 − − − − − −
26 Beijing 184/93 − − − − − −
27 H7N1 H7N1 + − + AIV, H7 type + − + AIV, H7 type
28 H5N1 H5N1 + + − AIV, H5 type + + − AIV, H5 type
29 IBV − − − − − −
30 H7N7 H7N7 + − + AIV, H7 type + − + AIV, H7 type
31 IBD Cux52/70 − − − − − −
32 H11N6 H11N6 + − − AIV + − − AIV
33 NDV − − − − − −
a Measured using conventional culturing and HI and NI test with reference antisera (Knipe and Howley, 2001).
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steps, while comparable sensitivity and specificity have been
achieved. The microarray-based platform can be widely
employed for routine screening of potential carriers in wild
birds and domestic poultries.
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The endemic of Avian Influenza Virus (AIV) in Asia and epizootics in some European regions have
caused serious economic losses. Multiplex reverse-transcriptase (RT) PCR has been developed to detect
and subtype AIV. However, the number of targets that can be amplified in a single run is limited
because of uncontrollable primer–primer interferences. In this paper, we describe a lab-on-a-chip device
for fast AIV screening by integrating DNA microarray-based solid-phase PCR on a microfluidic chip.
A simple UV cross-linking method was used to immobilize the DNA probes on unmodified glass
surface, which makes it convenient to integrate microarray with microfluidics. This solid-phase
RT-PCR method combined RT amplification of extracted RNA in the liquid phase and species-specific
nested PCR on the solid phase. Using the developed approach, AIV viruses and their subtypes were
unambiguously identified by the distinct patterns of amplification products. The whole process was
reduced to less than 1 hour and the sample volume used in the microfluidic chip was at least 10 times less
than in the literature. By spatially separating the primers, highly multiplexed amplification can be
performed in solid-phase PCR. Moreover, multiplex PCR and sequence detection were done in one
step, which greatly simplified the assay and reduced the processing time. Furthermore, by incorporating
the microarray into a microchamber-based PCR chip, the sample and the reagent consumption were
greatly reduced, and the problems of bubble formation and solution evaporation were effectively
prevented. This microarray-based PCR microchip can be widely employed for virus detection and
effective surveillance in wild avian and in poultry productions.
Introduction
Avian influenza virus (AIV) or ‘‘bird flu’’ is an infectious disease
caused by Influenza A virus. Based on antigenic differences in the
hemagglutinin (HA) and neuraminidase (NA) proteins, AIV is
divided into 16 HA and 9 NA subtypes.1 The AIV is classified as
either highly pathogenic avian influenza (HPAI) or low patho-
genic avian influenza (LPAI) based on the ability to cause disease
and mortality.2 Reverse transcriptase PCR (RT-PCR) has been
introduced as the most sensitive method for detection and
pathotyping of AIV.3 Identification and subtyping of HPAI virus
by RT-PCR often involve multi-step amplifications, which make
the assay complicated and time-consuming.4 Multiplex RT-PCR
was then developed by targeting multiple genes at once.5,6
Detection and subtyping of AIV were gained from a single test
run that otherwise would require several tests to perform.
However, analysis using multiplex PCR is constrained by two
main limitations: the formation of primer–dimers due to the
uncontrollable primer–primer interferences and preferential
amplification of one target sequence over another.7 Moreover,
identification of multiplex PCR amplicons typically requires
a secondary method, such as slab gel, melting curve, microarray
hybridization or capillary electrophoresis,8 for size separation or
sequence verification.
To minimize the interferences in multiplex PCR, a technique
called solid-phase PCR has been developed by grafting one or
both primers on a solid support while keeping other PCR
components in the liquid phase.9,10 The primers can be immo-
bilized on microtiter plates,11 flat surfaces,12 or microbeads.13 In
each case, enzymatic extension of the primer produces a tethered
amplicon. Solid-phase PCR on DNA microarray has become
increasingly popular as highly multiplexed amplification could
occur in a miniature space with hundreds or thousands of
discrete immobilized primers.14–16 The multiplexing capabilities
are produced by spatially encoding the array, in which each spot
on the array is used to target a specific analyte. As the primers are
aDTU Nanotech, Department of Micro- and Nanotechnology, Technical
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spatially separated, the interferences between various primers are
minimized, and the number of different targets able to be
amplified in a single PCR reaction is greatly improved. The
technique has been applied for a variety of applications,
including diagnosis of infectious diseases16 and single-nucleotide
polymorphism (SNP) analysis.17 Solid-phase PCR has shown its
advantages of high throughput, ease of operation and specific
detection. However, protocols for attaching probes on the glass
surface were complicated and the method has never been applied
for a fragile material like viral RNA.
In conventional solid-phase PCR, a self-adhesive frame7 or
a glass coverslip18 is mounted on the oligonucleotide array to seal
the reaction mixture. In both cases, a large amount of PCR
samples are required. Moreover, air bubbles are easily trapped in
the aqueous phase and the solutions are subject to evaporation,
which could adversely affect the efficiency of solid-phase PCR.
The problems can be addressed by using lab-on-a-chip tech-
nology. Since the concept of lab-on-a-chip was proposed, PCR
microchips have been rapidly developed.19–21 The micro-
fabricated chips have characteristic dimensions in the order of
mm, and PCR samples could be processed in a much shorter time
with a high degree of fluid control. With the advances of
microfabrication techniques, DNA microarrays have been
incorporated into PCR microchips to detect PCR products by
hybridization where unique DNA sequences are recognized
through base pairing.22–24 However, PCR microchips with
microarrays for solid-phase PCR have seldom been reported.
In this paper, we describe a lab-on-a-chip device for rapid AIV
detection by integrating DNA microarray-based solid-phase
PCR on microchip. A 2 ml hybrid PDMS–glass chamber-based
PCR microchip was fabricated and a DNA microarray for
interrogating different influenza types was integrated in the chip.
A very simple UV cross-linking procedure was used to immo-
bilize TC-tagged oligonucleotide probes on the glass surface
without any surface modification. The immobilization method is
fast and thermally stable, making it a convenient to integrate
microarrays into microfluidic systems. The fragile viral RNA was
used as templates. The on-chip solid-phase PCR combined
reverse-transcription amplification of RNA extract in the liquid
phase and the simultaneous sequence-specific enzymatic exten-
sion of probes on the solid phase. The amplicons remained
covalently bound to the glass and could be directly detected after
PCR by fluorescence scanning. Using the developed approach,
AIV viruses and their subtypes were unambiguously identified by
their distinct patterns. Parameters such as the ratio of aqueous
primers and solid probe densities were optimized for the system
to improve efficiency of solid-phase amplification. This is the first
demonstration of incorporation of solid-phase PCR into PCR
microchip. Highly multiplex PCR can be performed on chip for
viral classification attributed to the high-throughput capabilities
of microarrays. Amplification and sequence detection are done
during solid-phase PCR in a single, valveless chamber, which
eliminates the need for post-PCR step and greatly simplifies the
assay. Moreover, despite the sample volume being at least ten
times less than that in the literature, ten-fold increase in detection
sensitivity has been achieved when compared to both solution-
based multiplex PCR and standard microarray method. The
device can be considered as a versatile tool for identification of
other genetic targets or it can also be integrated with other
functionalities such as sample preparation to develop an auto-
mated and fully integrated sample-in–answer-out system.
Experimental
Design of on-chip solid-phase PCR
Previous studies revealed that solid-phase PCR is generally less
efficient than conventional solution-based reactions.9,10 This
inefficiency may be attributed to a low primer concentration, its
inability to diffuse through solution or inefficient enzymatic
extension. Huber et al. proposed a method to allow the reaction
to proceed in the liquid phase and on the surface of the solid
phase simultaneously, which dramatically increased the product
yield on the solid support.25 The liquid-phase amplification
produced DNA templates to initiate amplification on the solid
phase and the accumulation of targets in a solution also served to
accelerate the solid-phase amplification. In this study, we
extended this strategy and developed an approach where RT-
PCR occurs in the liquid solution and nested amplification
occurs on the microarray elements with specific oligonucleotide
probes. For the liquid-phase PCR, three pairs of primers were
designed to amplify AIV conserved region on the matrix (M)
gene and H5 and H7 regions on the HA gene. For the solid-phase
amplification, three nested probes were spotted on the glass
surface to target the M, H5 and H7 templates generated in the
liquid. Though a multitude of unbound primers were added to
the liquid phase, the potential for primer interference is coun-
teracted by the superior specificity of nested amplification on the
solid surface.
The working model for on-chip solid-phase PCR is illustrated
in Fig. 1. The viral RNA and RT-PCR mixture is pumped into
the chamber. Subsequently, the chamber is sealed and RT-PCR
is performed by temperature cycling (Fig. 1a). The RNA is first
reverse transcribed to complementary DNA (cDNA) in the
liquid (Fig. 1b). cDNA is then amplified with freely moving PCR
primers (Fig. 1c). Simultaneously, the newly amplified PCR
amplicons in the liquid phase interact with the nested probes
immobilized on the solid phase (Fig. 1d). If the probes match the
bases in the template DNA, they are extended by the polymerase
(Fig. 1e). In the next cycle, the extended probe served as
templates for the second strand elongation primed by the
forward primers in the liquid phase (Fig. 1f), thus generating new
templates for the solid-phase amplification (Fig. 1g). After the
reaction, PCR products remain attached to the glass slide
through covalent binding and could be directly visualized as the
forward primers in the liquid phase were labelled with Cy5 dyes.
Detection of influenza virus A and simultaneous identification of
two highly pathogenic AIV subtypes H5 and H7 are achieved by
examining the specific patterns of the microarray.
Viral strains
Four different inactivated AIV strains and one strain of New-
castle diseases virus (NDV) were used in this study. The
phenotypes, sources of isolation and HA titres of the viral strains
are listed in Table 1. They were provided by the National
Veterinary Institute of Denmark.
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RNA extraction
Isolation of RNAs from virus strains was performed using the
RNeasy Kit (Qiagen, Germany) according to the manufacturer’s
instruction. The RNAs were eluted using the RNase free water.
The isolated RNAs were used as templates for evaluation of the
solid-phase PCR.
Primer and probes
Table 2 shows a list of primers and probes used for AIV identi-
fication and subtyping. The M gene-specific primers and probes
were designed for AIV screening as it has been found that the
region on the M gene is conserved across all type A influenza
viruses.4 Primers and probes for H5 and H7 subtypes were
designed to target the H5 and H7 regions on HA gene of Influ-
enza virus with avian origin. Each forward primer was Cy5-
labeled at the 50 end so that the solid-phase PCR results could be
directly visualized on the microarray. The probes (immobilized
primers) were modified at the 50 end with a poly(T)10–poly(C)10
tail to facilitate the attachment on the solid substrate. All the
oligonucleotide primers and probes were synthesized at DNA
Technology A/S, Denmark.
Preparation of DNA microarrays on glass substrate
Microarray was produced on an unmodified glass substrate by
simple UV cross-linking according to a method developed in our
lab.26 Briefly, a glass chip of 10 mm  10 mm was diced from
a 0.5 mm glass wafer using a Dicing Saw (Disco, Japan) and was
used without any pre-treatment or modification. The three
oligonucleotide probes with poly(T)10–poly(C)10 tails were
diluted in 150 mM sodium phosphate buffer (pH 8.5) to a final
concentration from 5 to 50 mM and spotted using a non-contact
array nano-plotter 2.1 (GeSim, Dresden, Germany). The layout
is shown in Fig. 3a. The array was spotted at the centre of the
glass chip and each probe was repeated four times for easy
identification of the reaction products. The spot had a diameter
of 150 mm and the spot-to-spot distance was 300 mm. The spots
were allowed to dry and then exposed to UV irradiation at
254 nm with an energy of 0.3 J cm2 for 10 min (Stratalinker
2400, Stratagene, CA, USA). Subsequently, the glass chip was
washed under agitation in 0.1 standard saline citrate (SSC)
with 0.1% (w/v) sodium dodecyl sulfate (SDS) (Promega, WI,
USA) solution for 10 min, then rinsed in deionized water and
dried under nitrogen.
Microfabrication
The PCR microchamber was fabricated in polydimethylsiloxane
(PDMS) by rapid prototyping. The mask layout was designed
using a CAD program. The master for molding was fabricated in
SU-8 50 (MicroChem, MA, USA) by the standard photo-
lithography. A 10 : 1 mixture of PDMS pre-polymer and curing
agent (Sylgard 184, Dow Cornig, MI, USA) was stirred thor-
oughly and then poured onto the master and cured for 1 h at
65 C. After curing, the 1 mm thick PDMS replica was peeled
from the master. Inlet and outlet holes were punched by a needle.
The PDMS substrate and the glass chip with DNA microarray
were sealed by plasma bonding. Both PDMS and glass substrates
were exposed to oxygen plasma for 30 s at 100 W with an oxygen
flow rate of 240 ml min1 (Plasma Processor 300, PVA TePla,
Germany). Right after the removal from the plasma chamber,
the substrates were brought into conformal contact where an
irreversible seal formed spontaneously. Though the probe array
was also exposed to oxygen plasma, test showed that the func-
tionality of DNA as probes for PCR was not affected at such low
power exposure. As shown in Fig. 2, the outer dimension of the
Fig. 1 The concept of on-chip solid-phase PCR for rapid AIV detection.
(a) The viral RNA and RT-PCR mixture is pumped into the chamber. (b)
The RNA is reverse transcribed to cDNA in the liquid. (c) cDNA is
amplified with freely moving PCR primers. (d) The newly amplified PCR
amplicons in the liquid phase interact with the nested probes immobilized
on the solid support. (e) The matched probes are extended by the poly-
merase. (f) In the next cycle, the forward primers in the liquid phase are
annealed to the extended probes. (g) Complementary strands are gener-
ated and serve as new templates for the solid-phase amplification. After
the reaction, PCR products remain attached to the glass slide through
covalent binding and could be directly visualized as the forward primers
are labeled with Cy5 dyes.
Table 1 List of sources and hemagglutination titre (HA titre) of viral
strains used in this study
No. Viral strains and sources Titre (HA)
1 H1N1 A/DK/ALB 35/76 1 : 16
2 H5N1 A/CK/Scotland/ 59 06.04.67 1 : 256
3 H7N5-2 A/Chick/Nether/2993—
17/03 AV 506/03
1 : 128
4 Newcastle diseases, Ulster strain 1 : 128
5 H16N3—A/Gull/Denmark/68110/
02
1 : 128
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microchip was 10 mm  10 mm and the volume of the micro-
chamber was 2 ml.
On-chip solid-phase PCR
25 ml PCR reaction mix was prepared which consisted of 10 ml of
5 x RT-PCR buffer, 1 ml of 10 mM DNTP mix, 1 ml of 2 ml
/reaction enzyme mix, 2.5 ml of 2.5 mg ml1 BSA (Onestep RT-
PCR kit, Qiagen, Germany), three pairs of primers with a final
concentration of 1 mM for forward primers and 0.5 mM for
reverse primers, and 5 ml RNA sample. 2 ml of the mixture was
loaded into the microchamber. The whole chip was placed in
a homemade chip holder and the inlet and outlet were then sealed
by pressing rubber plugs down on the holes. The chip holder was
put on a flatbed thermocycler (MJ Research Inc., MA, USA).
PCR was carried out according to the following program: 15 min
at 50 C for reverse transcription, followed by 40 cycles of 1 s at
95 C, 5 s at 54 C and 3 s at 72 C, and finally 3 min at 72 C for
extension. After the cycling, the microchamber was washed with
0.1 SSC per 0.1% SDS and deionized water.
The microarray in the microchip was scanned by an array
scanner (LaVision BioTec, Germany). Fluorescence imaging and
processing software (LaVision BioTec, Germany) was used to
quantify the spots by calculating the average pixel intensity inside
the defined spots.
Sensitivity of solid-phase PCR
The sensitivity of the solid-phase PCR was evaluated. Ten-fold
serial dilution of an AIV strain H16N3 ranging from 100 to 109
was made and the RNA was isolated from the virus dilution
series according to the method described above. The hemagglu-
tination titre (HA titre) value for the AIV strain was measured to
be 1 : 64. The fifty percent egg infectious dose (EID50) calculated
for H16N3 strain was 6.7 log10 EID50 per ml. 5 ml of RNA was
used as template and added to 20 ml PCR master mix.
Results and discussion
DNA immobilization on unmodified glass surface
Conventionally, fabrication of DNA microarrays on glass slides
requires tedious and time-consuming procedures for surface
treatment and DNA immobilization,14,25 which seriously hinders
the integration of microarrays into microfluidic systems. In this
study, a much faster and easier immobilization method was
developed by us where DNA probes with poly(T)10–poly(C)10
tails were immobilized on the unmodified glass surface by simple
UV cross-linking. During UV exposure, covalent bonds are
formed between the TC tag and the glass surface. The probes
modified with TC tails offer up to 70% cost reduction when
compared to the commonly used amino group modifications of
the probes and make solid-phase PCR a convenient possibility
for AIV screening. Another advantage of our immobilization
method is that the probes are thermally stable. For other
immobilisation methods it can be a problem that the primer
detaches during thermo-cycling. A 60% loss of grafted primers
during thermo-cycling was reported.27 This is, however, not
Table 2 List of primers and probes specific to the conserved region of M gene and H5 and H7 regions of HA gene
Type or subtype Target gene Primers and probes Sequences (50–30) Amplicon (bp)
A Matrix Forward DB-MF CY5-AGA TGA GTC TTC TAA
CCG AGG TCG
98
Reverse DB-MR TGC AAA AAC ATC TTC AAG
TCT CTG
M gene probe TTTTTTTTTTCCCCCCCCCC
TCA GGC CCC CTC AAA
GCC GA
H5 HA Forward DB-H5LH1 CY5-ACA TAT GAC TAC CCA
CAR TAT TCA G
151
Reverse DB-H5RH1 AGA CCA GCT AYC ATG ATT
GC
H5 Probe TTTTTTTTTTCCCCCCCCCC
TCW ACA GTG GCG AGT
TCC CTA GCA
H7 HA Forward DB-LH6H7 CY5-GGC CAG TAT TAG AAA
CAA CAC CTA TGA
131
Reverse DB-R4H7 GCC CCG AAG CTA AAC CAA
AGT AT
H7 Probe TTTTTTTTTTCCCCCCCCCC
CCG CTG CTT AGT TTG
ACT GGG TCA ATC T
Fig. 2 Photograph of the hybrid PDMS–glass microchip. DNA
microarray was spotted on the glass substrate. The outer dimension of the
microchip was 10 mm  10 mm and the volume of the microchamber was
2 ml.
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a problem with our method. No significant decrease in fluores-
cence signal was observed after 20 min incubation in water at
100 C.26
Specificity of on-chip solid-phase PCR
On-chip solid-phase amplifications were conducted with RNA
extracts from four viral strains: H1N1, H5N1, H7N5, and NDV
respectively. As shown in Fig. 3, with the developed microchip,
three AIV viral strains were accurately identified by the distinct
patterns of amplified products. No positive signal was obtained
for the NDV. In particular, non-specific amplification was
almost negligible as the probes in solid-phase PCR were spatially
separated. The simple visual inspection of the fluorescence scan
images suggested that the multiplex solid-phase amplification is
an efficient and specific procedure. But it was also noticed that
significant amounts of spot intensity variations were produced
for different kinds of probes. As suggested by Huber et al.,28 this
was due to some inherent factors such as microarray substrate
quality, template quality, and sequence properties of the
analyzed DNA fragments. Nevertheless, all strains tested in this
study were unambiguously distinguished from each other based
on their specific combinations of fluorescence products. The
number of solid-phase probes can be continually extended to
include sequences for additional AIV subtypes.
Optimization of solid-phase amplification
In this study, parameters such as the ratio of aqueous primers
and solid-phase probe density that are likely to affect solid-phase
PCR were optimized to ensure efficient amplification. RNA
extracted from 101 AIV H16N3 strain was used as template for
the amplification.
As the aqueous forward primers were designed to bind to both
templates in the solution and amplicons tethered on the solid
support, the reverse primers were included at a limiting
concentration to lower the competition with solid probes. The
optimum primer ratios were identified by keeping the concen-
tration of reverse primers at 0.5 mM while increasing the
concentration of forward primers from 0.5 mM to 5 mM. When
the forward primers in the liquid were doubled from 0.5 mM to
1 mM, 20% increase in the amount of immobilized amplicons was
observed. Further increase in the concentration had no effect on
the yield of solid-phase amplifications. Therefore, 1 mM forward
primers were used to ensure amplification was not limited by the
amount of aqueous primers in the reaction.
The probe density is another important factor that could limit
the amount of amplicons. The density of probes immobilized on
the glass substrate was changed by varying the spotting
concentrations from 5 mM to 50 mM. As shown in Fig. 4, the
amount of amplicons increased linearly when the probe
concentration was raised from 5 mM to 20 mM. But increasing the
concentration from 20 mM to 40 mM had no significant effect on
the yield of the immobilized amplicons, while an excess number
of probes reduced the yield of solid-phase amplifications, indi-
cating that too high probe density negated amplification. The low
amplification efficiency at high probe concentration may have
several explanations. One explanation could be screening effect:
when the probes are immobilized at high density, the high
negative charges in close proximity to a solid support disturb
polymerase functioning on the surface and repel of target DNA
in solution, thus reducing the extension efficiency. Another
explanation could be that abnormal target–probe and probe–
probe interactions on planar microarrays are intensified at higher
probe density, therefore decreasing the amount of accessible
probes on the chip and reducing priming and amplification effi-
ciency. For this system, the maximum amplification efficiency
Fig. 3 Specificity of on-chip solid-phase PCR. (a) Microarray layout.
The DNA probes for M gene and HA genes specific for H5 and H7 are
represented as gray circles. Each dot is 150 mm in diameter with a center-
to-center distance of 300 mm. Green circles are guiding dots used for
orientation. Fluorescent images after 40 cycle amplification of four
different viral RNA strains: (b) AIV H1N1, (c) AIV H5N1, (d) AIV
H7N5 and (e) Newcastle disease virus (NDV). The strong fluorescence
outside of the chip is due to the autofluorescence of PDMS residues.
Fig. 4 Effect of probe concentration on solid-phase RT-PCR. Solid-
phase amplification of 101 H16N3 viral RNA was performed in replicate
reactions with probe concentration varied from 5 mM to 50 mM. 1 mM
forward primers and 0.5 mM reverse primers were contained in the PCR
solution. Fluorescence intensities of probes specific to M gene were
measured. Values represent the mean fluorescence and the standard
deviation of triplicate reactions for each probe concentration.
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was achieved at the combined condition of 1 mM forward primers
and 20 mM immobilized probes.
Detection limit of on-chip solid-phase PCR
The sensitivity of the on-chip solid-phase PCR was determined
and compared analytically with solution-based multiplex RT-
PCR. 10-Fold serial dilution (from 100 to 109) of RNA extracted
from AIV H16N3 strain was amplified in triplicate reactions. As
shown in Fig. 5, the lowest concentration of template at which
positive fluorescence signals could be detected for solid-phase
PCR was 106, or equivalent to 0.7 log10 EID50 per ml. The
fluorescence increased with template concentration, suggesting
that more amplification occurred on the surface at higher
template concentration. The signal reached a plateau when the
RNA template was present at 101, indicating the surface became
saturated with the PCR products. The coefficient of variation of
the replicate reactions was 8% on average. The detection limit of
the solution-based multiplex PCR using the same biological
model was 105, or equivalent to 1 log10 EID50 per ml, similar to
that published in the literature29 (see ESI†). Compared to liquid-
based amplification, 10-fold improvement was achieved by on-
chip solid-phase PCR.
Compared to solid-phase PCR using a coverslip or a self-adhesive
frame
In conventional solid-phase PCR, a glass coverslip or a self-
adhesive frame is mounted onto the oligonucleotide array to seal
the reaction mixture. In both cases, a large amount of PCR
samples (25 ml for standard Gene frame) are required.7 The large
sample mass requires lengthy time for denaturation and
annealing, and total reaction times are typically in excess of
2 hours. In addition, air bubbles are easily trapped under the
coverslip or in the frame even with very careful handling, which
could adversely affect the efficiency of solid-phase PCR. More-
over, self-seal reagent is usually contained in the reaction mixture
to prevent evaporation during PCR, which polymerizes upon
contact with air at high temperature and thereby seals the reac-
tion at the edges. While the effect of polymerization on solid-
phase PCR is still under investigation, MJ Research Inc. has
stopped the supply of the self-seal reagent and a substitute
product has not appeared in the market. This poses a great
challenge to solid-phase amplification.
In our approach, a 2 ml chamber-based PCR microchip was
fabricated to replace the conventional coverslip or frame. As the
sample volume was greatly reduced, the denaturation and
annealing steps occurred as soon as the correct temperature was
reached, and the process was only limited by the extension step.
Consequently, the total reaction time was shortened by half.
Furthermore, due to the micron sized feature dimension and the
closed fluidic format of the microchip, the small amount of
samples could be manipulated and processed with a high degree of
control. Solution evaporation and bubble formation were effec-
tively prevented. Compared to solid-phase PCR carried out using
the coverslip or frame, the amplification in PCR microchip
provided better performance as the detection limit achieved on-
chip (106) was 10-fold better than that obtained using the
coverslip (105)30 (see ESI†). PCR microchip and DNA micro-
array have been shown to be a perfect combination, which affords
gains in terms of control, speed, efficiency and functionality.
Conclusions
In conclusion, we have developed a simple lab-on-a-chip device
for rapid screening and subtyping AIV viral RNA based on on-
chip solid-phase PCR. The platform combines RT-PCR in the
liquid phase and simultaneous nested amplification with species-
specific oligonucleotide probes on the solid surface. Different
AIV viral strains were accurately identified by the distinct
patterns of reaction products. By immobilizing probes on the
glass surface, primer interference effects are minimized, such that
the number of AIV subtypes to be identified can easily be
extended by adding more species-specific oligonucleotides to the
microarray. Moreover, no post-PCR step is needed apart from
array scanning, which prevents potential cross-contamination
and facilitates the process for AIV detection. By combining the
superior specific multiplex format of solid-phase PCR with low
reagent consumption and fast cycling provided by the PCR
microchip, the platform can be widely employed by veterinarians
for on-site rapid screening of AIV in wild and industrial domestic
poultries.
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Supplementary Information to paper “A lab-on-a-chip device for rapid 
identification of avian influenza viral RNA by solid-phase PCR” 
 
The sensitivity of two other AIV identification methods - multiplex solution-based RT-PCR and 
conventional solid-phase PCR with cover slip, were determined. The limit of detection was 
compared to that achieved by on-chip solid-phase PCR as described in the paper. 
 
Sensitivity of solution-based multiplex RT-PCR  
  
10-fold serial dilution of AIV strain H16N3 ranging from 100 to 10-9 was prepared. 
Hemagglutination (HA) titre values for the AIV strains were measured to be 1:64. The fifty percent 
egg infectious dose (EID50) calculated for H16N3 strain was 6.7log10 EID50 per ml. RNA was 
isolated from the viral dilution series and 5µl of each dilution was used as template. The multiplex 
RT-PCR was performed using a RT-PCR kit (Qiagen, Hilden, Germany). The RT-PCR conditions 
were based on the manufacturer’s instruction with minor modification. Briefly, a 25 μl reaction 
mixture contains 5 μl of 5× RT-PCR buffer, 1 μl of 10 mM DNTP mix, 1 μl of enzyme mix, 5 μl of 
RNA sample, and three pairs of primers, each at a final concentration of 0.2 μM. PCR was carried 
out in a thermal cycler (MJ Research Inc., MA, USA) and the cycling protocol consisted of 30 min 
at 50 ºC for reverse transcription, 15 min at 95 ºC for enzyme activation, followed by 40 cycles of 
10 sec at 95 °C, 30 sec at 54 °C and 10 sec at 72 °C, finally 5 min at 72 °C for extension. The PCR 
amplicons were analyzed using slab gel. As shown in Fig. 1, the 100 bp PCR amplicon of M gene 
was observed up to 10-5 or equivalent to 1 log10 EID50/ml.  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Detection of H16N3 AIV by solution-based multiplex RT-PCR. Serial 10-fold dilutions of 
the extracted viral RNA templates, ranging from 100 to 10-9, were tested. Amplified products (100 
bp target for M gene) with different template concentrations are shown. Lane 1: 100 bp DNA 
ladder; Lane 2 – 9: 10-fold dilutions of the virus pool ranging from the original HA titre to 10-7, 
respectively; Lane 10: Negative control (virus free); Lane 11: Positive control. The virus strain was 
not recognized at the dilutions higher than 10-5 or equivalent to 1 log10EID50/ml.  
 
Sensitivity of conventional solid-phase PCR with cover slip 
 
10-fold serial dilution of AIV strain H16N3 ranging from 100 to 10-9 was prepared and RNA was 
isolated from the viral dilution series. Microarray was produced on the glass slides by using TC-
tagged probes as described in the paper. 25 μl reaction master mix for solid phase RT-PCR contains 
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10 μl of 5× RT-PCR buffer, 1 μl of 10 mM DNTP mix, 1 μl of enzyme mix, 5 μl of RNA sample, 
three pairs of primers with each at a final concentration of 1 μM, 2.5 μl of 2.5 μg/μl BSA and 6 μl 
self sealing reagent (MJ Research, Inc., MA, USA).  
 
10 μl master mix was loaded directly on the oligonucleotide microarrays and cover slips were 
mounted to seal the reaction droplets. The glass slides were transferred into a twin tower PTC 200 
slide thermocycler (MJ Research Inc., MA, USA). PCR was carried out according to the following 
program: 15 min at 50 ºC for reverse transcription, 10 min at 95 ºC for enzyme activation, followed 
by 40 cycles of 10 sec at 95 °C, 30 sec at 54 °C and 10 sec at 72 °C, and finally 5 min at 72 °C for 
extension. After cycling, the slides were washed with agitation in 0.1× SSC/0.1% SDS for 10 min, 
followed by a short rinse in deionized water. The microarrays were scanned by ScanArray Lite 
(Packard Bioscience, MA, USA), with appropriate laser power and PMT settings. ScanArray 
software (Packard Bioscience, MA, USA) was used to quantify the spots by calculating the average 
pixel intensity inside the defined spots. 
 
As shown in Fig. 2, similar detection limit was obtained for solid-phase RT-PCR with cover slips, 
where the lowest concentration of template at which positive fluorescence signals could be detected 
was also 10-5 or equivalent to 1 log10 EID50/ml. In this paper, for solid-phase PCR performed in the 
microchamber, the lowest concentration of template at which positive fluorescence signals could be 
detected was 10-6, or equivalent to 0.7 log10 EID50/ml. Compared to both solution-based multiplex 
PCR and solid-phase PCR with cover slips, 10-fold improvement was achieved by on-chip solid-
phase PCR.   
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Fig. 2 Detection of H16N3 AIV by conventional solid-phase PCR with cover slip. Serial 10-fold 
dilutions of the extracted viral RNA templates, ranging from 100 to 10-9, were tested. Fluorescence 
intensities of probes specific to M gene were measured. The detection limit was also 10-5 or 
equivalent to 1 log10 EID50/ml. 
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7.3 Development of simultaneous detection and haemagglutinin subtyping of Avian 
Influenza Viruses using solid-phase RT-PCR  
7.3.1 Introduction 
In section 7.1 and 7.2 solid-phase RT-PCR that combines 
multiplex reverse-transcription amplification of RNA target in 
the liquid-phase and sequence-specific nested PCR was 
developed successfully in both microscopic glass slide and 
PDMS chip. However, the developed method can only detect 
two subtypes H5 & H7 among 16 HA types. Subtyping of all 
the 16 HA types is essential for the identification of 
circulating AIV strains that could emerge as a pandemic 
influenza virus[44]. In this section, the research is therefore 
focused on development of simultaneous detection and 
haemagglutinin subtyping of all 16 HA subtypes of AIV.  
 
The standard diagnostic method for HA subtyping is 
haemagglutinin inhibition (HI) test (See section 3.4). The HI 
test is performed only at reference laboratories due to the 
limited supply of antisera, the highly variation within a 
subtype, and the cross-reactivity among different subtypes 
[61]. Thus a reliable subtyping method that can be easily 
applied at most diagnostic laboratories is needed. Subtyping of 
AIV based on rRT-PCR has been considered as sensitive and 
specific methods (see section 4.3 to 4.4) that can be performed 
in normal diagnostic laboratories.  However, rRT-PCR based 
on multiplexing has a limit for the number of targets that can be detected simultaneously because 
of the limit in availability of fluorescent dye combinations[108].  
 
Microarrays provide an opportunity to detect many targets simultaneously. Recently, great 
efforts were made in utilizing a combination of RT-PCR and a microarray for not only subtyping 
Figure 7.3.1 Scheme of 
simultaneous subtyping of 
all hemagglutinin types 
(H1-H16) using solid-phase 
RT-PCR.  
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but also for pathotyping of AIV[112-115]. However, in those studies the combination of RT-PCR 
amplification and microarray detection has often been performed in multiple steps and the 
protocol is complicated. In this study, we aimed to develop a method that combines microarray 
and solid phase RT-PCR for AIV detection and simultaneous HA subtyping (H1-H16) (Figure 
7.3.1). As a first step to develop such method, primers and probes were designed and tested.  
7.3.2 Materials and Methods 
Design of oligonucleotides 
The RT-PCR capture-probes (CP) and primers were designed based on sequence information 
obtained from the NCBI Influenza Virus Resource Database (IVRD)[178]. A total of 200 AIV 
strains with at least 10 sequences of each of 16 HA that originated from different geographical 
(Europe and Asian) locations were selected for this study. These sequences were aligned using 
the “Alignment tool” of CLC Workbench program, version 5.0.2 (CLC bio, Aarhus, Denmark). 
On the alignment the conserved regions of HA1 and HA2 serve as annealing sites for a forward 
and a reverse primer to amplify the HA cleavage site [179] whereas the variable region (within 
the two primers region) was used to search for the sequences that could be used as probes for 
subtyping HA (H1 to H16) of AIV (Figure 7.3.2). The 16 HA CP were designed according to the 
similarities within the HA subtypes. 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.3.2 Scheme of HA subtyping to detect all 16 HA subtypes at the HA cleavage site 
(reproduced from ref [180]).  
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RT-PCR 
A one-step RT-PCR was performed using One-Step RT-PCR kit (Qiagen, Copenhagen, 
Denmark). The RT-PCR mixture (10 μl per reaction) contained 2 μl of RNA, 0.4 μl of each 
primer (50 μM), 2 μl of RT-PCR buffer, 4.4 μl of RNase-free water, 0.4 μl of dNTP and 0.4 μl of 
enzyme mix. The RT-PCR cycling conditions were 50 °C for 30 min and 95 °C for 15 min 
followed by 40 cycles of 94°C for 10s , 50 °C for 30 s, and 72 °C for 10 s and finally 72 °C for 3 
min. The results were analysed by electrophoresis on a 1.5% agarose gel. 
 
AIV Subtyping  
The designed probes for subtyping the 16 HA types were first tested using RT-PCR. Each probe 
was used as a forward primer in a HA primer set and tested by RT-PCR. The specificity of each 
HA probe was tested using RT-PCR with RNA isolated from other HA subtypes.  
7.3.3 Results and Discussions 
Design of primers and capture-probes for subtyping of 16 HA Subtypes of the AIV 
Table 7.3.1 shows a list of primers and capture-probes that were designed in this study. Due to a 
high variation among the 16 HA subtypes, the consensus of HA primer includes some degenerate 
sequence with several bases that permit binding to all or most common known variants on the 
conversed region (Figure 7.3.3). These degenerated primers would also find genes or subtypes 
that would emerge by a change in the HA cleavage region. A number of publications have used 
degenerated primers for the amplification of HA or NA genes as well as for subtyping of 
AIV[179-182]. Our approach differs from these studies, since the use of solid-phase PCR that 
could provide a cost effective system needed in the future for fast and accurate identification of 
any emerging new AIV subtypes during large screening and surveillance[183]. The use of solid-
phase PCR with several probes specific for each of HA subtype can be used and reduces the risk 
of non-specific amplification involved in degenerate primers. 
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Figure 7.3.3 A simplified alignment of all 16HA subtypes of AIV. The big letter/bar in the 
sequence logo/conversation represents the consensus in all subtype. 
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Table 7.3.1 List of designed primers and probes for typing of 16 HA subtypes of AIV. The 
degenerate position are  R:A+G, Y:C+T, M:A+C, K:G+T, W:A+T, H:A+T+C, D:G+A+T, 
N:A+G+C+T 
Oligonucleotide Sequence (5’-3’) 
HA_Fwd GGD RMN TGY CCN ARR TAY RT 
HA_Rev GHY KRW ANC CRT ACC ANC C 
H1 Probe CAA GAG CAC CAA ACT AAG AAT GGC AA 
H2 Probe ATC GGA AAG ATT GGT ATT AGC AAC AGG 
H3 Probe AT GCG GAA TGT ACG AGA GAA GCA AA 
H4 Probe CAA ACA GGG CTC TCT AAA ACT TGC AA 
H5 Probe AA  ATC AGA TAG GTT GGT CCT TGC AAC T 
H6 Probe AAA AGT GAT AGC  CTA AGA CTG GCA AC 
H7 Probe GCA AGA GAG TCT GCT GTT GGC A    
H8 Probe T TAG GAA TAC GCC TTC TGT TGA ACC 
H9 Probe GGA GTG AAA AGT CTC AAA TTG GCA GT 
H10 Probe TMA GAR GAG TTT RMT GCT TGC AAC A 
H11 Probe TGT CAA ATC CTT AAA GCT TGC AAC AGG 
H12 Probe TC AGG GAG TTT AAA ATT GGC AAT AGG G 
H13 Probe A GTC TGG CCA ACT CAA GCT AGC 
H14 Probe CGC AAC ATC CCT GGC AAA CAG      
H15 Probe A ATC AAG CTT GCC GCT GGC CTT      
H16 Probe A GTC TGG GCA ACT AAA ACT TGC TAC T 
 
HA primer set for detection of AIV 
The designed HA primer set was tested and evaluated using RT-PCR with RNA from all 16 
different HA subtypes (Table 1 of section 6.1).  Figure 7.3.4 shows such results. Using, primer 
set namely HA_Fwd / HA_Rev (Table 7.3.1) all the 16 HA subtypes of the AIV were amplified 
successfully. A difference in the signal intensity of RT-PCR was observed that could be due to 
the differences in the binding energies and the preferential amplification of sequences containing 
G/C rich primer sites[184]. To determine the specificity of the HA primer set, RT-PCR was 
performed with RNA extracted from faecal sample as well as with RNA isolated from two 
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strains of NDV virus (La Sota and Ulster strains). Figure 7.3.5 shows the results of such 
experiment. Although the HA primers contain degeneracy, the specificity test showed no PCR 
amplification for both the RNA extracted from Chicken faecal (isolated from AIV-free Chicken) 
and the NDV virus strains were observed. This demonstrates the usefulness of the HA primer for 
amplification of HA cleavage region for further subtyping and pathotyping. 
 
Figure 7.3.4 RT-PCR results with the designed HA primers tested with 16HA types. On gel: lane 
1 to 16 represent subtype of H1 to H16. M: Marker 100bp (Inivtrogen) 
 
 
 
 
 
 
 
 
Figure 7.3.5 RT-PCR specificity test for A) HA primer set and B) control NDV primer set. Lanes 
1) with RNA from NDV virus strain La Sota, 2) with RNA from NDV virus strain Ulster strain, 
3) with RNA from chicken faecal sample, 4) negative control and 5) positive control.  M) Marker 
100bp (Inivtrogen).  
 
Subtyping of AIV 
 
Specific capture-probes were designed for subtyping each of the 16 HA genes. The probes were 
located within the region amplified by the HA primers. The first set of probes was tested for 
subtyping of H1, H2, H4 and H7. Figure 7.3.6 shows the RT-PCR results of such tests. In this 
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RT-PCR, the capture-probes were used as the forward primers while the HA_Rev was used as 
the reverse primer. The RT-PCR was amplified successfully (Figure 7.3.6). 
 
 
 
 
 
 
 Figure 7.3.6 Subtyping of AIV by RT-PCR. Lane 1, 2, 4 and 7 represent the corresponding HA 
subtypes H1; H2; H4 and H7 respectively.  
 
The designed H1, H2, H4 and H7 probes were further tested for their specificity. Each probe was 
used as a forward primer in a RT-PCR to amplify the RNA targets extracted from reference 
strains from H1 to H16. Figure 7.3.7 (a, b, c and d) shows the results of such experiment. Using 
the designed probe H1 (Figure 7.3.7 a) for example, a RT-PCR amplicon of 166 bp was obtained 
with RNA target from AIV reference strain subtype H1.  
A strong signal was observed for the particular (H1) subtype. However, amplicons with the same 
size are observed also with the RNA targets from other subtypes of H3, H6, H9 and H12. Similar 
results were observed with the designed H2, H4 and H7 subtype probes (Figure 7.3.7 b, c and d). 
The quantification of gel bands using ImageJ software (National Institute of Health, USA) 
reveals that the strongest non-specific band for H1, H2, H4 and H7 had relative band intensities 
of 75.07%, 96.33%, 42.38%, 89.83% respectively. 
 
The observation of non-specific bands could be due to the difference in the melting temperature 
(Tm) of probe (56.4°C) that was used as a forward primer and the reverse primer (50.4°C) in the 
RT-PCR reactions and overlapping of the target sequences. Immobilizing the capture probe on 
the solid substrate may reduce the probe Tm [185] and also the non-specific binding. Further 
optimization of the test in terms of selection of new probe sequence, RT-PCR reaction conditions 
and sequencing of RT-PCR product to understand the non-specificity is needed. 
  
 
 
100 
 
 a)  
 
 
 
 
 
 
 
 
 
b) 
 
 
 
 
 
 
 
 
c) 
 
 
 
 
 
d) 
 
 
 
 
 
 
Figure 7.3.7 Specificity test of the probes for sub-typing of  a) H1, b) H2, c) H4 and d) 
H7subtype  using RT-PCR with RNA extracted from 16 different HA subtypes. On gel: lane 1 to 
16 represent H1 to H16, respectively. N, negative control. 
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7.3.4 Conclusion 
A set of primer for RT-PCR amplifying the cleavage region of the HA gene for all the 16 HA 
subtypes (H1-H16) of AIV has been designed and tested successfully. Using the designed 
primers in a RT-PCR with RNA isolated from chicken faecal or NewCastle disease virus, no 
amplification was observed. The amplified region could be a good target for further 
differentiating all the 16 HA subtypes as well as for pathotyping of the AIV isolates. With an 
attempt to subtyping of AIV using different probes, 16 HA capture-probes were designed and 
four capture-probes of H1, H2, H4 and H7 were tested using RT-PCR. However, non-specificity 
of RT-PCR amplifications was observed when the designed capture-probes were used as one of 
primer in the RT-PCR. The newly developed method needs to be further optimized in such 
directions for development of one-step multiplex RT-PCR for detection and subtyping of AIV 
using solid-phase RT-PCR. 
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Chapter 8 
8 Immunoassays  
 
This chapter focuses on the development of two immunological assays; a fluorescent DNA 
barcode-based assay and a fluorescent bead-based assay for rapid detection of AIV. In both 
assays, the target AIV is sandwiched between the AIV nucleoproteins monoclonal antibody and 
the AIV matrix protein monoclonal antibody. Fluorophore-tagged oligonucleotides and 
fluorescent beads are used as the detection signals in the fluorescent DNA barcode-based 
immunoassay and the fluorescent bead-based immunoassay, respectively. The advantages of 
each method for rapid detection of the AIV are presented and discussed.  
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8.1 Detection of avian influenza virus by fluorescent DNA barcode-based immunoassay 
with sensitivity comparable to PCR 
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In this paper, a coupling of fluorophore-DNA barcode and bead-based immunoassay for detecting
avian influenza virus (AIV) with PCR-like sensitivity is reported. The assay is based on the use of
sandwich immunoassay and fluorophore-tagged oligonucleotides as representative barcodes.
The detection involves the sandwiching of the target AIV between magnetic immunoprobes and
barcode-carrying immunoprobes. Because each barcode-carrying immunoprobe is functionalized with
a multitude of fluorophore-DNA barcode strands, many DNA barcodes are released for each positive
binding event resulting in amplification of the signal. Using an inactivated H16N3 AIV as a model,
a linear response over five orders of magnitude was obtained, and the sensitivity of the detection was
comparable to conventional RT-PCR. Moreover, the entire detection required less than 2 hr. The
results indicate that the method has great potential as an alternative for surveillance of epidemic
outbreaks caused by AIV, other viruses and microorganisms.
Introduction
Avian influenza viruses (AIV), belonging to the Orthomyxoviridae
family, have attracted global concern due to the potential
pandemic threat for human health and enormous economic
losses. It has killed millions of poultry and hundreds of people
not only in Asia but also throughout Europe and Africa.1–3 To
control the epidemic diseases, there has been a surge of interest in
sensitive, specific and rapid detection of AIV.
Several decades ago, traditional viral detection methods such
as Madin-Darby canine kidney (MDCK) cell culture,4 comple-
ment fixation (CF),5 or hemagglutinin-inhibition (HI)6 were
mostly used. These approaches are laborious and time-
consuming (e.g., up to 4–10 days for the viral culture).
Furthermore, in some cases the techniques are insufficient due to
lack of specificity. Recently, reverse transcriptase PCR
(RT-PCR) has emerged as the most sensitive method for AIV
detection and pathotyping.3,7 RT-PCR involves an extraction of
viral nucleic acids (RNA), an in vitro reverse transcription
process to synthesize cDNA from the viral RNA, followed by an
enzymatic amplification and detection of the cDNA. Although
very sensitive, specific, and much faster than the aforementioned
procedures, RT-PCR also has some drawbacks such as
a complicated procedure, high cost, and high false positive rate
arising from cross contaminations between samples.
Furthermore, it still requires a day and experienced personnel to
obtain results.
Immunoassays could be an alternative for detection of AIV
via immunoreactions between surface antigens (nucleoproteins,
matrix proteins) of the AIV and their developed antibodies.
Many studies have been devoted to the development of enzyme-
linked immunosorbent assay (ELISA),7–10 immunochromato-
graphic strip test,1,11 or microsphere immunoassay (MIA) for
detection of AIV.12 Although these immunoassays have been
shown to be rapid, inexpensive to perform and possible to
automate, they have lower sensitivity compared to those
obtained from RT-PCR.8 Bio-barcode immunoassay, proposed
by Nam et al., is the only approach for detection of biological
targets that can obtain PCR-like sensitivity without the enzy-
matic amplification.13,14 Typically, the bio-barcode immunoassay
utilizes two types of particles: (1) a magnetic microparticle
(MMP) functionalized with antibody (primary antibody) which
is to capture and isolate the target analyte from the sample
solution, and (2) another particle (gold nanoparticle, polystyrene
or silica microparticle) anchored with secondary antibodies,
which is specific to the same target, and double-stranded
DNA.13–16 Only one strand of the double-stranded DNA is
covalently immobilized onto the secondary particle probe, and
after the sandwiching immunoreaction, the complementary
DNA strand can easily be released by increasing the temperature.
The DNA surrogates for the target of interest and is therefore
called a DNA bio-barcode. The surrogate DNA bio-barcode can
subsequently be detected by PCR, DNA microarrays, colori-
metric assays, or fluorophore-based assays. Unlike other
conventional sandwich immunoassays, where the signal intensity
is limited by number of antigenic valences for specific binding of
reporter-tagged antibody, each particle is functionalized with
a multitude of DNA strands and thus many DNA barcodes are
released for each positive binding event resulting in amplification
of the assay. Although the bio-barcode amplification assays have
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Lyngby, Denmark. E-mail: Anders.Wolff@nanotech.dtu.dk
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been the focus of many studies for detection of oligonucleotides
and proteins, there have been no publications dedicated to bio-
barcodes for detection of pathogenic organisms. In this paper, we
will address a detection strategy that incorporates the benefits of
fluorophore-DNA barcodes as a representatively optical reporter
with the use of bead-based immunoassay for the detection of
AIV. The method has not only a wide dynamic range of detection
but also a sensitivity equivalent to that of RT-PCR which
outperforms all detection limits of immune-based tests so far.
This, in combination with the shorter detection time and possi-
bility of adapting the method for detection of other viruses or
microorganisms, make it a potential tool for surveillance of
infectious diseases.
Materials and methods
Virus strain
An inactivated AIV virus subtype H16N3 was used as a model
for developing the method. The AIV strain was propagated in
SPF chicken eggs (Lohmann Tierzucht, Cuxhaven, Germany)
and harvested from the allantoic fluid. The virus sample was
prepared and titrated by Haemagglutin (HA) test at a concen-
tration of 1:128 according to the guidelines of the European
Union (EU) Council Directive 92/40/EEC.17 A Newcastle
Diseases Virus (NDV) Ulter strain was used to test the specificity
of the assay. Both of the virus strains were kindly prepared
by Poultry Virus Laboratory, National Veterinary Institute,
Technical University of Denmark (DTU-VET).
Chemicals
Magnetic microparticle (Dynabeads M-270 Amine, diameter
2.8 mm) was purchased from Invitrogen Dynal AS (Oslo,
Norway). Polystyrene microparticle (Polybead amino micro-
sphere, diameter 1 mm), glutaraldehyde kit, and BioMagPlus
amine protein coupling kit were supplied by Polysciences Europe
GmbH, Germany. Influenza type A virus nucleo-protein
monoclonal antibody (NP mAb) and influenza type A virus
matrix-protein monoclonal antibody (MP mAb) were purchased
from Statens Serum Institut, Denmark. Oligonucleotide
sequences were obtained from TAG Copenhagen A/S, Denmark;
primers used in RT-PCR were obtained from DNA Technology,
Aarhus, Denmark (Table 1). Other essential chemical reagents
were of analytical grade and supplied by Pierce, Sigma-Aldrich,
or Fluka unless otherwise stated. Ultrapure water (18.2 mU/cm)
produced by a Millipore Milli-Q system was used to prepare the
chemical solutions when needed.
Preparation of magnetic microparticle immunoprobe
The amino-functionalized magnetic microparticle (MMP) was
coated covalently with the NP mAb by using a BioMagPlus
amine protein coupling kit according to the manufacturer’s
protocol and a procedure reported previously with some modi-
fications.18 Briefly, 100 ml of MMP solution containing 2  108
beads (approximately 3 mg) was equilibrated and washed
intensively 2 times with a mixture of 3 ml EDTA (0.05 mM) and
6 ml pyridine wash buffer (0.01 M, pH 6). The MMPs were
separated after each washing step by a MultiSep magnetic
separator (Polysciences Inc.). Then, 3 ml of 5% glutaraldehyde
was added to activate the MMPs for about 3 h at room
temperature while shaking vigorously. After the activation,
the MMPs were washed two times, and suspended in 6 ml pyri-
dine wash buffer. 1 ml of NP mAb (80 mg/ml) was added to the
glutaraldehyde-activated MMP suspension; the mixture was
gently mixed and incubated for about 10 hr at room temperature
to ensure covalent coupling, followed by the washing step with
6 ml pyridine wash buffer. Afterwards, 3 ml BSA (0.2 mg/ml) was
added to the solution for an additional 5 hr to block the non-
specific adsorption of other proteins. The unreacted aldehyde
sites were subsequently deactivated by 10 ml of 1 M glycine
solution (pH 8) for 1 hr at room temperature. It should be noted
that the washing step with pyridine buffer was repeated after
each reaction to eliminate any remaining free reactants. The
resulting MMP immunoprobes were then suspended in 1 ml of
0.15 M PBS solution and stored at 4 C for up to 1 month
without loss of activity.
Preparation of polystyrene microbead immunoprobe (PMP)
The experimental steps for the preparation of PMP immunop-
robes were carried out by covalently immobilizing MP mAb and
barcode DNA complementary strand (Oligo 1) onto the Poly-
bead amino microsphere by using the glutaraldehyde kit.19 In
brief, after washing and normalizing 1 ml of PMPs (approxi-
mately 2.28  1010 beads/ml) by PBS buffer, the PMPs were
separated from the supernatant by centrifuging at 10 000 rpm for
10 min. Then, the PMP pellet was resuspended in 1 ml PBS buffer
and reacted with 1 ml of 8% glutaraldehyde for 5 hr at room
temperature. The reaction was performed in a 5 ml vial and
stirred gently by a magnet bar to avoid settlement of the PMPs.
The activated PMPs were centrifuged, washed, and resuspended
in 1 ml PBS as described above. 10 ml of MP mAb (1 mg/ml) was
added to the solution to conjugate with PMPs and incubated for
2 hr at room temperature with gentle stirring. Afterwards, 200 ml
of 100 mM barcode DNA complementary strand (Oligo 1) was
added continuously while stirring gently, and left to react over-
night. The beads were washed 2 times with PBS buffer and
unreacted glutaraldehyde sites of the PMP immunoprobes were
deactivated by mixing with 1 ml of 0.2 M ethanolamine. The
supernatant was removed by centrifuging at 13 000 rpm for
10 min, and 1 ml of 10% BSA was added to further block the
unbound regions of the particle surface (30 min incubation).
After washing with PBS and centrifugation, the resulting particle
pellet was resuspended in 2 ml PBS buffer. Finally, 200 ml of
100 mM DNA barcode (Oligo 2) was added and incubated with
the PMP immunoprobe for 1 hr. The barcode PMP
Table 1 List of primers and oligonucleotide sequences used in this study
Oligonucleotides Sequence (50/ 30)
Oligo 1 Amino-C6-AAAAAAAAAA AGG AAG GTG
TGG ACG ACG TCA AGT CAT CAT GGC C
Oligo 2 Cy5-C GCC ATG ATG ACT TGA CGT CGT CCA
CAC CTT CCT
Forward primer AGA TGA GTC TTC TAA CCG AGG TCG
Reverse primer TGC AAA AAC ATC TTC AAG TCT CTG
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immunoprobe was washed and collected by centrifugation and
resuspended in 2 ml of storage buffer. The final PMP probe was
stored at 4 C in a dark container to reduce photobleaching of
the fluorophore. By using this method, the average numbers of
mAb molecules and barcode DNA strands were respectively
determined at about 1457 and 1.45  104 per polystyrene particle
which are slightly lower than those reported previously.19
Immunoreaction and optical detection
In a typical experiment, a sandwiched immunoassay of MMP
immunoprobe/AIV/PMP immunoprobe was carried out, and
then the DNA bio-barcodes were collected by a magnetic sepa-
ration and thermal dehybridization. Briefly, 30 ml of MMP
immunoprobes was incubated with 40 ml of various 10-fold
dilutions of the inactivated H16N3 with a HA titre of 1:128 in an
Eppendorf tube. The reaction was kept for 30 min at room
temperature on a rotating mixer. 30 ml of PMP immunoprobes
was added and incubated for 30 min. When the immunoreaction
had finished, the MMP immunoprobe/AIV/PMP immunoprobe
complexes were separated in the magnetic separator, and the
supernatant was removed. The reacted complexes were washed
3 times with 0.15 M PBS buffer, and 30 ml of pure and DNA-free
water was added to the magnetically collected pellet. Finally, to
release the surrogate DNA barcodes, the complexes were heated
to 75 C for 15 min, immediately followed by magnetic separa-
tion. The upper aqueous solution containing the released
surrogate DNA barcode strands was collected and spotted onto
a microscope slide by using a non-contact inkjet Nano-plotter 2.1
(GeSiM, Germany). Fluorescence measurement was carried out
by a scanner ScanArray Lite (Packard Bioscience, USA) with
appropriate settings for the Cy5 fluorophore.
RT-PCR
Detection of AIV by RT-PCR for matrix gene (M1) was per-
formed according to a procedure published elsewhere with some
modifications.7,20 25 ml RT-PCR reaction contained 12 ml of
RNase free water, 5 ml RT-PCR buffer, 10 pmol of each primer
(Table 1),20 1 ml of dNTP, 1 ml of enzyme mix and 5 ml of viral
sample. RT-PCR was performed in a thermal cycler (Biometra,
Germany) with reverse transcription at 56 C for 30 min and
enzyme activation at 95 C for 15 min followed by 40 cycles with
denaturation at 94 C for 30 s, annealing 58 C for 1 min, and
extension at 72 C for 1 min. The final extension step was carried
out at 72 C for 7 min. The obtained RT-PCR products were
analysed using 1.5% agarose gel electrophoresis.
Results and discussion
The experimental procedure of the fluorescence-DNA barcode-
based immunoassay is depicted in Fig. 1. The detection is
initiated by sandwiching the target virus between the MMP
immunoprobes and the PMP immunoprobes. After separation of
the sandwich immunocomplex by a magnetic field, the surrogate
Fig. 1 Overall scheme illustrating procedure of the fluorophore-DNA barcode-based immunoassay for detection of AIV.
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fluorophore-DNA barcodes are released by heating the immu-
nocomplex at 75 C for 15 min, and collected. Because the bar-
code immunoprobe particle can carry thousands of the
representative barcodes, a single antibody–antigen binding event
is translated to a multitudinous number of surrogate DNA
barcodes leading to amplification of the assay. The fluorophore-
DNA barcodes are then detected by any fluorescence readout
available. In our lab, the most convenient way to detect the
liberated DNA barcode strands was to spot them onto a micro-
scope slide as microarrays following by a scanometric analysis,
the entire detection required less than 2 hr to complete. It should
be noticed that the Cy5- DNA barcode can be printed and
measured directly without the dissociation step from the immu-
nocomplex; however, due to the micro-sized nature of the
microbeads the fluorescence was not dispersed leading to
the fluctuation of the final results. Furthermore, the 3-D shape of
the microbeads could hinder the Cy5-DNA barcodes located
underneath leading to deterioration of the signal. To obtain more
uniform fluorescent spot, the Cy5-barcode was released from the
particles by heating and the results showed that the spot homo-
geneity was much better (See Fig. S1, ESI†). Therefore, the
dissociation step is required in the protocol.
There are many factors that may limit performance of the
DNA barcode-based immunoassay. These factors include the
type of particles or antibodies, attachment chemistry, effective-
ness of removal and washing steps, etc. Among them, immuno-
logical affinity of the immunoprobes towards their target analyte
plays the most important role; it could be a key factor to deter-
mine the success or failure of the whole assay and their immu-
nological activity could be deteriorated after the chemical
immobilization. It is therefore necessary to ensure that the
immunoprobes are able to capture the virus after enduring the
chemical conjugation process. To determine this, conventional
RT-PCR was exploited as a straightforward approach to validate
the usefulness of the immunoprobes: The MMP and PMP
immunoprobes were successively incubated with 103 dilution of
the HA-titrated H16N3, and the captured viruses were collected
by magnetic separation or centrifugation (in case of the PMP
immunoprobes) as described in the method section. After the
incubation period, the samples were washed several times with
1 ml of PBS buffer with 0.05% Tween 20 (pH 7.4). Finally, 50 ml
DNA-free water was added to dissolve the collected complexes
for the RT-PCR analysis. False-positive or false-negative results
could be obtained if the washing step is not performed
adequately in any immunoassays. For this reason, the washing
supernatants were also collected in 1 ml aliquots to be analyzed
with RT-PCR. Fig. 2A shows the gel electrophoresis image of the
RT-PCR products. As seen, both of the MMP and PMP
immunoprobes were PCR positive, and neither secondary
product nor contamination was observed. Moreover, both
washing solutions were virus-free after 4 times of washing as
shown by PCR negative signals in lane 3 and 5, indicating that
the positive bands (lane 2 and 4) resulted solely from specific
interactions between the virus and the immunoprobes. A number
of viruses were still observed in the washing solution until the
third washing step (data not shown). This could be because of
blocking effect of the microbeads or non-specific interactions of
the beads and the viruses, and this might contribute to a false-
positive result of the assay if the washing step is not carried out
carefully. Non-specific interaction of the immunoprobes with
other viruses is also important information that should be
elucidated to evaluate the specificity of the immunoprobes.
Newcastle Disease Virus (NDV) was used as the control virus
because NDV is the viral infectious disease that is closely related
to AIV in poultry. Briefly, NP mAb and MP mAb were conju-
gated to the magnetic beads. The immunoreactions with NDV
were performed as described above. Subsequently, the immu-
nocomplex was collected by a magnetic force; the captured NDV
was then determined by RT-PCR and gel electrophoresis that
were well-established at DTU-VET.21 As shown in Fig. 2B, both
of the PCR products obtained from NP mAb and MP mAb
coated microbeads were negative indicating that the non-specific
binding of NDV was negligible. Overall, this result shows how
many times the washing step is required, and indicates that the
immunoprobes were prepared successfully; they are sufficient
and specific for catching the AIV in the next experiments.
Fig. 2 (A) Agarose gel electrophoresis image illustrating validation of
the immunoprobes by RT-PCR for H16N3 AIV (HA titers ¼ 1:128). On
gel, lane 1: 100 bp DNA ladder (Qiagen); lane 2: MMP immunoprobe
sample (virus dilution 103); lane 3: Washing solution of MMP immu-
noprobe sample (4th); lane 4: PMP immunoprobe sample (virus dilution
103); lane 5: Washing solution of PMP immunoprobe sample (4th); lane
6: Negative control (virus free); lane 7: Positive control (virus dilution
103). (B) Investigation of non-specific binding of Newcastle Disease
Virus (NDV, HA titers ¼ 1:128) on the immunoprobes. On gel, lane
1: DNA ladder; lane 2: NP mAb coated magnetic microbead sample
(virus dilution 102); lane 3: MP mAb coated magnetic microbead
sample (virus dilution 102); lane 4: Negative control (virus free); lane
5: Positive control (virus dilution 102).
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To realize the principle illustrated in Fig. 1, a practical
experiment was implemented to detect the AIV subtype H16N3.
A series of 10-fold dilutions of the virus were prepared and
incubated with the immunoprobes. Fig. 3A illustrates that the
spot intensities were intuitively differentiated and proportional
to a certain range of viral dilutions (see Fig. S2 (ESI) for high
resolution image of the arrays†). The proportional relation was
observed on all 3 replicates of the experiment. More quantita-
tively, Fig. 3B shows the generalized logarithmic correlation
between the fluorescence values and the diluted concentrations
of the virus. As seen, this method is able to reliably detect AIV
with a very wide dynamic range of virus titres spanning from
1:128 up to 1:128  105 (five orders of magnitude) in which the
fluorescence intensities were proportional to a log scale of the
viral dilutions. The spot intensities at the dilutions higher than
1:128  105 were poorly discriminated because their signals did
not exceed 2 or 3 times of standard deviation from the blank
measurement (negative control sample, horizontal line); the
limit of detection (L.O.D) was therefore proposed to be
approximately 1:128  105 dilutions of the HA titre of the
virus.
To further evaluate the effectiveness of the strategy, the same
10-fold dilutions of the virus samples were analyzed by
conventional RT-PCR assay. The results of the fluorophore-
DNA barcode-based detection of H16N3 AIV agreed remark-
ably well with the RT-PCR analysis. A proportional
relationship was also obtained for the concentration range of
1:128 to 1:128  105 by RT-PCR (Fig. 4). Viral concentrations
lower than 105 of dilution could also not be detected by
RT-PCR owing to the extremely low number of virus particles.
Therefore, the results suggest that the fluorophore-DNA bar-
code-based immunoassay described in this study is as sensitive
as RT-PCR, it could be an alternative for detection of AIV
where RT-PCR is not available.
Fig. 3 Detection of fluorescent DNA barcodes. Scanometric image showing three replicated microarrays of surrogate Cy5-DNA barcode strands and
their corresponding fluorescence intensity to the diluted concentrations of H16N3 AIV (A); and (B) generalized correlation of the average intensity and
the diluted concentrations for the detection of H16N3 AIV (HA titre 1:128). NC negative control signal.
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Conclusion
An effective method using fluorophore-DNA barcode combined
with bead-based immunoassay was described for the first time to
detect AIV. The single immuno-recognition events were trans-
lated into multitude numbers of the Cy5-tagged DNA barcodes
which could be quantitatively measured by a fluorescence
readout device. The H16N3 AIV strain could be detected with
PCR-like sensitivity and a wide dynamic range of up to five
orders of magnitude. Although simple in design and concept, the
method introduced has PCR-comparably sensitive, is less time-
consuming (less than 2 hr for the entire detection), highly
applicable, and can be carried out using simple laboratory
equipment. For these reasons, the assay deserves attention as an
alternative for the surveillance and clinical detection of AIV
outbreaks.
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Fig. S1. Compared images before and after dissociating Cy5-biobarcodes from the 
immunocomplexes.  
 
 
Fig. S2. High resolution image of the Cy5-DNA barcode arrays.  
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8.2 Development of a fluorescent bead-based immunoassay for rapid detection of Avian 
influenza virus 
8.2.1 Introduction 
Currently, the POC tests or other commercial tests for AIV detection are largely based on 
immunoassays. These assays are rapid (5 to 30 minutes) but have low sensitivity, 105 to 106 of 
50% tissue culture infectious dose/ ml (TCID50/ml) [186]. The low sensitivity of these tests is a 
major concern for mass screening of the AIV. This problem has been addressed in the previous 
study of the development of a fluorophore-DNA barcode and bead-based immunoassay. Using 
the developed method the AIV can be detected with PCR-like sensitivity. However, the 
developed assay needs a heat step to release the barcode oligonucleotide for quantitative 
detection, therefore applying such assay for a POC or an integrated LOC is complicated. An 
alternative simple approach would be to detect the fluorescence signal directly with a simple 
optical detection system that is suitable for on-field screening tests.  
 
 
 
 
 
 
 
 
 
 
Figure 8.2.1: Schematic of a lab-on-a-chip (LOC) for fluorescent bead based detection system 
 
In the immunoassay based on fluorescence detection, nano and micro beads conjugation with 
antibodies or antigen have been used to obtain high sensitive sensing for detection of infectious 
disease[187]. These fluorescent beads carry a high amount of fluorophores that generate a photo-
stable and strong fluorescent signal. Moreover, with a high surface-to-volume ratio (SVR), the 
beads provide better binding sites for the targets. A fluorescent immunoassay (FIA) has been 
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developed for the detection of antibodies against nucleoprotein (NP), matrix and non-structural 
proteins of AIV[188]  and also for multiplex detection of both NP and H5[189] using 
commercial spectrophotometer instrument (Luminex, USA).  In these studies, the sensitivity of 
the assays were low (1:3200 dilution of the serum) i.e., can only detect higher concentration, 
which could be due to the use of fluorescent reporter dye. In addition, an expensive instrument is 
needed for the analysis. In this study, a fluorescent bead-based immunoassay was developed to 
detect the avian influenza virus suitable for a simple POC test using LOC (Figure 8.2.1).  
8.2.2 Materials and Methods 
Virus and antibodies 
In order to compare the result with the previous study, the H16N3 inactivated virus of the same 
batch with the HA titre of 128HAU. Monoclonal antibody (mAb) against the AIV nucleoprotein 
(NP) (HYB 340-05) and matrix proteins (MP) (HYB 344-01) of AIV were purchased from 
Staten Serum Institute (Copenhagen, Denmark) with a concentration of 100 mg/ml.  
 
Antibody conjugation to beads and fluorophore 
a) NP antibody conjugation to magnetic bead 
Super-paramagnetic polystyrene carboxylic acid beads (Myone, Invitrogen, Denmark) with 1.05 
µm diameter were used. The antibody was conjugated to the beads using protein coupling kit 
(PolyLink protein coupling kit for COOH microparticles, Polysciences, Eppelheim, Germany) 
according to the manufacturer´s instruction with modifications. Briefly, 250 μl of beads were 
washed twice with 1 ml of coupling buffer (50 mM MES, pH 5.2, 0.05% Proclin 300) and the 
beads were re-suspended in 100 μl of the same buffer. A magnetic separator (Dynal MPC, 
Invitrogen, Copenhagen, Denmark) was used to separate the beads in all the washing steps. The 
functional carboxyl groups on the surface of the bead were activated by adding 100 μl of 1-ethyl-
3-(3-dimethylaminopropyl) carbodiimide (EDC) (10 mg/ml) to the bead suspension and 
incubated for 30 min at room temperature on a rotator. To remove the excess EDC the beads was 
washed once with coupling buffer (500 μl). The activated beads were mixed with 100 μg of mAb 
NP diluted in coupling buffer in a total volume of 500 μl and incubated over night at room 
temperature on a rotator. The un-reacted sites on the surface of the beads were de-activated by 
mixing with 500 μl of 0.2 M ethanolamine and incubating for 30 min at room temperature. The 
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beads were further blocked with 1 ml of PBS containing 0.5% Casein (blocking buffer) and 
incubated for 30 min at room temperature. Finally, the beads were restored in 250 μl of PBS 
containing 1% Tween20 (storage buffer). 
 
b) Conjugation of MP antibody on fluorescent carboxyl beads 
The MP antibody was conjugated onto the surface of the (Ø1 µm) fluorescent carboxyl beads 
(ex:441nm, em:486nm) that were purchased from Polysciences (Eppenheim, Germany). A 
similar coupling procedure as mentioned above was performed. Briefly, the fluorescent beads 
(75 µl) were washed twice with 500 µl of coupling buffer and re-suspended in 480 µl of coupling 
buffer. Twenty μl of EDC (200 mg/ml) was added to the bead re-suspension and incubated for 30 
min at room temperature. After a washing to remove all the excess EDC, 50 μg of MP antibody 
was added and incubated overnight on a rotator at room temperature. The remaining steps were 
as described earlier, and finally the beads were suspended in 75 µl of storage buffer. During the 
procedure, the fluorescent beads were collected by centrifugation (Z233 M-2, Hermle 
Labortechnik GmBH, Wehningen, Germany) at 10,000 rpm for 5 min at room temperature. Both 
magnetic and fluorescent beads can be stored at 4 oC for up to 2 months without loss of activity. 
 
Antibody conjugation confirmation  
The presence of NP-mAb on the surface of carboxyl magnetic bead was confirmed by secondary 
goat anti-mouse antibody labelled with Alexa Fluor-488 SFX (Invitrogen, Taastrup, Denmark). 
Five µl of Alexa Fluor-488-labelled antibody was added to 5µg of NP-mAb coated magnetic 
beads and uncoated magnetic beads and mixed for 30 min at room temperature. Later, the beads 
were washed 3 times with 1 ml of PBS and finally restored in 25 µl. Five µl of bead mixture was 
transferred to a microscopic glass slide and the images were captured using a fluorescent 
microscope (model DMRB, Leica, Germany) with FITC filter set (450 to 490-nm bandpass 
excitation filter and 530 nm emission filter). 
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Development of fluorescent immunoassay 
A scheme of the fluorescent immunoassay (FIA) assay 
using fluorescent beads is shown in Figure 8.2.2. In 
brief, 5 μl of magnetic beads were added to 100 μl of 
H16N3 virus with HA titre value of 128 HAU 
(undiluted allantoic fluid) and incubated for 30 min on 
the rotator. After the incubation, 0.5 μ1 of MP 
antibody conjugated fluorescent beads were added to 
the mixture and incubated for further 30 min. In this, 
step a sandwich complex of magnetic bead-virus-
fluorescent bead was formed. The complex was 
separated and washed 4 times with 10 mM PBS 
containing 0.05% of Tween20 (washing buffer) using 
a magnetic separator and finally the complex was 
restored in 20 μl of washing buffer.  
 
The complex (entire volume) was transferred on a 
microscopic slide (without cover slip) and scanned 
using a fluorescence scanner (LaVision Biotech, 
Bielefeld, Germany) with FITC filter set. To avoid the interference of the beads during the 
scanning and for obtaining uniform results, a magnetic strip (IKEA, Aarhus, Denmark) was 
placed under the slide to pull down all the beads on the slide surface before scanning. A blank 
sample with 100 μl of washing buffer was used as a negative control and the assay was 
performed accordingly. To determine the sensitivity of the developed FIA, 10-fold serial 
dilutions of H16N3 virus were made and the assay was performed in triplicates.  
During the pilot experiments, the beads blocked with BSA as blocking buffer in the mAb 
conjugation procedure showed aggregation of the beads resulted in higher non-specific signal. 
Therefore, the BSA was replaced with Casein in the blocking buffer and used for the assay. 
Although Casein reduced the aggregation of beads, the non-specific interaction was controlled 
with the addition of Tween20.  
 
Figure 8.2.2 A scheme 
representing fluorescent bead 
based immunoassay for 
detection of AIV 
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In the FIA the effect of agglutination i.e., magnetic bead-virus-magnetic bead was studied using 
the magnetic bead based assay. In that assay, magnetic beads were incubated with three dilutions 
of 10-1, 10-2 and 10-3 of H16N3 virus (128 HAU) for 30 min at room temperature. After the 
incubation, magnetic beads were washed 3 times with the washing buffer and the agglutination 
effect was observed during the washing steps.  
8.2.3 Results and discussions 
Immunoassay based on ELISA is time-consuming (1-2 days) due to the immobilization of 
antibody on the microtiter wells (2D surface), washing and the planar assay for detection, where 
as the use of beads accelerate the kinetic reaction in a shorter time[190]. In this study, the FIA 
was developed using the two mAb specific for NP and MP of AIV for rapid detection of the 
AIV. In the preliminary experiments, it is noted that high non-specific signals were observed 
when the tosylactivated (hydrophobic) magnetic beads and the fluorescent beads (hydrophilic) 
were used. To reduce the non-specific signals, in the developed FIA, magnetic beads and 
fluorescent beads with the same surface chemistry, i.e. carboxylic acid (hydrophilic), were 
selected for the conjugation of mAb’s. The conjugation of mAb (NP) to the magnetic beads was 
confirmed by the secondary antibody labelled with Alexa Fluor-488 (Figure 8.2.3 a). The 
antibody on the surface of fluorescent beads was not confirmed by the secondary labelled 
antibody due to the strong signal from fluorescent beads which override the fluorophore.  
 
 
    a)                                                                b)        
  
 
 
 
 
Figure 8.2.3: Microscopic images using fluorescence microscopy (Leica, Germany), with FITC 
filter setting. The images confirming a) the presence of mAb (NP) on the surface of magnetic 
beads and b) no signal on uncoated beads.  
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Fluorescent immunoassay  
Figure 8.2.4 shows the images taken with fluorescent scanner for the FIA performed with H16N3 
virus and buffer. The two images differentiated by the quantity of fluorescent beads (white spots) 
confirm the capture of virus by magnetic bead and the formation of sandwich immunoassay. 
 
  a)                                                                  b)  
 
 
 
 
 
Figure 8.2.4: Images from fluorescent scanner for the FIA with a) buffer and b) H16N3 virus 
(undiluted allantoic fluid with 128HAU). The white spots are the fluorescent beads with the 
magnetic beads at the background. 
 
A low background and a low aggregation could be achieved in the developed FIA due to the 
combined effect of Casein as a blocking buffer and the presence of the Tween20. The 
replacement of BSA (Figure 8.2.5a) by Casein proved beneficial in reducing the non-specific 
binding. This could be due to the Casein protein having a smaller molecular mass i.e., more 
molecular surface compared to BSA and acts as an effective blocking agent[191]. The use of 
Tween20 in the storage buffer lowered the surface tension of the beads and thus reduced the non-
specific interaction (Figure 8.2.5b). 
 
a)                                                   b)                                
 
 
 
 
 
 
 
 
Figure 8.2.5: Images from fluorescent scanner for the FIA with a) BSA blocked beads showing 
aggregates and b) buffer sample without Tween20 showing higher non-specific signal. 
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Image analysis 
The images were analyzed by using ImageJ (Image processing and analysis in Java, National 
Institute of Health, USA). It is freely available software and provides a cost effective solution for 
fluorescence quantification. The acquired image (16-bit) was converted into 8 bit gray scale, 
which has intensity of pixel range from 0 (black) to 255 (white) (Figure 8.2.6 a). The brighter 
dots with gray values above 255 were also counted as having a gray value of 255. The signal 
from the background and magnetic beads were removed from image processing by setting the 
threshold or lowest intensity (min) to 60 (Figure 8.2.6 b). 
 
a)                                                  b) 
 
 
 
 
 
 
Figure 8.2.6 Analysis of 8-bit gray scale image using ImageJ. a) Fluorescent bead with the region 
(yellow) used for plot profile. b)Profile showing the distribution of grayscale (0 to 255) across 
the fluorescent bead. The gray scale value below 60 (red line) was considered as background.  
 
Using these settings, a histogram was plotted with the distribution of pixel intensity (gray scale) 
for 61-254 and the number of pixels found for each gray value of the image. Figure 8.2.7 shows 
such histogram of the images taken for H16N3 virus (undiluted) and the blank sample performed 
in triplicates. By comparing the two series it is noted that the virus sample (undiluted H16N3) 
has higher pixel counts for all the gray scale value (61 to 254) compared to the blank sample. 
This effect is due to the presence of the fluorescent beads and therefore represents the fluorescent 
emissions.  
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Figure 8.2.7 Histogram showing the intensity of gray value for FIA images of virus sample 
(series 1) and blank sample (series 2). 
 
The sensitivity of FIA was determined by using 10-fold serial dilutions of the H16N3 virus (128 
HAU). The total fluorescent intensity of the images was calculated by summing the gray 
intensity of all pixels in the range of 61-255 using ImageJ software. As seen in Figure 8.2.8, 
there were 10 fold differences in the signal intensity of the undiluted virus (55,507± 6,570) 
comparison to the negative control (buffer) (5,158±2,885). Up to the 10-2 dilution of the virus 
there was a significant difference between the virus and the negative control (buffer).  At the 
dilution of 10-3, there was a sudden decrease in the signal intensity (3,816±1,870) down to the 
range of the negative control. Similar results were observed for other dilutions of 10-3 and 10-4 
with signal intensity of 6410±4135 and 7753±1324 respectively. At a lower dilution of virus (10-
6) there was a positive signal observed (21,830 ±10,505) and declined (10-7) to the negative 
control. 
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Figure 8.2.8 Sensitivity of the FIA assay using a ten fold serial dilutions of H16N3 virus (128 
HAU). The ten fold serial dilutions of the virus range from 100 to 10-7 were made and used for 
the FIA assay. NC is a negative control (buffer). Based on the fluorescent intensities from the 
dilutions, results were divided into three zones of a, b and c (see the discussion). 
 
The observed phenomenal curve is due to the steric hindrance for the fluorescent beads to form 
sandwich assay. This effect can be explained similar to the formation of immunoprecipitation or 
agglutination curve [192]. In the FIA, with constant amount of mAb conjugated magnetic beads 
and the decreasing amount of virus, an agglutination curve is generated. This may be divided 
into three zones (Figure 8.2.8): a) excess of virus (100 to 10-2 dilution); where there are so many 
virus particles in relation to magnetic beads that only a single magnetic bead will bind to each 
virus particle. There are therefore no steric hindrance which occurs when 2 or more magnetic 
beads bind to a single virus particle, leaving no room for binding of fluorescent beads; b) the 
equivalence zone (10-3 to 10-5 dilution); where the low concentration of virus cause magnetic 
beads to form agglutination and create steric hindrance for binding to fluorescent beads; c) very 
low amount of virus (10-6 to 10-7 dilution), where the virus concentration is too low to form 
agglutination and the fluorescent beads have the possibility to form sandwich. For 10-6 dilution 
the signal deviation was higher, which could be due to the difference within the binding of AIV 
to the magnetic beads (for e.g., 1:1 or 1:3 respectively) that the increased or decreased the 
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binding of fluorescent beads to form the immunocomplex. The agglutination is formed due to the 
specific interaction between the virus and mAb coated magnetic beads and this effect was not 
controlled with the use of Tween20, which meant to reduce the non-specific interaction between 
the magnetic and fluorescent beads.  
 
To test the effect of agglutination, the magnetic bead based immunoassay was performed using 
three dilutions of 10-1, 10-2 and 10-3 of H16N3 virus and the results are shown in (Figure 8.2.9). 
The agglutination of magnetic beads was increasing with the dilution of virus and was visible to 
the naked eye 
 
a)                                    b)                                     c) 
 
 
 
 
 
 
 
Figure 8.2.9 Images of agglutination test. The mAb conjugated magnetic beads were used to 
capture the H16N3 virus in a) 10-1, b)10-2  and c)10-3 dilutions  and an increasing effect of the 
agglutination was observed. 
 
8.2.4 Conclusion 
A simple fluorescent bead-based immunoassay (FIA) has been developed for rapid detection of 
virus in less than 2h.  The FIA has detection limit of 10-2 dilution of the H16N3 virus (128 
HAU). For further dilutions of the virus, no linear response was obtained due to the steric 
hindrances. If the FIA is further optimized such as reducing the size of magnetic bead, sensitivity 
similar of the method could be similar or higher than RT-PCR could be achieved. The developed 
FIA can be easily integrated with LOC and using portable fluorescent scanner, the system can be 
used as a sensitive tool for screening of AIV in the fields.  
Magnetic stand Magnetic beads 
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Chapter 9 
9 Summary and Outlook 
 
Avian influenza virus (AIV) is a contagious disease among birds. Infection of AIV in poultry 
industries has killed several millions of birds and suffered massive economic loss. Contact with 
AIV infected poultry has spread the infection to humans and threatening the world with a human 
pandemic influenza. Therefore a simple, fast and reliable diagnostic method is needed urgently 
for early detection and surveillance of AIV. The combination of rapid diagnostics with the 
microfluidic lab-on-a-chip (LOC) technology offer great potential to create portable point-of-
care (POC) diagnostic system to detect and monitor infectious disease on field or at resource-
limited settings. This Ph.D-study has been focused on development of rapid diagnostic methods 
for the identification and subtyping of the AIV towards POC diagnostics.  
 
The key challenge in the realization of POC diagnostics is the sample preparation that has been 
addressed in this study with the development of an immunomagnetic bead-based assay (Section 
6.1). The magnetic beads conjugated with mAb were used successfully for immuno-separation, 
concentration and purification of AIV from spiked chicken faecal sample. The effective removal 
of RT-PCR inhibitors using magnetic bead-captured virus was observed. More importantly the 
developed method was used directly for RT-PCR without additional RNA release steps. The 
developed method was also realized and performed in a magnetic microsystem with microfludics 
(Section 6.2). This indicates the possibility to integrate the developed of sample preparation in a 
total analysis microsystem for AIV diagnostic. 
 
Further efforts were made to miniaturize the RT-PCR for AIV using microfluidic chip made of 
SU-8 and COC (Section 6.3). The use of SU-8 chip for RT-PCR showed inhibition effect by 
unknown factor. Efforts to address the inhibition were not successful due to insufficient 
information of chemical materials used for chip fabrication and also the batch-to-batch variation 
in fabrication. Although further optimization was planned to perform RT-PCR on SU-8 with 
different enzyme kits, no attempts were made due to the shortage of chip supply. The 
Sum ary d Outlook 
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performance of RT-PCR on COC chip was studied and successfully detected in less than two 
hours. These chips constitute a simple and cheap alternative (disposable chips) suitable for POC 
diagnostics.  
 
In section 7.1, a DNA microarray based solid-phase PCR platform for sub-typing of AIV to 
overcome the limitation of real-time RT-PCR in discriminating and sub-typing a number of 
targets, e.g. H5&H7 subtypes of the AIV simultaneously were developed.  A combined approach 
of reverse-transcription amplification of RNA extracts in the liquid-phase and sequence-specific 
nested PCR on the solid phase has been achieved. This approach with fewer steps generated a 
new method with high sensitivity and specificity comparable to in-tube multiplex PCR towards 
the development of a POC diagnostics. The developed solid-phase RT-PCR method was further 
incorporated into a microchip to reduce the sample volume and detection time 2h to 1h (Section 
7.2).  
 
As any subtype among the 16HA types (H1-H16) of the AIV could emerge as a pandemic 
influenza virus, it is important to develop a method that could not only detect but also subtype all 
the 16HA subtypes of AIV in one step. A multiplex DNA microarray based solid-phase RT-PCR 
for simultaneously detection and subtyping all the 16HA was initiated by designing new set of 
primers and probes (Section 7.3). The designed primer successfully identified all the 16 HA 
subtypes. Further, among the 16 probes that were designed to subtype the 16 HA, four probes 
were tested for RT-PCR which showed non-specificity. The developed method needs further 
optimization for subtyping using solid-phase PCR.  
 
In Chapter 8, two immunological assays; a fluorescent DNA barcode-based assay and a 
fluorescent bead-based assay was developed that could be used for rapid detection of AIV in less 
than 2h.  Both the fluorophore-tagged oligonucleotides and fluorescent beads can be used as the 
detection signals in the immunoassay for AIV. The bead based DNA barcode immunoassay 
offers an alternative approach for detecting AIV with PCR-like sensitivity. While, the developed 
fluorescent immunoassays can be integrated with LOC and using portable fluorescent scanner, it 
can be used as a sensitive tool for screening of AIV in the fields.  
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In this thesis, several approaches for rapid detection of AIV have been developed. The different 
steps of a molecular diagnostic LOC such as sample preparation (magnetic beads), RT-PCR 
amplification and detection (DNA microarray) have been demonstrated in different microfluidic 
system. The integration of all these steps in to one system will ensure the realization of a true 
LOC in the near future. This total integrated LOC will be a good tool for on-site rapid screening 
of AIV, especially the infectious agents and can improve the quality of life and economic.  
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